Targeting multidrug resistance in cancer

Nature Reviews Drug Discovery
5, 219-234
DOI: 10.1038/nrd1984

Citation Report

#	Article	IF	Citations
1	Association of dietary intake of folate, vitamin B6 and B12 and MTHFR genotype with susceptibility of breast cancer. Pakistan Journal of Medical Sciences, 1969, 30, 106-10.	0.3	19
2	Reversal of ABC Transporter-Dependent Multidrug Resistance in Cancer. American Journal of Cancer, 2006, 5, 285-297.	0.4	12
3	Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride. Canadian Journal of Physiology and Pharmacology, 2006, 84, 1285-1290.	0.7	4
4	Synthesis, Structureâ"Activity Relationships, and Antitumor Studies of 2-Benzoxazolyl Hydrazones Derived from Alpha-(N)-acyl Heteroaromatics. Journal of Medicinal Chemistry, 2006, 49, 6343-6350.	2.9	176
5	Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncology, The, 2006, 7, 792-793.	5.1	46
6	The Great Multidrug-Resistance Paradox. ACS Chemical Biology, 2006, 1, 271-273.	1.6	18
7	The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resistance Updates, 2006, 9, 227-246.	6.5	186
8	Free radical theory of autoimmunity. , 2006, 3, 22.		35
9	Medium-Throughput Microarray-Based Approach for Toxicogenomic Profiling of Small Molecules. QSAR and Combinatorial Science, 2006, 25, 1039-1046.	1.5	0
10	Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer, 2006, 6, 789-802.	12.8	1,824
11	A cationic chalcogenoxanthylium photosensitizer effective in vitro in chemosensitive and multidrug-resistant cells. Bioorganic and Medicinal Chemistry, 2006, 14, 8635-8643.	1.4	21
12	Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5700-5703.	1.0	12
13	Quantitative determination of oxidized carbon nanotube probes in yeast by capillary electrophoresis with laser-induced fluorescence detection. Analytica Chimica Acta, 2006, 580, 194-199.	2.6	10
14	Photochemical internalization (PCI): A novel technology for activation of endocytosed therapeutic agents. Medical Laser Application: International Journal for Laser Treatment and Research, 2006, 21, 239-250.	0.4	26
15	Role of drug efflux carriers in the healthy and diseased brain. Annals of Neurology, 2006, 60, 489-498.	2.8	60
16	Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor. Cancer Research, 2006, 66, 11305-11313.	0.4	79
17	Functional interrogation of breast cancer: from models to drugs. Expert Opinion on Drug Discovery, 2006, 1, 569-584.	2.5	3
18	Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiological Reviews, 2006, 86, 1179-1236.	13.1	637

#	Article	IF	Citations
19	DualChipÂ®microarray as a new tool in cancer research. Expert Review of Molecular Diagnostics, 2006, 6, 295-306.	1.5	13
20	Targeting the Hedgehog Pathway to Mitigate Treatment Resistance. Cell Cycle, 2007, 6, 1826-1830.	1.3	31
21	Targeting hedgehog in cancer stem cells: how a paradigm shift can improve treatment response. Future Oncology, 2007, 3, 569-574.	1.1	11
22	Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 67, 380-388.	0.5	89
23	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistanceâ€“linked ABCG2 transporter. Molecular Cancer Therapeutics, 2007, 6, 3287-3296.	1.9	89
24	Drug Resistance and Methylation in Myelodysplastic Syndrome. Current Pharmaceutical Biotechnology, 2007, 8, 77-81.	0.9	3
25	The Non-ABC Drug Transporter RLIP76 (RALBP-1) Plays a Major Role in the Mechanisms of Drug Resistance. Current Drug Metabolism, 2007, 8, 315-323.	0.7	46
26	Epithelial Organic Cation Transporters Ensure pH-Dependent Drug Absorption in the Airway. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 53-60.	1.4	104
27	Chemogenomics of Sensitivity and Resistance to Anticancer Drugs. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 11-19.	0.3	0
28	Multidrug resistance in lymphoma: Is it time for clinical trials?. Leukemia and Lymphoma, 2007, 48, 643-644.	0.6	1
29	Towards Solid Tumor Treatment by Irreversible Electroporation: Intrinsic Redistribution of Fields and Currents in Tissue. Technology in Cancer Research and Treatment, 2007, 6, 261-273.	0.8	93
30	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12117-12122.	3.3	279
31	Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling. Clinical Cancer Research, 2007, 13, 2199-2206.	3.2	131
32	Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. Rna, 2007, 13, 890-898.	1.6	113
33	ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment. Molecular Cancer Therapeutics, 2007, 6, 979-986.	1.9	52
34	Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process. Cancer Research, 2007, 67, 1130-1137.	0.4	53
35	MÃ©canismes de rÃ©sistance Ã la chimiothÃ©rapie. , 2007, , 139-155.		0
36	Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials. Clinical Cancer Research, 2007, 13, 7059-7066.	3.2	40

#	Article	IF	Citations
37	Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Annals of Oncology, 2007, 18, v3-v8.	0.6	180
38	New inhibitors of ABCG2 identified by high-throughput screening. Molecular Cancer Therapeutics, 2007, 6, 3271-3278.	1.9	57
39	Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugsâ€"from bench to bedside. Nature Clinical Practice Rheumatology, 2007, 3, 26-34.	3.2	100
40	ABCG2/BCRP Expression Modulates <scp>d</scp>-Luciferinâ€"Based Bioluminescence Imaging. Cancer Research, 2007, 67, 9389-9397.	0.4	80
41	Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Molecular Cancer Therapeutics, 2007, 6, 1089-1098.	1.9	107
42	Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anti-Cancer Drugs, 2007, 18, 389-404.	0.7	18
43	Cancer stem cells and oncology therapeutics. Current Opinion in Oncology, 2007, 19, 61-64.	1.1	129
44	Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends in Pharmacological Sciences, 2007, 28, 128-134.	4.0	64
45	Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resistance Updates, 2007, 10, 144-151.	6.5	88
46	Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1011-1020.	1.1	13
47	Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 2698-2713.	1.4	118
48	Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochemical and Biophysical Research Communications, 2007, 361, 549-554.	1.0	59
49	The role of membrane transporters in drug delivery to brain tumors. Cancer Letters, 2007, 254, 11-29.	3.2	53
50	Cell killing by antibodyâ€"drug conjugates. Cancer Letters, 2007, 255, 232-240.	3.2	218
51	Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. Journal of Pediatric Surgery, 2007, 42, 2040-2045.	0.8	59
52	Molecularâ€"functional imaging of cancer: to image and imagine. Trends in Molecular Medicine, 2007, 13, 287-297.	3.5	73
53	Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. Psychoneuroendocrinology, 2007, 32, 1028-1040.	1.3	17
54	Self-Organizing Maps for Identification of New Inhibitors of P-Glycoprotein. Journal of Medicinal Chemistry, 2007, 50, 1698-1702.	2.9	55

#	Article	IF	Citations
55	Human ABCB6 Localizes to Both the Outer Mitochondrial Membrane and the Plasma Membrane. Biochemistry, 2007, 46, 9443-9452.	1.2	117
56	Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Review of Anticancer Therapy, 2007, 7, 1369-1378.	1.1	94
57	The P-Glycoprotein (ABCB1) Linker Domain Encodes High-Affinity Binding Sequences to Î±- and Î²-Tubulins. Biochemistry, 2007, 46, 7337-7342.	1.2	29
58	Polymeric nanovehicles for anticancer drugs with triggering release mechanisms. Journal of Materials Chemistry, 2007, 17, 3987.	6.7	181
59	Surfactantâ€“Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux. Molecular Pharmaceutics, 2007, 4, 730-738.	2.3	102
60	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology, 2007, 4, 17.	0.9	20
61	DNA damage response and development of targeted cancer treatments. Annals of Medicine, 2007, 39, 457-464.	1.5	17
62	Expression of 25 Human ABC Transporters in the Yeast Pichia pastoris and Characterization of the Purified ABCC3 ATPase Activity. Biochemistry, 2007, 46, 7992-8003.	1.2	42
63	Development of a Practical Synthesis of STA-5312, a Novel Indolizine Oxalylamide Microtubule Inhibitor. Organic Process Research and Development, 2007, 11, 246-250.	1.3	55
64	RALBP1/RLIP76 mediates multidrug resistance. International Journal of Oncology, 2007, , .	1.4	16
65	Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating Pâ€glycoprotein activity and PI3K/Akt pathway. International Journal of Cancer, 2008, 122, 1012-1018.	2.3	72
66	Production of Pâ€glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to firstâ€line chemotherapy in advanced breast cancer. International Journal of Cancer, 2008, 122, 1058-1067.	2.3	17
67	Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. Journal of Cellular Biochemistry, 2007, 102, 1117-1129.	1.2	45
68	Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes and Cancer, 2007, 46, 1069-1079.	1.5	37
69	Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes. ChemMedChem, 2007, 2, 920-942.	1.6	142
70	Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by Î²-fluorination to overcome cellular efflux by P-glycoprotein. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2697-2702.	1.0	52
71	Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5390-5395.	1.0	27
72	Effects of propolis extract on sensitivity to chemotherapeutic agents in HeLa and resistant sublines. Phytotherapy Research, 2007, 21, 841-846.	2.8	13

#	Article	IF	Citations
73	Similarity-Based Descriptors (SIBAR) as Tool for QSAR Studies on P-Glycoprotein Inhibitors: Influence of the Reference Set. QSAR and Combinatorial Science, 2007, 26, 669-678.	1.5	12
74	Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene, 2007, 26, 4749-4760.	2.6	125
75	Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene, 2007, 26, 5674-5679.	2.6	214
76	Waltzing transporters and 'the dance macabre' between humans and bacteria. Nature Reviews Drug Discovery, 2007, 6, 56-65.	21.5	163
77	ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia, 2007, 21, 1172-1176.	3.3	118
78	Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. British Journal of Cancer, 2007, 96, 918-927.	2.9	27
79	The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). British Journal of Pharmacology, 2007, 151, 163-174.	2.7	63
80	Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1469-1473.	1.4	6
81	Sipholenol A, a marineâ€derived sipholane triterpene, potently reverses Pâ€glycoprotein (ABCB1)â€mediated multidrug resistance in cancer cells. Cancer Science, 2007, 98, 1373-1380.	1.7	56
82	Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R -[11 C]verapamil. Epilepsia, 2007, 48, 1774-1784.	2.6	119
83	Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical Pharmacology, 2007, 73, 1873-1886.	2.0	88
84	C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochemical Pharmacology, 2007, 74, 41-53.	2.0	42
85	Harnessing drug resistance: Using ABC transporter proteins to target cancer cells. Biochemical Pharmacology, 2007, 74, 1677-1685.	2.0	34
86	Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochemical Pharmacology, 2007, 74, 1713-1726.	2.0	69
87	P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Experimental Hematology, 2007, 35, 1793-1800.	0.2	22
88	Drugâ€"drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1). Drug Discovery Today, 2007, 12, 833-837.	3.2	37
89	P-Glycoprotein is not present in mitochondrial membranes. Experimental Cell Research, 2007, 313, 3100-3105.	1.2	29
90	Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer. IUBMB Life, 2007, 59, 752-757.	1.5	182

#	Article	IF	Citations
91	Antibody-based targeting of the tumor vasculature. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1776, 175-192.	3.3	43
92	Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Archives of Toxicology, 2007, 81, 553-563.	1.9	51
93	Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. Journal of Neuro-Oncology, 2007, 85, 1-10.	1.4	15
94	A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Investigational New Drugs, 2007, 25, 313-326.	1.2	89
95	Molecular basis of antifolate resistance. Cancer and Metastasis Reviews, 2007, 26, 153-181.	2.7	304
96	Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 81-87.	1.4	27
97	Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status. Journal of Cancer Research and Clinical Oncology, 2007, 133, 957-967.	1.2	8
98	Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria. Pharmaceutical Research, 2008, 25, 1469-1483.	1.7	453
99	Doxorubicin Loaded pH-sensitive Micelle: Antitumoral Efficacy against Ovarian A2780/DOXR Tumor. Pharmaceutical Research, 2008, 25, 2074-82.	1.7	112
100	An overview of cancer multidrug resistance: a still unsolved problem. Cellular and Molecular Life Sciences, 2008, 65, 3145-3167.	2.4	375
101	A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemotherapy and Pharmacology, 2008, 61, 953-963.	1.1	27
102	Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemotherapy and Pharmacology, 2008, 62, 867-873.	1.1	119
103	Drug delivery to brain tumors. Current Neurology and Neuroscience Reports, 2008, 8, 235-241.	2.0	75
104	Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. Journal of Cancer Research and Clinical Oncology, 2008, 134, 597-607.	1.2	80
105	Genotyping panel for assessing response to cancer chemotherapy. BMC Medical Genomics, 2008, 1, 24.	0.7	24
106	Phenylnannolones Aâ€“C: Biosynthesis of New Secondary Metabolites from the Myxobacterium Nannocystis exedens. ChemBioChem, 2008, 9, 2997-3003.	1.3	18
107	Recent advances in the development of novel antiâ€cancer drugs targeting cancer stem/progenitor cells. Drug Development Research, 2008, 69, 415-430.	1.4	17
108	Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leukemia Research, 2008, 32, 465-473.	0.4	29

#	Article	IF	Citations
109	Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorganic and Medicinal Chemistry, 2008, 16, 171-180.	1.4	85
110	Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells. Bioorganic and Medicinal Chemistry, 2008, 16, 9323-9330.	1.4	30
111	Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells. Bioorganic and Medicinal Chemistry, 2008, 16, 9745-9756.	1.4	16
112	Synthesis and biological evaluation of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer. Chinese Chemical Letters, 2008, 19, 169-171.	4.8	8
113	Cytotoxic effects and in vitro reversal of multidrug resistance by therapeutic ultrasound in human hepatocarcinoma cell line (HepG2). Ultrasonics, 2008, 48, 297-302.	2.1	12
114	l-Histidine-based pH-sensitive anticancer drug carrier micelle: Reconstitution and brief evaluation of its systemic toxicity. International Journal of Pharmaceutics, 2008, 358, 177-183.	2.6	62
115	Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Molecular Cancer Therapeutics, 2008, 7, 2152-2159.	1.9	580
116	Optimization of Ultrasound-Mediated In Vitro Reversal of Multidrug Resistance in Human Hepatocarcinoma Cell Line HepG2. Ultrasound in Medicine and Biology, 2008, 34, 1697-1702.	0.7	5
117	Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochemistry (Moscow), 2008, 73, 29-37.	0.7	30
118	Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Moscow), 2008, 73, 592-604.	0.7	97
119	Resistance to chemotherapy: new treatments and novel insights into an old problem. British Journal of Cancer, 2008, 99, 387-391.	2.9	239
120	Taxanes, microtubules and chemoresistant breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 96-132.	3.3	313
121	Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein). European Journal of Pharmaceutical Sciences, 2008, 35, 293-306.	1.9	70
122	The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADMEâ€“Tox). Drug Discovery Today, 2008, 13, 379-393.	3.2	482
123	Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. Journal of Controlled Release, 2008, 130, 98-106.	4.8	1,091
124	Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. Journal of Controlled Release, 2008, 129, 228-236.	4.8	376
125	Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. Journal of Controlled Release, 2008, 131, 220-227.	4.8	85
126	Caveolin-1: A tumor-promoting role in human cancer. International Journal of Radiation Biology, 2008, 84, 177-189.	1.0	110

#	Article	IF	Citations
127	Design of a Tumor-Homing Cell-Penetrating Peptide. Bioconjugate Chemistry, 2008, 19, 70-75.	1.8	124
128	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 2008, 38, 802-832.	0.5	499
129	High-Throughput Flow Cytometry to Detect Selective Inhibitors of ABCB1, ABCC1, and ABCG2 Transporters. Assay and Drug Development Technologies, 2008, 6, 263-276.	0.6	67
130	Central Metal Determines Pharmacokinetics of Chlorophyll-Derived Xenobiotics. Journal of Medicinal Chemistry, 2008, 51, 4412-4418.	2.9	34
131	Conjugation of Poly-l-lysine to Bacterial Cytosine Deaminase Improves the Efficacy of Enzyme/Prodrug Cancer Therapy. Journal of Medicinal Chemistry, 2008, 51, 3572-3582.	2.9	17
132	Chapter 4 Molecular Mechanisms of Adaptation to Folate Deficiency. Vitamins and Hormones, 2008, 79, 99-143.	0.7	48
133	Development of inhibitors of ATP-binding cassette drug transporters â€“ present status and challenges. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 205-223.	1.5	225
134	Overexpression of Cell Surface Cytokeratin 8 in Multidrug-Resistant MCF-7/MX Cells Enhances Cell Adhesion to the Extracellular Matrix. Neoplasia, 2008, 10, 1275-1284.	2.3	35
135	Drugs That Modulate Resistance to Antitumor Agents. , 2008, , 387-416.		2
136	Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Life Sciences, 2008, 83, 496-501.	2.0	20
137	Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. Life Sciences, 2008, 83, 700-708.	2.0	16
138	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. Journal of Molecular Biology, 2008, 383, 281-291.	2.0	230
139	ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 2008, 9, 105-127.	0.6	854
140	Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treatment Reviews, 2008, 34, 505-520.	3.4	100
141	Bypassing cancer drug resistance by activating multiple death pathways â€“ A proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Letters, 2008, 259, 127-137.	3.2	73
142	Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resistance Updates, 2008, 11, 51-60.	6.5	29
143	Resistance against novel anticancer metal compounds: Differences and similarities. Drug Resistance Updates, 2008, 11, 1-16.	6.5	201
144	Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochemical and Biophysical Research Communications, 2008, 369, 363-368.	1.0	31

#	Article	IF	Citations
145	Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews, 2008, 34, 592-602.	3.4	381
146	Recent Advances on the Molecular Mechanisms Involved in the Drug Resistance of Cancer Cells and Novel Targeting Therapies. Clinical Pharmacology and Therapeutics, 2008, 83, 673-691.	2.3	157
147	The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology, 2008, 48, 495-535.	4.2	415
148	In silicoprediction of substrate properties for ABC-multidrug transporters. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1167-1180.	1.5	44
149	Discovery of a new series of jatrophane and lathyrane diterpenes as potent and specific P-glycoprotein modulators. Organic and Biomolecular Chemistry, 2008, 6, 1756.	1.5	53
150	Simultaneous optical and fluorescent microscopic measurement of drug retention in single cancer cells. , 2008, , .		1
151	Efflux Transporters: Newly Appreciated Roles in Protection against Pollutants. Environmental Science & Technology, 2008, 42, 3914-3920.	4.6	152
152	ATP Occlusion by P-Glycoprotein as a Surrogate Measure for Drug Coupling. Biochemistry, 2008, 47, 3294-3307.	1.2	15
153	Aptamer-Based SERRS Sensor for Thrombin Detection. Nano Letters, 2008, 8, 4386-4390.	4.5	185
154	Interaction of the P-Glycoprotein Multidrug Efflux Pump with Cholesterol: Effects on ATPase Activity, Drug Binding and Transport. Biochemistry, 2008, 47, 13686-13698.	1.2	102
155	Multidrug Resistance-Associated Proteinâ€“Overexpressing Teniposide-Resistant Human Lymphomas Undergo Apoptosis by a Tubulin-Binding Agent. Cancer Research, 2008, 68, 1495-1503.	0.4	31
156	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Bloodâ€“Brain Barrier Studied with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2008, 49, 1328-1335.	2.8	104
157	The Effects of ABCB1 3â€²-Untranslated Region Variants on mRNA Stability. Drug Metabolism and Disposition, 2008, 36, 10-15.	1.7	16
158	Image-Guided Enzyme/Prodrug Cancer Therapy. Clinical Cancer Research, 2008, 14, 515-522.	3.2	41
159	Effects of the High-Affinity Peptide Reversin 121 on Multidrug Resistance Proteins in Experimental Pancreatic Cancer. Tumor Biology, 2008, 29, 351-358.	0.8	7
160	Epothilones in breast cancer: current status and future directions. Expert Review of Anticancer Therapy, 2008, 8, 1299-1311.	1.1	8
161	Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research, 2008, 14, 7900-7908.	3.2	44
162	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Molecular Cancer Therapeutics, 2008, 7, 3081-3091.	1.9	151

#	Article	IF	Citations
163	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer. Cancer Research, 2008, 68, 5380-5389.	0.4	102
164	Psorospermin structural requirements for P-glycoprotein resistance reversal. Molecular Cancer Therapeutics, 2008, 7, 3617-3623.	1.9	5
165	Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. Journal of Leukocyte Biology, 2008, 84, 561-576.	1.5	12
166	Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Molecular Cancer Therapeutics, 2008, 7, 2377-2385.	1.9	28
167	99mTc-MIBI in the Evaluation of Breast Cancer Biology. , 2008, , 71-81.		0
168	Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development. Current Medicinal Chemistry, 2008, 15, 1981-2039.	1.2	330
169	Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryotic Cell, 2008, 7, 747-764.	3.4	238
170	Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation. Molecular Pharmacology, 2008, 74, 807-822.	1.0	54
171	MRP7/ABCC10expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Molecular Cancer Therapeutics, 2008, 7, 1150-1155.	1.9	75
172	Characterization of a side population of astrocytoma cells in response to temozolomide. Journal of Neurosurgery, 2008, 109, 856-866.	0.9	71
173	ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opinion on Therapeutic Targets, 2008, 12, 491-504.	1.5	29
174	Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells. Cancer Research, 2008, 68, 2349-2357.	0.4	79
175	Complete In Vivo Reversal of the Multidrug Resistance Phenotype by Jet-injection of Anti-MDR1 Short Hairpin RNA-encoding Plasmid DNA. Molecular Therapy, 2008, 16, 178-186.	3.7	60
176	Reversal of P-Glycoprotein and Multidrug Resistance-Associated Protein 1 Mediated Multidrug Resistance in Cancer Cells by HZ08 Isomers, Tetrataisohydroquinolin Derivatives. Biological and Pharmaceutical Bulletin, 2008, 31, 1258-1264.	0.6	28
177	Molecular basis of bortezomib resistance: proteasome subunit Î²5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112, 2489-2499.	0.6	406
178	An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiatric Disease and Treatment, 2008, 4, 1073.	1.0	9
179	Mining Potential Functionally Significant Polymorphisms at the ATP-Binding- Cassette Transporter Genes. Current Pharmacogenomics and Personalized Medicine, 2009, 7, 40-58.	0.2	7
180	A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer Chemotherapy. PLoS ONE, 2009, 4, e5676.	1.1	41

#	Article	IF	Citations
181	NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance. PLoS ONE, 2009, 4, e7415.	1.1	40
182	HIGHLIGHTING RELATIONSHIPS BETWEEN HETEROGENEOUS BIOLOGICAL DATA THROUGH GRAPHICAL DISPLAYS BASED ON REGULARIZED CANONICAL CORRELATION ANALYSIS. Journal of Biological Systems, 2009, 17, 173-199.	0.5	47
183	Meayamycin inhibits preâ€“messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Molecular Cancer Therapeutics, 2009, 8, 2308-2318.	1.9	90
184	Identification of Inhibitors of ABCG2 by a Bioluminescence Imagingâ€“Based High-Throughput Assay. Cancer Research, 2009, 69, 5867-5875.	0.4	44
185	Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance. Current Pharmaceutical Design, 2009, 15, 1844-1853.	0.9	45
186	Reversal of P-glycoproteinâ€“Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3. Cancer Research, 2009, 69, 416-421.	0.4	89
187	Chemistry and Biology of Landomycins, an Expanding Family of Polyketide Natural Products. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1040-1051.	1.1	31
188	Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?. Current Cancer Drug Targets, 2009, 9, 252-272.	0.8	44
189	The Reversal of Drug-Resistance in Tumors Using a Drug-Carrying Nanoparticular System. International Journal of Molecular Sciences, 2009, 10, 3776-3792.	1.8	42
190	YQ36: A Novel Bisindolylmaleimide Analogue Induces KB/VCR Cell Death. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-11.	3.0	1
191	Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions. PLoS Pathogens, 2009, 5, e1000673.	2.1	135
192	A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance. Assay and Drug Development Technologies, 2009, 7, 233-249.	0.6	53
193	Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter. American Journal of Physiology - Cell Physiology, 2009, 296, C1086-C1097.	2.1	9
194	Nuclear receptor-like transcription factors in fungi. Genes and Development, 2009, 23, 419-432.	2.7	43
195	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer. Cancer Research, 2009, 69, 6396-6404.	0.4	88
196	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics, 2009, 8, 2057-2066.	1.9	41
197	Therapeutic potential of RNA interference in drug-resistant cancers. Future Oncology, 2009, 5, 169-185.	1.1	24
198	Influence of Melanosome Dynamics on Melanoma Drug Sensitivity. Journal of the National Cancer Institute, 2009, 101, 1259-1271.	3.0	79

#	Article	IF	Citations
199	RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Reviews in Molecular Medicine, 2009, 11, e15.	1.6	6
200	A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Bloodâ€“Brain Barrier with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2009, 50, 1954-1961.	2.8	99
201	ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome. Molecular Cancer Research, 2009, 7, 79-87.	1.5	114
202	Drug interactions at the blood-brain barrier: Fact or fantasy?â˜†. , 2009, 123, 80-104.		173
203	Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. Journal of Controlled Release, 2009, 136, 21-29.	4.8	297
204	Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer, 2009, 9, 399.	1.1	139
205	Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 266-280.	3.3	28
206	Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines. Experimental Hematology, 2009, 37, 1284-1294.	0.2	19
207	Mathematical modeling as a tool for planning anticancer therapy. European Journal of Pharmacology, 2009, 625, 108-121.	1.7	97
208	Breast cancer resistance protein (BCRP/ABCG2): New inhibitors and QSAR studies by a 3D linear solvation energy approach. European Journal of Pharmaceutical Sciences, 2009, 38, 39-46.	1.9	41
209	The pH sensitive probe 5â€(andâ€6)â€carboxyl seminaphthorhodafluor is a substrate for the multidrug resistanceâ€related protein MRP1. International Journal of Cancer, 2009, 124, 233-238.	2.3	8
210	Double impact on pâ€glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. International Journal of Cancer, 2010, 126, 2025-2035.	2.3	47
211	Flavonoid Dimers as Bivalent Modulators for Pâ€Glycoproteinâ€Based Multidrug Resistance: Structureâ€“Activity Relationships. ChemMedChem, 2009, 4, 594-614.	1.6	45
212	Activators of Pâ€glycoprotein: Structureâ€“Activity Relationships and Investigation of their Mode of Action. ChemMedChem, 2009, 4, 1897-1911.	1.6	33
213	Reversal of Multidrug Resistance by Methoxypolyethylene Glycol-Block-Polycaprolactone Diblock Copolymers Through the Inhibition of P-Glycoprotein Function. Journal of Pharmaceutical Sciences, 2009, 98, 945-958.	1.6	32
214	Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. Journal of Biological Inorganic Chemistry, 2009, 14, 101-109.	1.1	93
215	Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Child's Nervous System, 2009, 25, 39-45.	0.6	17
216	Synthesis and multidrug resistance reversal activity of dihydroptychantol A and its novel derivatives. Bioorganic and Medicinal Chemistry, 2009, 17, 4981-4989.	1.4	22

#	Article	IF	Citations
217	Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice. Pharmaceutical Research, 2009, 26, 480-487.	1.7	128
218	Maurocalcine as a Non Toxic Drug Carrier Overcomes Doxorubicin Resistance in the Cancer Cell Line MDA-MB 231. Pharmaceutical Research, 2009, 26, 836-845.	1.7	66
219	Jatrophane diterpenes from Euphorbia spp. as modulators of multidrug resistance in cancer therapy. Phytochemistry Reviews, 2009, 8, 431-447.	3.1	66
220	A Novel Docetaxel-Loaded Poly (Îµ-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment. Nanoscale Research Letters, 2009, 4, 1530-9.	3.1	113
221	Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemotherapy and Pharmacology, 2009, 63, 711-722.	1.1	132
222	Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 341-346.	1.1	39
223	mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatric Blood and Cancer, 2009, 53, 996-1004.	0.8	31
224	Similarity Based Descriptors â€“ Useful for Classification of Substrates of the Human Multidrug Transporter Pâ€Glycoprotein?. QSAR and Combinatorial Science, 2009, 28, 834-839.	1.5	6
225	Proteomic approaches for investigation of therapy resistance in cancer. Proteomics - Clinical Applications, 2009, 3, 883-911.	0.8	4
226	Dofequidar fumarate sensitizes cancer stemâ€like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRPâ€mediated drug export. Cancer Science, 2009, 100, 2060-2068.	1.7	73
227	Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications. Clinical Pharmacology and Therapeutics, 2009, 86, 368-377.	2.3	169
228	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Reviews Drug Discovery, 2009, 8, 806-823.	21.5	755
229	Competition between innate multidrug resistance and intracellular binding of rhodamine dyes. FEBS Journal, 2009, 276, 637-648.	2.2	8
230	Highâ€Content Analysis of Cancerâ€Cellâ€Specific Apoptosis and Inhibition of in Vivo Angiogenesis by Synthetic (â˜)â€Pironetin and Analogs. Chemical Biology and Drug Design, 2009, 74, 358-368.	1.5	31
231	Genetics of basal cell carcinoma. Australasian Journal of Dermatology, 2010, 51, 81-92.	0.4	60
232	Upregulation of stem cell genes in multidrug resistant K562 leukemia cells. Leukemia Research, 2009, 33, 1379-1385.	0.4	23
233	A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 860-871.	1.1	281
234	Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorganic and Medicinal Chemistry, 2009, 17, 2524-2535.	1.4	50

#	Article	IF	Citations
235	New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorganic and Medicinal Chemistry, 2009, 17, 6942-6951.	1.4	46
236	A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5376-5379.	1.0	17
237	Using the Golden Triangle to optimize clearance and oral absorption. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5560-5564.	1.0	244
238	Analogs of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate specificity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6102-6105.	1.0	17
239	In Vivo Near-Infrared Mediated Tumor Destruction by Photothermal Effect of Carbon Nanotubes. ACS Nano, 2009, 3, 3707-3713.	7.3	739
240	Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Bloodâ^'Brain Barrier. Journal of Medicinal Chemistry, 2009, 52, 6073-6082.	2.9	71
241	Aromatic 2-(Thio)ureidocarboxylic Acids As a New Family of Modulators of Multidrug Resistance-Associated Protein 1: Synthesis, Biological Evaluation, and Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 4586-4595.	2.9	24
242	Polymeric Carriers for Anticancer Drugs. , 2009, , 207-243.		0
243	Ins and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays. Advanced Drug Delivery Reviews, 2009, 61, 47-56.	6.6	57
244	QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Advanced Drug Delivery Reviews, 2009, 61, 34-46.	6.6	68
245	In Vivo Evaluation of Doxorubicin-Loaded Polymeric Micelles Targeting Folate Receptors and Early Endosomal pH in Drug-Resistant Ovarian Cancer. Molecular Pharmaceutics, 2009, 6, 1353-1362.	2.3	166
246	EGFR-Nrf2 pathway plays a role in cancer cell's chemoresistance. Bioscience Hypotheses, 2009, 2, 261-263.	0.2	4
247	Treatment of resistant human colon cancer xenografts by a fluoxetineâ€“doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Letters, 2009, 274, 118-125.	3.2	43
248	Naturally-occurring shikonin analogues â€“ A class of necroptotic inducers that circumvent cancer drug resistance. Cancer Letters, 2009, 274, 233-242.	3.2	113
249	The Na+/K+-ATPase is the Achilles Heel of multi-drug-resistant cancer cells. Cancer Letters, 2009, 282, 30-34.	3.2	39
250	Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells. Biochemical and Biophysical Research Communications, 2009, 380, 5-10.	1.0	17
251	PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells. Cell Stem Cell, 2009, 4, 226-235.	5.2	740
252	Is resistance useless? Multidrug resistance and collateral sensitivity. Trends in Pharmacological Sciences, 2009, 30, 546-556.	4.0	223

#	Article	IF	Citations
253	Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Toxicology in Vitro, 2009, 23, 29-36.	1.1	40
254	The ABC of dendritic cell development and function. Trends in Immunology, 2009, 30, 421-429.	2.9	37
255	P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. Archives of Biochemistry and Biophysics, 2009, 491, 53-60.	1.4	41
256	Interaction of LDS-751 with the drug-binding site of P-glycoprotein: A Trp fluorescence steady-state and lifetime study. Archives of Biochemistry and Biophysics, 2009, 492, 17-28.	1.4	14
257	ABC Efflux Pump-Based Resistance to Chemotherapy Drugs. Chemical Reviews, 2009, 109, 2989-3011.	23.0	529
258	Synthesis of the Bicyclic Welwitindolinone Core via an Alkylation/Cyclization Cascade Reaction. Organic Letters, 2009, 11, 5330-5333.	2.4	41
259	Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer, 2009, 65, 105-111.	0.9	87
260	Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Multidrug Resistance by Bivalent Apigenin Homodimers and Their Derivatives. Journal of Medicinal Chemistry, 2009, 52, 5311-5322.	2.9	76
261	ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines. Pancreatology, 2009, 9, 136-144.	0.5	75
262	Potential Molecular Therapeutic Targets in Cancer Stem/Progenitor Cells: Are ATP-Binding Cassette Membrane Transporters Appropriate Targets to Eliminate Cancer-Initiating Cells?. , 2009, , 385-421.		0
263	N,N-bis(Cyclohexanol)amine Aryl Esters: A New Class of Highly Potent Transporter-Dependent Multidrug Resistance Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 807-817.	2.9	30
264	Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics, 2009, 10, 1839-1851.	0.6	17
265	Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Science, 2009, 323, 1718-1722.	6.0	1,788
266	ABC Transporters in Saccharomyces cerevisiae and Their Interactors: New Technology Advances the Biology of the ABCC (MRP) Subfamily. Microbiology and Molecular Biology Reviews, 2009, 73, 577-593.	2.9	161
267	Rhodamine Inhibitors of P-Glycoprotein: An Amide/Thioamide â€œSwitchâ€•for ATPase Activity. Journal of Medicinal Chemistry, 2009, 52, 3328-3341.	2.9	58
268	Small-Molecule Multidrug Resistanceâ€“Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Research, 2009, 69, 6573-6580.	0.4	100
269	1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) Enhances the Cytotoxicity of Combretastatin A4 Independently of Mitogen-Activated Protein Kinase Kinase. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 326-333.	1.3	23
270	Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells. Cancer Research, 2009, 69, 8293-8301.	0.4	96

#	Article	IF	Citations
271	Involvement of Annexin A1 in Multidrug Resistance of K562/ADR Cells Identified by the Proteomic Study. OMICS A Journal of Integrative Biology, 2009, 13, 467-476.	1.0	26
272	Oligomerization of human ATP-binding cassette transporters and its potential significance in human disease. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1049-1063.	1.5	20
273	Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells. Molecular Pharmaceutics, 2009, 6, 928-939.	2.3	416
274	Molecular Characterization of Preneoplastic Lesions Provides Insight on the Development of Renal Tumors. American Journal of Pathology, 2009, 175, 1686-1698.	1.9	19
275	Synthesis, Activity, and Pharmacophore Development for Isatin-Î²-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells. Journal of Medicinal Chemistry, 2009, 52, 3191-3204.	2.9	146
276	Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell and Melanoma Research, 2009, 22, 740-749.	1.5	142
277	Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance. Neoplasia, 2009, 11, 1359-IN11.	2.3	100
278	Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia, 2009, 11, 96-101.	2.3	71
279	Identification of gene signatures involved in the mechanisms of multidrug resistance. Personalized Medicine, 2009, 6, 133-134.	0.8	0
283	Montelukast Is a Potent and Durable Inhibitor of Multidrug Resistance Protein 2-Mediated Efflux of Taxol and Saquinavir. Biological and Pharmaceutical Bulletin, 2009, 32, 2002-2009.	0.6	19
285	Interaction of Macrocyclic Lactones with the Multidrug Transporters: The Bases of the Pharmacokinetics of Lipid-Like Drugs. Current Drug Metabolism, 2009, 10, 272-288.	0.7	41
286	Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance. Current Medicinal Chemistry, 2009, 16, 1688-1703.	1.2	124
287	Intracellular Trafficking of MDR Transporters and Relevance of SNPs. Current Topics in Medicinal Chemistry, 2009, 9, 197-208.	1.0	25
288	Nuclear Factor (Erythroid-Derived 2)-Like 2 Regulates Drug Resistance in Pancreatic Cancer Cells. Pancreas, 2010, 39, 463-472.	0.5	83
289	PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein. Nuclear Medicine Communications, 2010, 31, 985-993.	0.5	12
290	The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. Oncology Letters, 2010, 1, 151-154.	0.8	11
291	Escape from stress granule sequestration: another way to drug resistance?. Biochemical Society Transactions, 2010, 38, 1537-1542.	1.6	12
292	Augmentation of Therapeutic Efficacy in Drug-Resistant Tumor Models Using Ceramide Coadministration in Temporal-Controlled Polymer-Blend Nanoparticle Delivery Systems. AAPS Journal, 2010, 12, 171-180.	2.2	51

#	Article	IF	Citations
293	Optimization of the Antitumor Activity of Sequence-specific Pyrrolobenzodiazepine Derivatives Based on their Affinity for ABC Transporters. AAPS Journal, 2010, 12, 617-627.	2.2	15
294	The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells. Journal of Pharmacy and Pharmacology, 2010, 60, 647-653.	1.2	4
295	Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resistance Updates, 2010, 13, 109-118.	6.5	313
296	Overcoming drug resistance by regulating nuclear receptors. Advanced Drug Delivery Reviews, 2010, 62, 1257-1264.	6.6	69
297	New Concepts on the Critical Functions of Cancer- and Metastasis-Initiating Cells in Treatment Resistance and Disease Relapse: Molecular Mechanisms, Signaling Transduction Elements and Novel Targeting Therapies. Cancer Metastasis - Biology and Treatment, 2010, , 175-207.	0.1	0
298	Uptake and intracellular release kinetics of liposome formulations in glioma cells. International Journal of Pharmaceutics, 2010, 395, 251-259.	2.6	43
299	Papyriferic acid derivatives as reversal agents of multidrug resistance in cancer cells. Bioorganic and Medicinal Chemistry, 2010, 18, 2964-2975.	1.4	4
300	Carbon nanotubes for in vivo cancer nanotechnology. Science China Chemistry, 2010, 53, 2217-2225.	4.2	20
301	Overcoming multidrug resistance (MDR) in cancer by nanotechnology. Science China Chemistry, 2010, 53, 2226-2232.	4.2	22
302	Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARÎ³ activation by troglitazone. Journal of Huazhong University of Science and Technology [Medical Sciences], 2010, 30, 326-331.	1.0	10
303	Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response. Medical Oncology, 2010, 27, 466-473.	1.2	7
304	Multiple Drug Resistance Mechanisms in Cancer. Molecular Biotechnology, 2010, 46, 308-316.	1.3	426
305	Effects of Single and Multiple Flavonoids on BCRP-Mediated Accumulation, Cytotoxicity and Transport of Mitoxantrone In Vitro. Pharmaceutical Research, 2010, 27, 1296-1308.	1.7	27
306	Novel Mixed Polymeric Micelles for Enhancing Delivery of Anticancer Drug and Overcoming Multidrug Resistance in Tumor Cell Lines Simultaneously. Pharmaceutical Research, 2010, 27, 1498-1511.	1.7	63
307	Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. Journal of Controlled Release, 2010, 141, 137-144.	4.8	239
308	Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. Journal of Controlled Release, 2010, 143, 290-301.	4.8	142
309	Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. Journal of Controlled Release, 2010, 148, 2-12.	4.8	248
310	Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomedicine, 2010, 17, 441-448.	2.3	58

#	Article	IF	Citations
311	Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization. European Journal of Pharmaceutical Sciences, 2010, 41, 53-59.	1.9	14
312	Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 258-267.	3.3	163
313	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochemical Pharmacology, 2010, 79, 817-824.	2.0	312
314	Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochemical Pharmacology, 2010, 80, 72-79.	2.0	28
315	Inhibition of cell growth and potentiation of tumor necrosis factor-Î± (TNF-Î±)-induced apoptosis by a phenanthroindolizidine alkaloid antofine in human colon cancer cells. Biochemical Pharmacology, 2010, 80, 1356-1364.	2.0	52
316	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2010, 80, 1497-1506.	2.0	57
317	Oxidative stress, inflammation, and cancer: How are they linked?. Free Radical Biology and Medicine, 2010, 49, 1603-1616.	1.3	3,991
318	Role of microRNA in anticancer drug resistance. International Journal of Cancer, 2010, 126, 2-10.	2.3	223
319	Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. International Journal of Cancer, 2010, 127, 555-567.	2.3	151
320	miRâ€181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. International Journal of Cancer, 2010, 127, 2520-2529.	2.3	266
321	Differential interactions between statins and Pâ€glycoprotein: Implications for exploiting statins as anticancer agents. International Journal of Cancer, 2010, 127, 2936-2948.	2.3	54
322	Bypassing Multidrug Resistance in Cancer Cells with Biodegradable Polymer Capsules. Advanced Materials, 2010, 22, 5398-5403.	11.1	85
323	Characterization, Synthesis and Selfâ€Aggregation of (â^')â€Alternarlactam: A New Fungal Cytotoxin with Cyclopentenone and Isoquinolinone Scaffolds. Chemistry - A European Journal, 2010, 16, 14479-14485.	1.7	30
324	Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer. Journal of Proteomics, 2010, 73, 1954-1973.	1.2	18
325	Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leukemia Research, 2010, 34, 487-491.	0.4	14
326	Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leukemia Research, 2010, 34, 757-762.	0.4	49
327	Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials, 2010, 31, 5634-5642.	5.7	141
328	Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: A hybrid pharmacophore approach. Bioorganic and Medicinal Chemistry, 2010, 18, 1563-1572.	1.4	120

#	Article	IF	Citations
329	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorganic and Medicinal Chemistry, 2010, 18, 5489-5497.	1.4	73
330	Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity. Bioorganic and Medicinal Chemistry, 2010, 18, 6725-6733.	1.4	42
331	Design, synthesis and evaluation of progesteroneâ€"adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3165-3168.	1.0	6
332	Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. Chinese Medicine, 2010, 5, 26.	1.6	58
333	Evaluation of ABCG2 Expression in Human Embryonic Stem Cells: Crossing the Same River Twice? Â. Stem Cells, 2010, 28, 174-176.	1.4	30
334	Euphorbiasteroid reverses Pâ€glycoproteinâ€mediated multiâ€drug resistance in human sarcoma cell line MESâ€SA/Dx5. Phytotherapy Research, 2010, 24, 1042-1046.	2.8	12
335	Differences in the expression of endogenous efflux transporters in MDR1â€transfected versus wildtype cell lines affect Pâ€glycoprotein mediated drug transport. British Journal of Pharmacology, 2010, 160, 1453-1463.	2.7	90
336	Dihydropyridines and Multidrug Resistance: Previous Attempts, Present State, and Future Trends. Chemical Biology and Drug Design, 2010, 76, 369-381.	1.5	13
337	Cloning and heterologous expression of the ovine (Ovis aries) P-glycoprotein (Mdr1) in Madin-Darby canine kidney (MDCK) cells. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 304-311.	0.6	7
338	Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. British Journal of Cancer, 2010, 102, 1636-1644.	2.9	140
339	ABC proteins in antigen translocation and viral inhibition. Nature Chemical Biology, 2010, 6, 572-580.	3.9	106
340	ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer, 2010, 10, 147-156.	12.8	920
341	Understanding transport through pharmacological barriers â€" are we there yet?. Nature Reviews Drug Discovery, 2010, 9, 897-898.	21.5	15
342	Multidrug resistanceâ€associated proteins and implications in drug development. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 115-120.	0.9	44
343	Overcoming Multidrug Resistance in Human Cancer Cells by Natural Compounds. Toxins, 2010, 2, 1207-1224.	1.5	72
344	Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line. Journal of Oncology, 2010, 2010, 1-7.	0.6	22
345	The Interaction of N-Acylhomoserine Lactone Quorum Sensing Signaling Molecules with Biological Membranes: Implications for Inter-Kingdom Signaling. PLoS ONE, 2010, 5, e13522.	1.1	76
346	Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anti-Cancer Drugs, 2010, 21, 65-76.	0.7	65

#	Article	IF	Citations
347	Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 2970-2981.	1.9	28
348	Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines. Cancer Research, 2010, 70, 9846-9854.	0.4	109
349	New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncology, 2010, 6, 527-537.	1.1	86
350	Overcoming Multidrug Resistance by RNA Interference. Methods in Molecular Biology, 2010, 596, 447-465.	0.4	16
351	N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier. Drug Metabolism and Disposition, 2010, 38, 917-922.	1.7	40
352	Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics, 2010, 11, 421-437.	0.6	16
353	Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells. Technology in Cancer Research and Treatment, 2010, 9, 77-86.	0.8	111
354	Aptamer-based surface plasmon fibre sensor for thrombin detection. , 2010, , .		7
355	Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy. Metal-Based Drugs, 2010, 2010, 1-7.	3.8	212
356	Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. Journal of Antimicrobial Chemotherapy, 2010, 65, 1672-1680.	1.3	67
357	Chemotherapy and signaling. Cancer Biology and Therapy, 2010, 10, 839-853.	1.5	88
358	Cyclin Gâ€“Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking. Molecular Cancer Therapeutics, 2010, 9, 3342-3350.	1.9	34
359	Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells. Cancer Research, 2010, 70, 7723-7733.	0.4	36
360	Multidrug Resistance Reversal Agent, NSC77037, Identified with a Cell-Based Screening Assay. Journal of Biomolecular Screening, 2010, 15, 287-296.	2.6	28
361	Human ovarian cancer stem cells. Reproduction, 2010, 140, 33-41.	1.1	90
362	High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood, 2010, 116, 1747-1754.	0.6	84
363	Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance. Cancer Research, 2010, 70, 2528-2537.	0.4	244
364	Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1477-1491.	1.5	36

#	Article	IF	Citations
365	Intrinsic Resistance to Chemotherapy in Breast Cancer. Women's Health, 2010, 6, 821-830.	0.7	25
366	Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases. Current Topics in Medicinal Chemistry, 2010, 10, 1732-1756.	1.0	26
368	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metabolism Reviews, 2010, 42, 590-611.	1.5	43
369	Multidrug Resistance in Cancer. Methods in Molecular Biology, 2010, 596, 1-14.	0.4	114
370	Molecular Mechanisms of Drug Resistance in Single-Step and Multi-Step Drug-Selected Cancer Cells. Methods in Molecular Biology, 2010, 596, 77-93.	0.4	37
371	Biocompatible Protein Nanocontainers for Controlled Drugs Release. ACS Nano, 2010, 4, 2838-2844.	7.3	68
372	Nanoparticle Technologies for Cancer Therapy. Handbook of Experimental Pharmacology, 2010, , 55-86.	0.9	262
373	Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacological Research, 2010, 61, 259-263.	3.1	74
374	TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3Î² pathway and activation of caspases. Molecular Cancer, 2010, 9, 199.	7.9	44
375	Synthesis and Uptake of Fluorescence-Labeled Combi-molecules by P-Glycoprotein-Proficient and -Deficient Uterine Sarcoma Cells MES-SA and MES-SA/DX5. Journal of Medicinal Chemistry, 2010, 53, 2104-2113.	2.9	10
376	A Novel Non-Natural Nucleoside That Influences P-Glycoprotein Activity and Mediates Drug Resistance. Biochemistry, 2010, 49, 1640-1648.	1.2	5
377	Total Synthesis and Evaluation of a Key Series of C5-Substituted Vinblastine Derivatives. Journal of the American Chemical Society, 2010, 132, 8489-8495.	6.6	61
378	Antitumor Agents 286. Design, Synthesis, and Structureâ^'Activity Relationships of 3â€²R,4â€²R-Disubstituted-2â€²,2â€²-dimethyldihydropyrano[2,3-f]chromone (DSP) Analogues as Potent Chemosensitizers to Overcome Multidrug Resistance. Journal of Medicinal Chemistry, 2010, 53, 8700-8708.	2.9	29
379	Development of an Activity Assay for Discovery of Inhibitors of Lipopolysaccharide Transport. Journal of the American Chemical Society, 2010, 132, 2518-2519.	6.6	33
380	Potent and Fully Noncompetitive Peptidomimetic Inhibitor of Multidrug Resistance P-Glycoprotein. Journal of Medicinal Chemistry, 2010, 53, 6720-6729.	2.9	26
381	Flow Cytometric Evaluation of Multidrug Resistance Proteins. Methods in Molecular Biology, 2010, 596, 123-139.	0.4	1
382	Magnetic iron oxide nanoparticles for biomedical applications. Future Medicinal Chemistry, 2010, 2, 427-449.	1.1	158
383	Overcoming multidrug-resistance in cancer: Statins offer a logical candidate. Medical Hypotheses, 2010, 74, 237-239.	0.8	11

#	Article	IF	Citations
384	Considerations concerning design and mechanism of action of a new class of anticancer dual DNA intercalators. Medical Hypotheses, 2010, 75, 627-629.	0.8	18
385	Molecular therapy in support to radiotherapy. Mutation Research - Reviews in Mutation Research, 2010, 704, 182-189.	2.4	27
386	Regulation of human dendritic cells by a novel specific nuclear factorâ€“ÎºB inhibitor, dehydroxymethylepoxyquinomicin. Human Immunology, 2010, 71, 763-770.	1.2	9
387	Structure of a human multidrug transporter in an inward-facing conformation. Journal of Structural Biology, 2010, 170, 540-547.	1.3	28
388	Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 260-268.	2.0	81
389	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. Biology of Blood and Marrow Transplantation, 2010, 16, 709-720.	2.0	34
390	Detection and characterization of side population in Ewingâ€™s sarcoma SK-ES-1 cells in vitro. Biochemical and Biophysical Research Communications, 2010, 391, 1062-1066.	1.0	38
391	Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochemical and Biophysical Research Communications, 2010, 395, 104-110.	1.0	76
392	The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells, Molecules, and Diseases, 2010, 45, 86-92.	0.6	133
394	Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line. ACS Nano, 2010, 4, 4539-4550.	7.3	817
395	Glutathione transferases and development of new principles to overcome drug resistance. Archives of Biochemistry and Biophysics, 2010, 500, 116-122.	1.4	209
396	Mechanisms of Multidrug Resistance in Cancer. Methods in Molecular Biology, 2010, 596, 47-76.	0.4	555
397	The ER-Localized TWD1 Immunophilin Is Necessary for Localization of Multidrug Resistance-Like Proteins Required for Polar Auxin Transport in Arabidopsis Roots. Plant Cell, 2010, 22, 3295-3304.	3.1	98
398	Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan. Biochemical Pharmacology, 2010, 80, 362-369.	2.0	2
399	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. NeuroImage, 2010, 49, 1406-1415.	2.1	47
400	Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells. Neoplasia, 2010, 12, 1023-IN17.	2.3	51
401	Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?. Surgical Oncology Clinics of North America, 2010, 19, 649-668.	0.6	11
402	Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer. Molecular Pharmaceutics, 2010, 7, 863-869.	2.3	143

#	Article	IF	Citations
403	Polymer-Caged Nanobins for Synergistic Cisplatinâ"Doxorubicin Combination Chemotherapy. Journal of the American Chemical Society, 2010, 132, 17130-17138.	6.6	190
404	From Taxuspine X to Structurally Simplified Taxanes with Remarkable P-Glycoprotein Inhibitory Activity. ACS Medicinal Chemistry Letters, 2010, 1, 416-421.	1.3	6
405	Ixabepilone for the treatment of breast cancer. Annals of Medicine, 2011, 43, 477-486.	1.5	10
406	Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica, 2011, 41, 320-326.	0.5	23
407	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18708-18713.	3.3	381
408	Magnetic nanobeads decorated by thermo-responsive PNIPAM shell as medical platforms for the efficient delivery of doxorubicin to tumour cells. Nanoscale, 2011, 3, 619-629.	2.8	84
409	Preparation of blood-brain barrier-permeable paclitaxel-carrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model. MedChemComm, 2011, 2, 270.	3.5	15
410	An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancer. Dalton Transactions, 2011, 40, 10873.	1.6	21
411	Combination Drug Delivery Strategy for the Treatment of Multidrug Resistant Ovarian Cancer. Molecular Pharmaceutics, 2011, 8, 260-269.	2.3	46
412	A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice. Pharmacological Reviews, 2011, 63, 390-410.	7.1	108
413	Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity. ACS Medicinal Chemistry Letters, 2011, 2, 494-497.	1.3	63
414	The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes. Journal of Natural Products, 2011, 74, 567-573.	1.5	36
415	Peptide-Chlorambucil Conjugates Combat Pgp-Dependent Drug Efflux. ACS Medicinal Chemistry Letters, 2011, 2, 419-423.	1.3	21
416	microRNAs, an active and versatile group in cancers. International Journal of Oral Science, 2011, 3, 165-175.	3.6	62
417	Controlled Intracellular Release of Doxorubicin in Multidrug-Resistant Cancer Cells by Tuning the Shell-Pore Sizes of Mesoporous Silica Nanoparticles. ACS Nano, 2011, 5, 9788-9798.	7.3	353
418	Amonafide: a potential role in treating acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2011, 20, 995-1003.	1.9	21
419	The P-glycoprotein multidrug transporter. Essays in Biochemistry, 2011, 50, 161-178.	2.1	403
420	Thiolated chitosans: influence of various sulfhydryl ligands on permeation-enhancing and P-gp inhibitory properties. Drug Development and Industrial Pharmacy, 2011, 37, 648-655.	0.9	34

#	Article	IF	Citations
422	Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 623-642.	1.5	108
423	A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil. Clinical Pharmacokinetics, 2011, 50, 111-120.	1.6	31
424	The multidrug transporter Pdr5: a molecular diode?. Biological Chemistry, 2011, 392, 53-60.	1.2	24
425	Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation. Current Medicinal Chemistry, 2011, 18, 3387-3401.	1.2	32
426	Multidrug Resistance Protein 4 (MRP4/ABCC4) Regulates cAMP Cellular Levels and Controls Human Leukemia Cell Proliferation and Differentiation. Journal of Biological Chemistry, 2011, 286, 6979-6988.	1.6	142
427	First characterization of fish P-glycoprotein (abcb1) substrate specificity using determinations of its ATPase activity and calcein-AM assay with PLHC-1/dox cell line. Aquatic Toxicology, 2011, 103, 53-62.	1.9	29
428	Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer Model. American Journal of Pathology, 2011, 178, 838-852.	1.9	127
429	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GAâ€“CGâ€“SVM method. Computers in Biology and Medicine, 2011, 41, 1006-1013.	3.9	32
430	Molecular modeling based approach, design synthesis and cytotoxic activity of 7-chloro-4-(2,5-dioxo-4-substitutedarylidine) piperazinoquinoline a hybrid pharmacophore, targeting EGFR, Tyrosine Kinase. Bulletin of Faculty of Pharmacy, Cairo University, 2011, 49, 59-66.	0.2	1
431	Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOX-P) in vitro. Cancer Letters, 2011, 311, 187-194.	3.2	48
432	Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine. Cancer Letters, 2011, 311, 101-112.	3.2	19
433	Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resistance Updates, 2011, 14, 150-163.	6.5	415
434	The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resistance Updates, 2011, 14, 203-211.	6.5	60
435	Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 154-163.	1.4	34
436	Sphingolipids and expression regulation of genes in cancer. Progress in Lipid Research, 2011, 50, 104-114.	5.3	87
437	Synthesis and Evaluation of Hydrophilic Linkers for Antibodyâ€“Maytansinoid Conjugates. Journal of Medicinal Chemistry, 2011, 54, 3606-3623.	2.9	181
438	Transcription factors that mediate epithelialâ€“mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death and Disease, 2011, 2, e179-e179.	2.7	305
439	ATP-Binding Cassette Transporters Modulate Both Coelenterazine- and D-Luciferin-Based Bioluminescence Imaging. Molecular Imaging, 2011, 10, 7290.2010.00045.	0.7	13

#	Article	IF	Citations
440	Anticancer Properties of Curcumin. , 0, , .		4
441	Neoamphimedine Circumvents Metnase-Enhanced DNA Topoisomerase IIÎ± Activity Through ATP-Competitive Inhibition. Marine Drugs, 2011, 9, 2397-2408.	2.2	19
442	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Frontiers in Bioscience - Landmark, 2011, 16, 368.	3.0	49
443	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. , 0, , .		0
444	Piceatannol, an Antitumor Compound from Euphorbia lagascae Seeds. , 2011, , 453-460.		0
445	Targeted Therapy in Head and Neck Cancer. Tumori, 2011, 97, 137-141.	0.6	10
446	Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells. PLoS ONE, 2011, 6, e17981.	1.1	18
447	The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter. PLoS ONE, 2011, 6, e19329.	1.1	71
448	Strain- and Sex-Dependent Circadian Changes in Abcc2 Transporter Expression: Implications for Irinotecan Chronotolerance in Mouse Ileum. PLoS ONE, 2011, 6, e20393.	1.1	36
449	A Gene Optimization Strategy that Enhances Production of Fully Functional P-Glycoprotein in Pichia pastoris. PLoS ONE, 2011, 6, e22577.	1.1	92
450	The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment. Current Drug Metabolism, 2011, 12, 975-984.	0.7	19
451	Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer. Current Pharmaceutical Biotechnology, 2011, 12, 686-692.	0.9	62
452	PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo. Current Drug Metabolism, 2011, 12, 774-792.	0.7	59
453	Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments. Current Drug Metabolism, 2011, 12, 793-807.	0.7	25
454	Gene Silencing with siRNA Encapsulated Nanoparticles to Overcome Tumor Multidrug Resistance. , 2011, , 298-314.		0
455	The controversial role of ABC transporters in clinical oncology. Essays in Biochemistry, 2011, 50, 209-232.	2.1	185
456	A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. International Journal of Nanomedicine, 2011, 6, 2123.	3.3	23
457	Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 609-620.	0.9	150

#	Article	IF	Citations
458	Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer. Cancer Science, 2011, 102, 130-136.	1.7	2
459	Secondary mutations of BRCA1/2 and drug resistance. Cancer Science, 2011, 102, 663-669.	1.7	113
460	Side population cells isolated from human osteosarcoma are enriched with tumorâ€initiating cells. Cancer Science, 2011, 102, 1774-1781.	1.7	49
461	3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells. Cell Proliferation, 2011, 44, 401-409.	2.4	19
462	Brain metastases as preventive and therapeutic targets. Nature Reviews Cancer, 2011, 11, 352-363.	12.8	308
463	Effect of cholesterol on the functional activity of proteins responsible for the resistance of human lymphocytes to xenobiotics. Biophysics (Russian Federation), 2011, 56, 436-443.	0.2	1
464	Prediction of nonsmall cell lung cancer sensitivity to cisplastin and paclitaxel based on marker gene expression. Molecular Biology, 2011, 45, 600-607.	0.4	2
465	Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. Journal of Controlled Release, 2011, 152, 76-83.	4.8	254
466	Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma. Oral Oncology, 2011, 47, 1134-1140.	0.8	14
467	Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain. European Journal of Medicinal Chemistry, 2011, 46, 4078-4088.	2.6	50
468	One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3â€²,4â€²,5â€²-trimethoxybenzoyl)thiazole: A unique, highly active antimicrotubule agent. European Journal of Medicinal Chemistry, 2011, 46, 6015-6024.	2.6	32
469	In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochemical Pharmacology, 2011, 82, 1562-1571.	2.0	17
470	H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochemical Pharmacology, 2011, 82, 1593-1603.	2.0	42
471	N,N-Bis(cyclohexanol)amine aryl esters inhibit P-glycoprotein as transport substrates. Biochemical Pharmacology, 2011, 82, 1822-1831.	2.0	6
472	Membrane-active host defense peptides â€“ Challenges and perspectives for the development of novel anticancer drugs. Chemistry and Physics of Lipids, 2011, 164, 766-781.	1.5	359
473	Synthesis and Structureâ€“Activity Evaluation of Isatin-Î²-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-Glycoprotein. Journal of Medicinal Chemistry, 2011, 54, 5878-5889.	2.9	101
474	Cyclophosphamide Perturbs Cytosine Methylation in Jurkat-T Cells through LSD1-Mediated Stabilization of DNMT1 Protein. Chemical Research in Toxicology, 2011, 24, 2040-2043.	1.7	27
475	Gut bitter taste receptor signalling induces ABCB1 through a mechanism involving CCK. Biochemical Journal, 2011, 438, 33-37.	1.7	105

#	Article	IF	Citations
476	Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer. Frontiers of Medicine, 2011, 5, 379-387.	1.5	45
477	ATP binding cassette systems: structures, mechanisms, and functions. Open Life Sciences, 2011, 6, 785-801.	0.6	25
478	Cancer Cell Invasion: Treatment and Monitoring Opportunities in Nanomedicine. Advanced Drug Delivery Reviews, 2011, 63, 582-596.	6.6	118
479	Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells. Clinical and Experimental Metastasis, 2011, 28, 75-90.	1.7	63
480	Paclitaxel-Loaded Poly(n-butylcyanoacrylate) Nanoparticle Delivery System to Overcome Multidrug Resistance in Ovarian Cancer. Pharmaceutical Research, 2011, 28, 897-906.	1.7	48
481	Regulation of miR-19 to Breast Cancer Chemoresistance Through Targeting PTEN. Pharmaceutical Research, 2011, 28, 3091-3100.	1.7	114
482	Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Human Genetics, 2011, 130, 93-101.	1.8	13
483	H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemotherapy and Pharmacology, 2011, 67, 1017-1025.	1.1	40
484	Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology, 2011, 68, 603-610.	1.1	48
485	Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 383, 1-11.	1.4	18
486	Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cellular Oncology (Dordrecht), 2011, 34, 33-44.	2.1	34
487	Cancer stem cells and cancer therapy. Tumor Biology, 2011, 32, 425-440.	0.8	124
488	Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Delivery and Translational Research, 2011, 1, 420-428.	3.0	39
489	MicroRNAs and drug modulation in cancer: an intertwined new story. Frontiers in Biology, 2011, 6, 351-356.	0.7	1
490	In Silico Quantitative Structure-Activity Relationship Studies on P-gp Modulators of Tetrahydroisoquinoline-Ethyl-Phenylamine Series. BMC Structural Biology, 2011, 11, 5.	2.3	20
491	Co-cultivation of murine BMDCs with 67NR mouse mammary carcinoma cells give rise to highly drug resistant cells. Cancer Cell International, 2011, 11, 21.	1.8	32
492	Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. Journal of Ovarian Research, 2011, 4, 21.	1.3	61
493	Paclitaxel-Loaded Polymer Nanoparticles for the Reversal of Multidrug Resistance in Breast Cancer Cells. Advanced Functional Materials, 2011, 21, 4211-4218.	7.8	46

#	Article	IF	Citations
494	Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers. Advanced Materials, 2011, 23, H217-47.	11.1	432
495	Mammalian plasma membrane proteins as potential biomarkers and drug targets. Electrophoresis, 2011, 32, 1549-1564.	1.3	43
496	The two faces of FBW7 in cancer drug resistance. BioEssays, 2011, 33, 851-859.	1.2	39
497	Design and Synthesis of Selenazoleâ€Containing Peptides for Cocrystallization with Pâ€Glycoprotein. ChemBioChem, 2011, 12, 868-873.	1.3	20
498	Synonymous codon usage of the VP2 gene of a very virulent infectious bursal disease virus isolate serial passaged in chicken embryos. BioSystems, 2011, 104, 42-47.	0.9	4
499	The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials, 2011, 32, 3285-3302.	5.7	142
500	Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials, 2011, 32, 5148-5157.	5.7	157
501	Ultrasound Reverses Multidrug Resistance in Human Cancer Cells by Altering Gene Expression of ABC Transporter Proteins and Bax Protein. Ultrasound in Medicine and Biology, 2011, 37, 151-159.	0.7	33
502	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. Journal of the National Cancer Institute, 2011, 103, 1236-1251.	3.0	113
503	Epothilones in the treatment of ovarian cancer. Future Oncology, 2011, 7, 559-568.	1.1	15
504	Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1). Current Medicinal Chemistry, 2011, 18, 439-481.	1.2	120
505	Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy. Mini-Reviews in Medicinal Chemistry, 2011, 11, 611-624.	1.1	15
506	Doxorubicin induces drug efflux pumps inCandida albicans. Medical Mycology, 2011, 49, 132-142.	0.3	20
507	Pancreatic cancer: understanding and overcoming chemoresistance. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 27-33.	8.2	303
508	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research, 2011, 71, 3029-3041.	0.4	157
509	Long-Chain Polyunsaturated Fatty Acids Promote Paclitaxel Cytotoxicity via Inhibition of the MDR1 Gene in the Human Colon Cancer Caco-2 Cell Line. Journal of the American College of Nutrition, 2011, 30, 265-273.	1.1	60
510	Roles of Sildenafil in Enhancing Drug Sensitivity in Cancer. Cancer Research, 2011, 71, 3735-3738.	0.4	57
511	Treatment Resistance Mechanisms of Malignant Glioma Tumor Stem Cells. Cancers, 2011, 3, 621-635.	1.7	23

#	Article	IF	Citations
512	Mechanisms and Therapeutic Implications of Cell Death Induction by Indole Compounds. Cancers, 2011, 3, 2955-2974.	1.7	39
513	Reversal of Multidrug Resistance by Guggulsterone in Drug-Resistant MCF-7 Cell Lines. Chemotherapy, 2011, 57, 62-70.	0.8	22
514	Overcoming of P-glycoprotein-mediated multidrug resistance in K562/A02 cells using riccardin F and pakyonol, bisbibenzyl derivatives from liverworts. BioScience Trends, 2011, 5, 192-197.	1.1	12
515	Forced Expression of Heat Shock Protein 27 (Hsp27) Reverses P-Glycoprotein (ABCB1)-mediated Drug Efflux and MDR1 Gene Expression in Adriamycin-resistant Human Breast Cancer Cells. Journal of Biological Chemistry, 2011, 286, 33289-33300.	1.6	69
516	The choreography of multidrug export. Biochemical Society Transactions, 2011, 39, 807-811.	1.6	11
517	Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata. Pharmaceuticals, 2011, 4, 169-186.	1.7	48
518	Co-operative Membrane Disruption Between Cell-penetrating Peptide and Cargo: Implications for the Therapeutic Use of the Bcl-2 Converter Peptide D-NuBCP-9-r8. Molecular Therapy, 2011, 19, 2124-2132.	3.7	20
519	Amelioration of Doxorubicin-Induced Cardiotoxicity by an Anticancer-Antioxidant Dual-Function Compound, HO-3867. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 350-357.	1.3	43
520	Imaging beyond the diagnosis: image-guided enzyme/prodrug cancer therapy. Acta Biochimica Et Biophysica Sinica, 2011, 43, 4-12.	0.9	4
521	Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. British Journal of Cancer, 2011, 105, 513-522.	2.9	14
522	Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 570-594.	0.9	185
523	Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research, 2011, 17, 6553-6562.	3.2	50
524	Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma. Cancers, 2011, 3, 106-125.	1.7	39
525	miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochemical Journal, 2012, 446, 291-300.	1.7	79
526	MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?. International Journal of Molecular Sciences, 2012, 13, 840-865.	1.8	29
527	Enhancement of Drug Resistance by Lysophosphatidic Acid Receptor-3 in Mouse Mammary Tumor FM3A Cells. Journal of Toxicologic Pathology, 2012, 25, 225-228.	0.3	7
528	PPAR Medicines and Human Disease: The ABCs of It All. PPAR Research, 2012, 2012, 1-16.	1.1	19
529	Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol. Cancer Prevention Research, 2012, 5, 1053-1060.	0.7	12

#	Article	IF	Citations
530	Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biology, 2012, 2, 120066.	1.5	169
531	Chemotherapy with cytotoxic and cytostatic agents in brain cancer. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 229-254.	1.0	9
532	TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens. Molecular Cancer Therapeutics, 2012, 11, 700-709.	1.9	66
533	Cardiotonic Steroids-Mediated Targeting of the Na+/K+-ATPase to Combat Chemoresistant Cancers. Current Medicinal Chemistry, 2012, 19, 627-646.	1.2	86
534	Emerging nanodelivery strategies of RNAi molecules for colon cancer therapy: preclinical developments. Therapeutic Delivery, 2012, 3, 1117-1130.	1.2	6
535	Advances in Cancer Stem Cell Biology. , 2012, , .		3
536	Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death and Disease, 2012, 3, e293-e293.	2.7	77
537	Doxorubicin and chloroquine coencapsulated liposomes: preparation and improved cytotoxicity on human breast cancer cells. Journal of Liposome Research, 2012, 22, 245-253.	1.5	20
538	Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients. PLoS ONE, 2012, 7, e38150.	1.1	47
539	ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Frontiers in Oncology, 2012, 2, 178.	1.3	34
540	Pharmacological and Toxicological Advances in PPAR-Related Medicines. PPAR Research, 2012, 2012, 1-2.	1.1	3
541	Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells. Journal of Extracellular Vesicles, 2012, 1, .	5.5	108
542	Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. ISRN Oncology, 2012, 2012, 1-21.	2.1	464
543	Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA. Molecular Pharmacology, 2012, 81, 527-540.	1.0	53
544	Colon Adenocarcinoma Multidrug Resistance Reverted by Euphorbia Diterpenes: Structure-Activity Relationships and Pharmacophore Modeling. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 1015-1024.	0.9	22
545	Anticancer Effects of the Organosilicon Multidrug Resistance Modulator SILA 421. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 663-671.	0.9	3
546	Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Anti-Cancer Drugs, 2012, 23, 865-873.	0.7	23
547	Genomics and Cancer Drug Resistance. Current Pharmaceutical Biotechnology, 2012, 13, 651-673.	0.9	39

#	Article	IF	Citations
548	Role of ABC transporters in cancer chemotherapy. Chinese Journal of Cancer, 2012, 31, 51-57.	4.9	103
549	Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy. Oncology Letters, 2012, 3, 525-529.	0.8	7
550	Physiology and Pathophysiology of the Blood-Brain Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery. Journal of Investigative Medicine, 2012, 60, 1131-1140.	0.7	34
551	Î³-secretase inhibition combined with cisplatin enhances apoptosis of nasopharyngeal carcinoma cells. Experimental and Therapeutic Medicine, 2012, 3, 357-361.	0.8	21
552	ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. European Journal of Cancer, 2012, 48, 3186-3197.	1.3	79
553	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular Cancer Therapeutics, 2012, 11, 2033-2044.	1.9	81
554	Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opinion on Drug Delivery, 2012, 9, 567-583.	2.4	39
555	ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. Nature Genetics, 2012, 44, 170-173.	9.4	127
556	HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1. Cancer Research, 2012, 72, 4204-4213.	0.4	12
557	Preparation, characterization and cytotoxicity of carbon nanotubeâ€“chitosanâ€“phycocyanin complex. Nanotechnology, 2012, 23, 035101.	1.3	32
559	Investigational ABC transporter inhibitors. Expert Opinion on Investigational Drugs, 2012, 21, 657-666.	1.9	100
560	Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 597-606.	1.5	28
561	New Ruthenium(II)â€“Letrozole Complexes as Anticancer Therapeutics. Journal of Medicinal Chemistry, 2012, 55, 8799-8806.	2.9	103
562	The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials, 2012, 33, 8451-8460.	5.7	105
563	Synthesis and Biological Evaluation of Colchicine B-Ring Analogues Tethered with Halogenated Benzyl Moieties. Journal of Medicinal Chemistry, 2012, 55, 11062-11066.	2.9	27
564	Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7693-7696.	1.0	21
565	Stem Cells and Cancer Stem Cells: New Insights. , 2012, , 17-31.		0
566	Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation. Molecular Pharmacology, 2012, 82, 1008-1021.	1.0	84

#	Article	IF	Citations
567	B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycinâ€resistant cell line. IUBMB Life, 2012, 64, 889-900.	1.5	22
568	Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. Journal of Gene Medicine, 2012, 14, 776-787.	1.4	26
569	Formulation and Characterization of Polyester/Polycarbonate Nanoparticles for Delivery of a Novel Microtubule Destabilizing Agent. Pharmaceutical Research, 2012, 29, 3064-3074.	1.7	18
570	P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 58-75.	1.4	153
571	Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. Journal of Pediatric Surgery, 2012, 47, 1797-1805.	0.8	43
572	Increased Accumulation and Retention of Micellar Paclitaxel inÂDrug-Sensitive and P-Glycoproteinâ€“Expressing Cell Lines Following Ultrasound Exposure. Ultrasound in Medicine and Biology, 2012, 38, 736-744.	0.7	28
573	Different Roles of TM5, TM6, and ECL3 in the Oligomerization and Function of Human ABCG2. Biochemistry, 2012, 51, 3634-3641.	1.2	10
574	The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP. Antimicrobial Agents and Chemotherapy, 2012, 56, 3535-3543.	1.4	27
575	Synthesis of calcium phosphate/GPC-mPEG hybrid porous nanospheres for drug delivery to overcome multidrug resistance in human breast cancer. Journal of Materials Chemistry, 2012, 22, 5128.	6.7	17
576	Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Molecular Pharmacology, 2012, 82, 47-58.	1.0	87
577	Hollow superparamagnetic iron oxide nanoshells as a hydrophobic anticancer drug carrier: intracelluar pH-dependent drug release and enhanced cytotoxicity. Nanoscale, 2012, 4, 5744.	2.8	65
578	Synthesis and Evaluation of (2-(4-Methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) Isomers To Reverse Multidrug Resistance in Cancer. Journal of Medicinal Chemistry, 2012, 55, 3113-3121.	2.9	42
579	Structureâ€“Activity Relationship (SAR) Study of Ethyl 2-Amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the Potential of the Lead against Multidrug Resistance in Cancer Treatment. Journal of Medicinal Chemistry, 2012, 55, 5566-5581.	2.9	41
580	PLGA Micro- and Nanoparticles Loaded Into Gelatin Scaffold for Controlled Drug Release. IEEE Nanotechnology Magazine, 2012, 11, 546-553.	1.1	20
581	New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib. Molecular Cancer Therapeutics, 2012, 11, 1693-1702.	1.9	48
582	Recent applications of multicomponent reactions in medicinal chemistry. MedChemComm, 2012, 3, 1189.	3.5	403
583	Multidrug Resistanceâ€“Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research, 2012, 18, 3197-3206.	3.2	60
584	Nontoxic concentrations of PEGylated graphene nanoribbons for selective cancer cell imaging and photothermal therapy. Journal of Materials Chemistry, 2012, 22, 20626.	6.7	195

#	Article	IF	Citations
585	Pâ€glycoprotein trafficking at the bloodâ€“brain barrier altered by peripheral inflammatory hyperalgesia. Journal of Neurochemistry, 2012, 122, 962-975.	2.1	66
586	Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. International Journal of Nanomedicine, 2012, 7, 187.	3.3	49
587	Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacologica Sinica, 2012, 33, 823-831.	2.8	101
588	Increased Expression of P-Glycoprotein and Doxorubicin Chemoresistance of Metastatic Breast Cancer Is Regulated by miR-298. American Journal of Pathology, 2012, 180, 2490-2503.	1.9	236
589	Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. Journal of Controlled Release, 2012, 162, 233-241.	4.8	83
590	In vitro effect of quercetin on human gastric carcinoma: Targeting cancer cells death and MDR. Food and Chemical Toxicology, 2012, 50, 3375-3383.	1.8	102
591	The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. Biomedicine and Pharmacotherapy, 2012, 66, 271-278.	2.5	39
592	A laccase-catalysed one-pot synthesis of aminonaphthoquinones and their anticancer activity. Bioorganic and Medicinal Chemistry, 2012, 20, 4472-4481.	1.4	70
593	Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1). Bioorganic and Medicinal Chemistry, 2012, 20, 4290-4302.	1.4	9
594	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5208-5214.	1.0	19
595	Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Letters, 2012, 315, 198-205.	3.2	83
596	Breast cancer, side population cells and ABCG2 expression. Cancer Letters, 2012, 323, 97-105.	3.2	107
597	Cell-derived microvesicles and antitumoral multidrug resistance. Comptes Rendus - Biologies, 2012, 335, 103-106.	0.1	8
598	Microparticles and their emerging role in cancer multidrug resistance. Cancer Treatment Reviews, 2012, 38, 226-234.	3.4	146
599	Drug resistance in the mouse cancer clinic. Drug Resistance Updates, 2012, 15, 81-89.	6.5	33
600	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates, 2012, 15, 70-80.	6.5	143
601	Contribution of tumoral and host solute carriers to clinical drug response. Drug Resistance Updates, 2012, 15, 5-20.	6.5	25
602	Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resistance Updates, 2012, 15, 50-61.	6.5	190

#	Article	IF	Citations
603	Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resistance Updates, 2012, 15, 98-105.	6.5	269
604	TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer, 2012, 12, 391.	1.1	80
605	1â€™-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations. BMC Complementary and Alternative Medicine, 2012, 12, 179.	3.7	24
606	Network insights on oxaliplatin antiâ€cancer mechanisms. Clinical and Translational Medicine, 2012, 1, 26.	1.7	25
607	Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncology, 2012, 8, 135-144.	1.1	21
608	Diaryl ether derivatives as anticancer agents â€“ a review. MedChemComm, 2012, 3, 1356.	3.5	59
609	The PIM kinases in hematological cancers. Expert Review of Hematology, 2012, 5, 81-96.	1.0	69
611	Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert Opinion on Drug Delivery, 2012, 9, 287-301.	2.4	42
612	Overcoming drug resistance in multi-drug resistant cancers and microorganisms. Bioengineered, 2012, 3, 262-270.	1.4	43
613	The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. Xenobiotica, 2012, 42, 1197-1205.	0.5	27
614	Amine Linked Flavonoid Dimers as Modulators for P-Glycoprotein-Based Multidrug Resistance: Structureâ€“Activity Relationship and Mechanism of Modulation. Journal of Medicinal Chemistry, 2012, 55, 1999-2014.	2.9	67
615	Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. Journal of Drug Targeting, 2012, 20, 736-763.	2.1	99
616	Multifunctional Biodegradable Polyacrylamide Nanocarriers for Cancer Theranosticsâ€”A â€œSee and Treatâ€•Strategy. ACS Nano, 2012, 6, 6843-6851.	7.3	109
617	Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors. Methods in Molecular Biology, 2012, 795, 1-34.	0.4	117
618	Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Delivery, 2012, 19, 363-370.	2.5	50
619	The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Archives of Biochemistry and Biophysics, 2012, 527, 67-73.	1.4	97
620	Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEGâ€“PE micelles in ovarian cancer cell spheroid model. Journal of Controlled Release, 2012, 164, 95-102.	4.8	125
621	The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase. International Journal of Biochemistry and Cell Biology, 2012, 44, 1770-1778.	1.2	34

#	Article	IF	Citations
622	A small molecule IFB07188 inhibits proliferation of human cancer cells by inducing G2/M cell cycle arrest and apoptosis. Biomedicine and Pharmacotherapy, 2012, 66, 512-518.	2.5	2
623	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 5388-5395.	1.4	70
624	Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treatment Reviews, 2012, 38, 890-903.	3.4	221
625	Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. Drug Resistance Updates, 2012, 15, 183-210.	6.5	351
626	Understanding resistance to combination chemotherapy. Drug Resistance Updates, 2012, 15, 249-257.	6.5	74
627	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. European Journal of Medicinal Chemistry, 2012, 54, 413-422.	2.6	59
628	Progesteroneâ€“adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. Steroids, 2012, 77, 1177-1191.	0.8	8
629	Photo and pH dual-responsive polydiacetylene smart nanocontainer. Materials Chemistry and Physics, 2012, 136, 219-224.	2.0	25
630	Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opinion on Drug Delivery, 2012, 9, 1443-1447.	2.4	12
631	Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance. Marine Drugs, 2012, 10, 2312-2321.	2.2	61
632	Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance. Chronobiology International, 2012, 29, 443-453.	0.9	37
633	Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert Opinion on Drug Delivery, 2012, 9, 767-781.	2.4	21
634	The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics, 2012, 13, 1257-1269.	0.6	36
635	Kinase Inhibitors. Methods in Molecular Biology, 2012, , .	0.4	2
636	Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme. PLoS ONE, 2012, 7, e33829.	1.1	25
637	Overcoming Multidrug Resistance via Photodestruction of ABCG2-Rich Extracellular Vesicles Sequestering Photosensitive Chemotherapeutics. PLoS ONE, 2012, 7, e35487.	1.1	43
638	Shifting the Paradigm: The Putative Mitochondrial Protein ABCB6 Resides in the Lysosomes of Cells and in the Plasma Membrane of Erythrocytes. PLoS ONE, 2012, 7, e37378.	1.1	82
639	Tuning the Drug Efflux Activity of an ABC Transporter in vivo by in vitro Selected DARPin Binders. PLoS ONE, 2012, 7, e37845.	1.1	20

#	Article	IF	Citations
640	Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway. PLoS ONE, 2012, 7, e40021.	1.1	99
641	Gene Silencing of FANCF Potentiates the Sensitivity to Mitoxantrone through Activation of JNK and p38 Signal Pathways in Breast Cancer Cells. PLoS ONE, 2012, 7, e44254.	1.1	28
642	A Marine Anthraquinone SZ-685C Overrides Adriamycin-Resistance in Breast Cancer Cells through Suppressing Akt Signaling. Marine Drugs, 2012, 10, 694-711.	2.2	31
643	Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chinese Journal of Cancer, 2012, 31, 100-109.	4.9	125
644	Small Molecule Drugs and Targeted Therapies for Neuroblastoma. , 0, , .		0
645	Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. International Journal of Nanomedicine, 2012, 7, 2473.	3.3	35
646	Role of Mitochondrial Translocation of Telomerase in Hepatocellular Carcinoma Cells with Multidrug Resistance. International Journal of Medical Sciences, 2012, 9, 545-554.	1.1	30
647	Structureâ€“Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein. Journal of Medicinal Chemistry, 2012, 55, 3261-3273.	2.9	99
648	Chalcogenopyrylium Compounds as Modulators of the ATP-Binding Cassette Transporters P-Glycoprotein (P-gp/ABCB1) and Multidrug Resistance Protein 1 (MRP1/ABCC1). Journal of Medicinal Chemistry, 2012, 55, 4683-4699.	2.9	39
649	The use of a glucose-reduced graphene oxide suspension for photothermal cancer therapy. Journal of Materials Chemistry, 2012, 22, 13773.	6.7	393
650	Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes and Cancer, 2012, 51, 832-840.	1.5	23
651	A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. International Journal of Cancer, 2012, 131, 2920-2928.	2.3	60
652	Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by downâ€regulating the Vâ€ATPases/mTOR/HIFâ€1Î±/Pâ€gp and MRP1 signaling pathway in vitro and in vivo. Journal of Cellular Biochemistry, 2012, 113, 2474-2487.	1.2	76
653	Impact of mutant Î²-catenin on ABCB1 expression and therapy response in colon cancer cells. British Journal of Cancer, 2012, 106, 1395-1405.	2.9	18
654	6â€Halogenochromones Bearing Tryptamine: Oneâ€Step Access to Potent and Highly Selective Inhibitors of Breast Cancer Resistance Protein. ChemMedChem, 2012, 7, 1177-1180.	1.6	13
655	Synthesis and Evaluation of 1,5-Disubstituted Tetrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative and Antitumor Activity. Journal of Medicinal Chemistry, 2012, 55, 475-488.	2.9	109
656	Drug Transporters in Drug Efficacy and Toxicity. Annual Review of Pharmacology and Toxicology, 2012, 52, 249-273.	4.2	308
657	Sorcin, a potential therapeutic target for reversing multidrug resistance in cancer. Journal of Physiology and Biochemistry, 2012, 68, 281-287.	1.3	12

#	Article	IF	Citations
658	Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. Journal of Bioenergetics and Biomembranes, 2012, 44, 31-38.	1.0	43
659	Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. Journal of Bioenergetics and Biomembranes, 2012, 44, 17-29.	1.0	112
660	The molecular interaction of a copper chelate with human P-glycoprotein. Molecular and Cellular Biochemistry, 2012, 364, 309-320.	1.4	18
661	Glycogen synthase kinase 3Î² inhibitor (2â€²Z,3â€²E)-6-bromo-indirubin-3â€²-oxime enhances drug resistance to 5-fluorouracil chemotherapy in colon cancer cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 116-123.	0.7	7
662	Chemotherapy-Resistant Metastatic Breast Cancer. Current Treatment Options in Oncology, 2012, 13, 263-275.	1.3	86
663	Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Medical Oncology, 2012, 29, 534-538.	1.2	41
664	Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 603-610.	1.2	10
665	Interactions between antidepressants and Pâ€glycoprotein at the bloodâ€“brain barrier: clinical significance of in vitro and in vivo findings. British Journal of Pharmacology, 2012, 165, 289-312.	2.7	171
666	pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation. Colloids and Surfaces B: Biointerfaces, 2012, 94, 184-191.	2.5	93
667	Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discovery Today, 2012, 17, 71-80.	3.2	569
668	Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discovery Today, 2012, 17, 343-351.	3.2	122
669	Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance. International Journal of Pharmaceutics, 2012, 422, 390-397.	2.6	48
670	Novel isoxazole polycyclic aromatic hydrocarbons as DNA-intercalating agents. European Journal of Medicinal Chemistry, 2012, 51, 163-173.	2.6	44
671	Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. European Journal of Pharmaceutical Sciences, 2012, 46, 484-491.	1.9	22
672	Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochemical Pharmacology, 2012, 83, 586-597.	2.0	111
673	Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochemical Pharmacology, 2012, 83, 1112-1126.	2.0	188
674	Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochemical Pharmacology, 2012, 83, 1340-1348.	2.0	67
675	Impact of terminal dimethylation on the resistance profile of Î±-N-heterocyclic thiosemicarbazones. Biochemical Pharmacology, 2012, 83, 1623-1633.	2.0	16

#	Article	IF	Citations
676	Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials, 2012, 33, 1536-1546.	5.7	210
677	Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials, 2012, 33, 1808-1820.	5.7	87
678	TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials, 2012, 33, 6155-6161.	5.7	182
679	Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase. Stem Cell Research, 2012, 8, 247-258.	0.3	20
680	Pharmacogenomic determination of genes associated with sensitivity or resistance of tumor cells to curcumin and curcumin derivatives. Journal of Nutritional Biochemistry, 2012, 23, 875-884.	1.9	15
681	Nanotechnology applied to overcome tumor drug resistance. Journal of Controlled Release, 2012, 162, 45-55.	4.8	278
682	Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecologic Oncology, 2012, 126, 118-123.	0.6	29
683	<scp>PDE</scp>5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (<scp>ATP</scp>â€binding Cassette <scp>C</scp>10) transporter. Cancer Science, 2012, 103, 1531-1537.	1.7	37
684	Acquisition of MDR phenotype by leukemic cells is associated with increased caspaseâ€3 activity and a collateral sensitivity to cold stress. Journal of Cellular Biochemistry, 2012, 113, 1416-1425.	1.2	8
685	Overcoming tumor multidrug resistance using drugs able to evade Pâ€glycoprotein or to exploit its expression. Medicinal Research Reviews, 2012, 32, 1220-1262.	5.0	147
686	miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Medical Oncology, 2012, 29, 384-391.	1.2	159
687	A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 149-159.	3.3	23
688	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemotherapy and Pharmacology, 2012, 69, 723-731.	1.1	185
689	Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity. Oncogene, 2013, 32, 1144-1154.	2.6	24
690	miRâ€1915 inhibits Bclâ€2 to modulate multidrug resistance by increasing drugâ€sensitivity in human colorectal carcinoma cells. Molecular Carcinogenesis, 2013, 52, 70-78.	1.3	92
691	Lysophosphatidic acid receptorâ€3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells. Molecular Carcinogenesis, 2013, 52, 247-254.	1.3	33
692	Drug resistance associates with activation of Nrf2 in <scp>MCF</scp>â€7/<scp>DOX</scp> cells, and wogonin reverses it by downâ€regulating Nrf2â€mediated cellular defense response. Molecular Carcinogenesis, 2013, 52, 824-834.	1.3	88
693	Screening of Venezuelan Medicinal Plant Extracts for Cytostatic and Cytotoxic Activity Against Tumor Cell Lines. Phytotherapy Research, 2013, 27, 530-539.	2.8	23

#	Article	IF	Citations
694	Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38, 149-157.	0.6	10
695	Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 437-449.	0.8	15
696	Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 605-617.	1.4	17
697	Organic Anion Transporting Polypeptides Expressed in Pancreatic Cancer May Serve As Potential Diagnostic Markers and Therapeutic Targets for Early Stage Adenocarcinomas. Pharmaceutical Research, 2013, 30, 2260-2269.	1.7	44
698	Delivering flavonoids into solid tumors using nanotechnologies. Expert Opinion on Drug Delivery, 2013, 10, 1411-1428.	2.4	39
699	Validation of inhibitors of an ABC transporter required to transport lipopolysaccharide to the cell surface in Escherichia coli. Bioorganic and Medicinal Chemistry, 2013, 21, 4846-4851.	1.4	40
700	ABC multidrug transporters in schistosomes and other parasitic flatworms. Parasitology International, 2013, 62, 647-653.	0.6	37
701	A Multifunctional Bichromophoric Nanoaggregate for Fluorescence Imaging and Simultaneous Photogeneration of RNOS and ROS. Chemistry - an Asian Journal, 2013, 8, 2634-2641.	1.7	18
702	Antibodyâ€“Drug Conjugate Payloads. Methods in Molecular Biology, 2013, 1045, 51-70.	0.4	55
703	Mapping the functional yeast ABC transporter interactome. Nature Chemical Biology, 2013, 9, 565-572.	3.9	93
704	Magnetic nanoparticles for cancer therapy. Nanotechnology Reviews, 2013, 2, 395-409.	2.6	77
705	Enhanced intracellular drug delivery of pH-sensitive doxorubicin/poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 307 Td (gl KB carcinoma cells. Biomaterials Science, 2013, 1, 361.	2.6	28
706	Sunitinib Reverse Multidrug Resistance in Gastric Cancer Cells by Modulating Stat3 and Inhibiting P-gp Function. Cell Biochemistry and Biophysics, 2013, 67, 575-581.	0.9	20
707	Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer. Biomaterials, 2013, 34, 6163-6174.	5.7	77
708	Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin. Journal of Gastroenterology, 2013, 48, 203-213.	2.3	14
709	miR-135a/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1. Pathology and Oncology Research, 2013, 19, 677-683.	0.9	44
710	Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines. Archives of Pharmacal Research, 2013, 36, 1392-1402.	2.7	19
711	Design of potent, non-toxic anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa. Archives of Pharmacal Research, 2013, 36, 1302-1310.	2.7	61

#	Article	IF	Citations
712	Menadione serves as a substrate for P-glycoprotein: implication in chemosensitizing activity. Archives of Pharmacal Research, 2013, 36, 509-516.	2.7	18
713	Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. Journal of Experimental and Clinical Cancer Research, 2013, 32, 48.	3.5	72
714	Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Letters, 2013, 341, 139-149.	3.2	226
715	Rationally designed nanovehicles to overcome cancer chemoresistance. Advanced Drug Delivery Reviews, 2013, 65, 1716-1730.	6.6	185
716	On-chip investigation of cellâ€“drug interactions. Advanced Drug Delivery Reviews, 2013, 65, 1556-1574.	6.6	33
717	Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. Cancer Chemotherapy and Pharmacology, 2013, 71, 1585-1590.	1.1	8
718	Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. European Journal of Medicinal Chemistry, 2013, 62, 614-631.	2.6	94
719	MicroRNAâ€106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Letters, 2013, 587, 3069-3075.	1.3	68
720	Local bystander effect induces dormancy in human medullary thyroid carcinoma model in vivo. Cancer Letters, 2013, 335, 299-305.	3.2	11
721	Polymers influencing transportability profile of drug. Saudi Pharmaceutical Journal, 2013, 21, 327-335.	1.2	24
722	Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials, 2013, 34, 2719-2730.	5.7	228
723	Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Letters, 2013, 336, 149-157.	3.2	62
725	RECK regulated endoplasmic reticulum stress response and enhanced cisplatin-induced cell death in neuroblastoma cells. Surgery, 2013, 154, 968-979.	1.0	7
726	In Vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel. Mitochondrion, 2013, 13, 464-472.	1.6	32
727	MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochemical and Biophysical Research Communications, 2013, 440, 604-610.	1.0	81
728	The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochemical Pharmacology, 2013, 85, 514-524.	2.0	80
729	A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer. European Journal of Pharmaceutical Sciences, 2013, 49, 737-747.	1.9	19
730	A Novel SERCA Inhibitor Demonstrates Synergy with Classic SERCA Inhibitors and Targets Multidrug-Resistant AML. Molecular Pharmaceutics, 2013, 10, 4358-4366.	2.3	29

#	Article	IF	Citations
731	Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. Nanoscale, 2013, 5, 3904.	2.8	44
732	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis, 2013, 34, 725-738.	1.3	86
733	Identification of Transporters Associated with Etoposide Sensitivity of Stomach Cancer Cell Lines and Methotrexate Sensitivity of Breast Cancer Cell Lines by Quantitative Targeted Absolute Proteomics. Molecular Pharmacology, 2013, 83, 490-500.	1.0	23
734	Dose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells. Molecular Pharmaceutics, 2013, 10, 2323-2330.	2.3	19
735	Transannular Dielsâ€“Alder/1,3-Dipolar Cycloaddition Cascade of 1,3,4-Oxadiazoles: Total Synthesis of a Unique Set of Vinblastine Analogues. Organic Letters, 2013, 15, 5306-5309.	2.4	39
736	Building a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy. Journal of the American Chemical Society, 2013, 135, 18644-18650.	6.6	229
737	Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors. Cancer Research, 2013, 73, 4439-4450.	0.4	33
738	Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2). Bioorganic and Medicinal Chemistry, 2013, 21, 7858-7873.	1.4	84
739	Targeting monocarboxylate transporter by Î±-cyano-4-hydroxycinnamate modulates apoptosis and cisplatin resistance of Colo205 cells: implication of altered cell survival regulation. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1574-1585.	2.2	21
740	Expression pattern of human ATP â€binding cassette transporters in skin. Pharmacology Research and Perspectives, 2013, 1, e00005.	1.1	26
741	Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. Journal of Molecular Graphics and Modelling, 2013, 46, 10-21.	1.3	35
742	Nullifying Tumor Efflux by Prolonged Endolysosome Vesicles: Development of Low Dose Anticancer-Carbon Nanotube Drug. ACS Nano, 2013, 7, 8484-8497.	7.3	42
743	Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Advanced Drug Delivery Reviews, 2013, 65, 1686-1698.	6.6	209
744	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Advanced Drug Delivery Reviews, 2013, 65, 1731-1747.	6.6	218
745	Design and synthesis of novel 2â€²-hydroxy group substituted 2-pyridone derivatives as anticancer agents. European Journal of Medicinal Chemistry, 2013, 67, 447-453.	2.6	27
746	The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulation. Experimental Cell Research, 2013, 319, 1013-1027.	1.2	31
747	Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing â€œGenerally Recognized As Safeâ€•(GRAS) nanopharmaceuticals: A review. Advanced Drug Delivery Reviews, 2013, 65, 1828-1851.	6.6	86
748	Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance. British Journal of Cancer, 2013, 109, 2356-2367.	2.9	22

#	Article	IF	Citations
749	Pattern of sensitivity of progressive cutaneous squamous cell carcinoma cells to UVB and oxidative stress-induced cell death. Photochemical and Photobiological Sciences, 2013, 12, 104-110.	1.6	3
750	Materials innovation for co-delivery of diverse therapeutic cargos. RSC Advances, 2013, 3, 24794.	1.7	46
751	Drug transporters in drug discovery and development. , 2013, , 633-674.		3
752	AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models. Molecular Cancer Therapeutics, 2013, 12, 2356-2366.	1.9	42
753	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology, 2013, 58, 1054-1064.	3.6	138
754	Drug delivery by a self-assembled DNA tetrahedron for overcoming drug resistance in breast cancer cells. Chemical Communications, 2013, 49, 2010.	2.2	216
755	Dual-targeting delivery system for selective cancer cell death and imaging. Chemical Science, 2013, 4, 947-956.	3.7	35
756	Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: Relationship between copolymer concentration and inhibitory activity. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 266-274.	2.0	71
757	The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 267-285.	1.5	33
758	Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives. Journal of Medicinal Chemistry, 2013, 56, 1136-1148.	2.9	81
759	A conserved interdomain communication pathway of pseudosymmetrically distributed residues affects substrate specificity of the fungal multidrug transporter Cdr1p. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 479-490.	1.4	17
760	Gold nanoparticles: Emerging paradigm for targeted drug delivery system. Biotechnology Advances, 2013, 31, 593-606.	6.0	308
761	Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials, 2013, 34, 1-10.	5.7	111
762	In vitro antiproliferative effect of Î²-phenylethylamine derivatives and doxorubicin combinations on MCF/ADR cell lines. Medicinal Chemistry Research, 2013, 22, 548-557.	1.1	1
763	ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. Cancer Letters, 2013, 333, 152-158.	3.2	39
764	Detection and isolation of circulating tumor cells: Principles and methods. Biotechnology Advances, 2013, 31, 1063-1084.	6.0	157
765	Loss of O6-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochemical Pharmacology, 2013, 85, 186-196.	2.0	31
766	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer, 2013, 49, 3366-3375.	1.3	75

#	Article	IF	Citations
768	pH-responsive lipid core micelles for tumour targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 346-357.	2.0	20
769	Steroidal saponin of Trillium tschonoskii. Reverses multidrug resistance of hepatocellular carcinoma. Phytomedicine, 2013, 20, 985-991.	2.3	40
770	Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer. Molecular Cancer Therapeutics, 2013, 12, 1829-1836.	1.9	97
771	Particle Carriers for Combating Multidrug-Resistant Cancer. ACS Nano, 2013, 7, 9512-9517.	7.3	89
772	Regulation of the MDR1 promoter by E2F1 and EAPP. FEBS Letters, 2013, 587, 1504-1509.	1.3	27
773	Hollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles. Nano Research, 2013, 6, 1-9.	5.8	99
774	Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Advanced Drug Delivery Reviews, 2013, 65, 663-676.	6.6	259
775	Synthesis and Biological Evaluation of 2-(Alkoxycarbonyl)-3-Anilinobenzo[b]thiophenes and Thieno[2,3-b]pyridines as New Potent Anticancer Agents. Journal of Medicinal Chemistry, 2013, 56, 2606-2618.	2.9	80
776	A new application of rhodanine as a green sulfur transferring agent for a clean functional group interconversion of amide to thioamide using reusable MCM-41 mesoporous silica. Tetrahedron Letters, 2013, 54, 2164-2170.	0.7	29
777	Azaindole derivatives are inhibitors of microtubule dynamics, with antiâ€cancer and antiâ€angiogenic activities. British Journal of Pharmacology, 2013, 168, 673-685.	2.7	30
778	Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation. Journal of Molecular Graphics and Modelling, 2013, 40, 91-98.	1.3	18
779	Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3662-3666.	1.0	35
780	Nano-graphene in biomedicine: theranostic applications. Chemical Society Reviews, 2013, 42, 530-547.	18.7	1,483
782	Biological rationale for the design of polymeric anti-cancer nanomedicines. Journal of Drug Targeting, 2013, 21, 1-26.	2.1	63
783	Multifunctional Albumin Nanoparticles As Combination Drug Carriers for Intraâ€Tumoral Chemotherapy. Advanced Healthcare Materials, 2013, 2, 1236-1245.	3.9	55
784	Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects. Pharmacology, 2013, 91, 12-19.	0.9	22
785	Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochemical Pharmacology, 2013, 85, 1441-1453.	2.0	40
786	Acid-Active Cell-Penetrating Peptides for in Vivo Tumor-Targeted Drug Delivery. Journal of the American Chemical Society, 2013, 135, 933-940.	6.6	303

#	Article	IF	Citations
787	Multifaceted Transport Characteristics of Nanomedicine: Needs for Characterization in Dynamic Environment. Molecular Pharmaceutics, 2013, 10, 2111-2126.	2.3	49
788	The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics, 2013, 14, 515-529.	0.6	127
789	Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. Journal of Controlled Release, 2013, 169, 48-61.	4.8	120
790	Facile synthesis of PEGylated PLGA nanoparticles encapsulating doxorubicin and its in vitro evaluation as potent drug delivery vehicle. Drug Delivery and Translational Research, 2013, 3, 299-308.	3.0	24
791	Lipid Bilayer Properties Control Membrane Partitioning, Binding, and Transport of P-Glycoprotein Substrates. Biochemistry, 2013, 52, 343-354.	1.2	67
792	Therapeutic Agents Triggering Nonapoptotic Cancer Cell Death. Journal of Medicinal Chemistry, 2013, 56, 4823-4839.	2.9	73
793	Targeted Delivery of Doxorubicin to Mitochondria. ACS Chemical Biology, 2013, 8, 1389-1395.	1.6	170
794	Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chemical Society Reviews, 2013, 42, 7289.	18.7	822
795	MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochemical and Biophysical Research Communications, 2013, 434, 688-694.	1.0	162
796	Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials, 2013, 34, 4452-4465.	5.7	114
797	Recent advances in delivery of drugâ€“nucleic acid combinations for cancer treatment. Journal of Controlled Release, 2013, 172, 589-600.	4.8	182
798	Zinc-pheophorbide aâ€”Highly efficient low-cost photosensitizer against human adenocarcinoma in cellular and animal models. Photodiagnosis and Photodynamic Therapy, 2013, 10, 266-277.	1.3	22
799	Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. Journal of Controlled Release, 2013, 169, 112-125.	4.8	304
800	Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Molecular Carcinogenesis, 2013, 53, n/a-n/a.	1.3	64
801	New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology, 2013, 140, 1534-1546.	0.7	89
802	Magnetic field triggered drug release from polymersomes for cancer therapeutics. Journal of Controlled Release, 2013, 169, 165-170.	4.8	267
803	20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs. Bioorganic and Medicinal Chemistry, 2013, 21, 4279-4287.	1.4	18
804	Natural Products with Activity against Multidrug-Resistant Tumor Cells. , 2013, , 237-244.		1

#	Article	IF	Citations
805	Accurate Models for P-gp Drug Recognition Induced from a Cancer Cell Line Cytotoxicity Screen. Journal of Medicinal Chemistry, 2013, 56, 5691-5708.	2.9	45
806	Optimization of Marine Triterpene Sipholenols as Inhibitors of Breast Cancer Migration and Invasion. ChemMedChem, 2013, 8, 497-510.	1.6	25
808	Reversal of Multidrug Resistance by Mitochondrial Targeted Self-Assembled Nanocarrier Based on Stearylamine. Molecular Pharmaceutics, 2013, 10, 2426-2434.	2.3	30
809	Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chemistry, 2013, 138, 2267-2274.	4.2	88
810	Gold Nanorod-Cored Biodegradable Micelles as a Robust and Remotely Controllable Doxorubicin Release System for Potent Inhibition of Drug-Sensitive and -Resistant Cancer Cells. Biomacromolecules, 2013, 14, 2411-2419.	2.6	112
811	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 189-199.	1.1	48
812	Association of multiple drug resistance-1 gene polymorphism with multiple drug resistance in breast cancer patients from an ethnic Saudi Arabian population. Cancer Epidemiology, 2013, 37, 762-766.	0.8	14
813	The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance. International Journal of Nanomedicine, 2013, 8, 379.	3.3	14
814	Different strategies to overcome multidrug resistance in cancer. Biotechnology Advances, 2013, 31, 1397-1407.	6.0	215
815	Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bioorganic and Medicinal Chemistry, 2013, 21, 1324-1332.	1.4	26
816	ABCG2: recent discovery of potent and highly selective inhibitors. Future Medicinal Chemistry, 2013, 5, 1037-1045.	1.1	26
817	First steps in experimental cancer evolution. Evolutionary Applications, 2013, 6, 535-548.	1.5	25
818	Smart pH-Sensitive and Temporal-Controlled Polymeric Micelles for Effective Combination Therapy of Doxorubicin and Disulfiram. ACS Nano, 2013, 7, 5858-5869.	7.3	353
819	Transporter Gene Expression in Human Head and Neck Squamous Cell Carcinoma and Associated Epigenetic Regulatory Mechanisms. American Journal of Pathology, 2013, 182, 234-243.	1.9	9
820	Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death and Disease, 2013, 4, e838-e838.	2.7	977
821	Non-Hodgkinâ€™s B-cell lymphoma: Advances in molecular strategies targeting drug resistance. Experimental Biology and Medicine, 2013, 238, 971-990.	1.1	52
822	Nanocarriers for siRNA delivery to overcome cancer multidrug resistance. Science Bulletin, 2013, 58, 4021-4030.	1.7	7
823	Functional Impact of a Single Mutation within the Transmembrane Domain of the Multidrug ABC Transporter Pdr5. Biochemistry, 2013, 52, 2184-2195.	1.2	15

#	Article	IF	Citations
824	Liposomal Sphingomyelin Influences the Cellular Lipid Profile of Human Lymphoblastic Leukemia Cells without Effect on P-Glycoprotein Activity. Molecular Pharmaceutics, 2013, 10, 1020-1034.	2.3	6
825	Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer Chemotherapy and Pharmacology, 2013, 71, 153-163.	1.1	30
826	Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer. International Journal of Oncology, 2013, 43, 513-520.	1.4	14
827	CJY, an isoflavone, interacts with ATPase of P-glycoprotein in the rat brain microvessel endothelial cells (RBMECs). Journal of Chemotherapy, 2013, 25, 347-354.	0.7	1
828	Effect of Phorbol 12-Myristate 13-Acetate on Function and Gene Expression of P-Glycoprotein in Adriamycin-Resistant K562/ADM Cells. Pharmacology, 2013, 92, 121-130.	0.9	6
829	Markers of response to platinum-based chemotherapy in lung cancer. Lung Cancer Management, 2013, 2, 227-239.	1.5	4
830	Cytotoxicity and Modes of Action of the Methanol Extracts of Six Cameroonian Medicinal Plants against Multidrug-Resistant Tumor Cells. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	64
831	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST Ä†ELIJA NESITNOÄ†ELIJSKOG KARCINOMA PLUÄ†A RAZLIÄŒITE OSETUIVOSTI NA DOKSORUBICIN. Journal of Medical Biochemistry, 2013, 32, 406-416.	0.7	2
832	Chemoresistance and Cancer-Related Inflammation: Two Hallmarks of Cancer Connected by an Atypical Link, PKCÎ¶. Frontiers in Oncology, 2013, 3, 232.	1.3	15
833	siRNA-based nanomedicine. Nanomedicine, 2013, 8, 859-862.	1.7	35
834	ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity. Frontiers in Pharmacology, 2013, 4, 138.	1.6	14
835	Coniferyl Ferulate, a Strong Inhibitor of Glutathione S-Transferase Isolated from RadixAngelicae sinensis, Reverses Multidrug Resistance and Downregulates P-Glycoprotein. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	15
836	Sphingosin 1-phosphate contributes in tumor progression. Journal of Cancer Research and Therapeutics, 2013, 9, 556.	0.3	44
837	Analysis of the inhibition potential of zosuquidar derivatives on selected bacterial and fungal ABC transporters. Molecular Membrane Biology, 2013, 30, 217-227.	2.0	7
838	miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochimica Et Biophysica Sinica, 2013, 45, 80-86.	0.9	50
839	Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2013, 12, 2874-2884.	1.9	53
840	Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9704-9709.	3.3	156
841	Association of Dietary Intake of Folate, Vitamin B₆and B₁₂and MTHFR Genotype with Breast Cancer Risk. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5189-5192.	0.5	15

#	Article	IF	Citations
842	Interaction of ¹¹C-Tariquidar and ¹¹C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2013, 54, 1181-1187.	2.8	45
843	Cost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos. Journal of Experimental Biology, 2013, 216, 3896-905.	0.8	17
844	Molecular insight into conformational transmission of human P-glycoprotein. Journal of Chemical Physics, 2013, 139, 225102.	1.2	22
845	Radioligands targeting P€glycoprotein and other drug efflux proteins at the blood–brain barrier. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 68-77.	0.5	45
846	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer, 2013, 133, 1222-1233.	2.3	26
847	TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Research, 2013, 41, e165-e165.	6.5	113
848	MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. Journal of Cellular and Molecular Medicine, 2013, 17, 1207-1217.	1.6	21
849	Enhanced doxorubicin transport to multidrug resistant breast cancer cells via TiO2 nanocarriers. RSC Advances, 2013, 3, 20855.	1.7	47
851	Molecular Disruption of the Power Stroke in the ATP-binding Cassette Transport Protein MsbA. Journal of Biological Chemistry, 2013, 288, 6801-6813.	1.6	39
852	FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death and Disease, 2013, 4, e923-e923.	2.7	91
853	Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. Cell Death and Disease, 2013, 4, e905-e905.	2.7	25
854	On the Origin of Large Flexibility of P-glycoprotein in the Inward-facing State. Journal of Biological Chemistry, 2013, 288, 19211-19220.	1.6	120
855	Androgen receptor decreases the cytotoxic effects of chemotherapeutic drugs in upper urinary tract urothelial carcinoma cells. Oncology Letters, 2013, 5, 1325-1330.	0.8	9
856	Establishment and characterization of a paclitaxel-resistant human esophageal carcinoma cell line. International Journal of Oncology, 2013, 43, 1607-1617.	1.4	29
857	Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistant gastric cancer cells to cisplatin. Oncology Reports, 2013, 30, 2288-2296.	1.2	10
858	Deregulated MicroRNAs Identified in Isolated Glioblastoma Stem Cells: An Overview. Cell Transplantation, 2013, 22, 741-753.	1.2	12
859	miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. International Journal of Molecular Medicine, 2013, 32, 593-598.	1.8	83
860	Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides. Frontiers in Microbiology, 2013, 4, 321.	1.5	159

#	Article	IF	Citations
861	Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells. International Journal of Oncology, 2013, 42, 1692-1708.	1.4	13
862	Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR). International Journal of Nanomedicine, 2013, 8, 2567.	3.3	15
863	Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression. Journal of Gynecologic Oncology, 2013, 24, 273.	1.0	10
864	Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. PLoS ONE, 2013, 8, e55576.	1.1	34
865	Klotho Sensitizes Human Lung Cancer Cell Line to Cisplatin via PI3k/Akt Pathway. PLoS ONE, 2013, 8, e57391.	1.1	63
866	Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference. PLoS ONE, 2013, 8, e60334.	1.1	42
867	Fabrication and Intracellular Delivery of Doxorubicin/Carbonate Apatite Nanocomposites: Effect on Growth Retardation of Established Colon Tumor. PLoS ONE, 2013, 8, e60428.	1.1	40
868	Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer. PLoS ONE, 2013, 8, e63404.	1.1	111
869	BBA, a Synthetic Derivative of 23-hydroxybutulinic Acid, Reverses Multidrug Resistance by Inhibiting the Efflux Activity of MRP7 (ABCC10). PLoS ONE, 2013, 8, e74573.	1.1	13
870	Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). PLoS ONE, 2013, 8, e75520.	1.1	6
871	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	29
872	Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug. Current Medicinal Chemistry, 2013, 20, 1541-1565.	1.2	75
873	The epimer of kaurenoic acid from Croton antisyphiliticus is cytotoxic toward B-16 and HeLa tumor cells through apoptosis induction. Genetics and Molecular Research, 2013, 12, 1005-1011.	0.3	12
874	Drug resistance: as complex and diverse as the disease itself. , 0, , 921-928.		0
875	Peptidomimetics as a new generation of antimicrobial agents: current progress. Infection and Drug Resistance, 2014, 7, 229.	1.1	62
876	Interstitial fluid flow in cancer: implications for disease progression and treatment. Cancer Management and Research, 2014, 6, 317.	0.9	169
877	Lamellarin O, a Pyrrole Alkaloid from an Australian Marine Sponge, Ianthella sp., Reverses BCRP Mediated Drug Resistance in Cancer Cells. Marine Drugs, 2014, 12, 3818-3837.	2.2	63
878	In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2). PLoS ONE, 2014, 9, e90689.	1.1	16

#	Article	IF	Citations
879	Non-Coding Polymorphisms in Nucleotide Binding Domain 1 in ABCC1 Gene Associate with Transcript Level and Survival of Patients with Breast Cancer. PLoS ONE, 2014, 9, e101740.	1.1	14
880	Integrative Genomic and Transcriptomic Analysis Identified Candidate Genes Implicated in the Pathogenesis of Hepatosplenic T-Cell Lymphoma. PLoS ONE, 2014, 9, e102977.	1.1	48
881	Inhibition of Breast Cancer Resistance Protein (ABCG2) in Human Myeloid Dendritic Cells Induces Potent Tolerogenic Functions during LPS Stimulation. PLoS ONE, 2014, 9, e104753.	1.1	7
882	Identification and Analysis of Genome-Wide SNPs Provide Insight into Signatures of Selection and Domestication in Channel Catfish (Ictalurus punctatus). PLoS ONE, 2014, 9, e109666.	1.1	55
883	Codelivery of Chemotherapeutics via Crosslinked Multilamellar Liposomal Vesicles to Overcome Multidrug Resistance in Tumor. PLoS ONE, 2014, 9, e110611.	1.1	31
884	The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression. International Journal of Nanomedicine, 2014, 9, 3425.	3.3	17
885	The Role of miRNAs Playing in Human Cancers Chemosensitivity. Biochemistry & Pharmacology: Open Access, 2014, 03, .	0.2	0
886	Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget, 2014, 5, 8027-8038.	0.8	177
887	Editorial (Thematic Issue: Structure-Based Drug Design: Strategies and Challenges). Current Pharmaceutical Design, 2014, 20, 685-686.	0.9	3
888	Lapatinib Antagonizes Multidrug Resistance-Associated Protein 1-Mediated Multidrug Resistance by Inhibiting Its Transport Function. Molecular Medicine, 2014, 20, 390-399.	1.9	39
889	MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget, 2014, 5, 7013-7026.	0.8	202
891	Calcium-channel blocking and nanoparticles-based drug delivery for treatment of drug-resistant human cancers. Therapeutic Delivery, 2014, 5, 763-780.	1.2	8
892	PEGylated polymer micelles for anticancer drug delivery carrier. , 2014, , 285-298.		2
893	Utilizing liposomes and lipid nanoparticles to overcome challenges in breast cancer treatment. Clinical Lipidology, 2014, 9, 571-585.	0.4	2
894	ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [11C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig. EJNMMI Research, 2014, 4, 64.	1.1	5
895	Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer, 2014, 14, 722.	1.1	61
896	Cysteines Introduced into Extracellular Loops 1 and 4 of Human P-Glycoprotein That Are Close Only in the Open Conformation Spontaneously Form a Disulfide Bond That Inhibits Drug Efflux and ATPase Activity. Journal of Biological Chemistry, 2014, 289, 24749-24758.	1.6	11
897	Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy. Journal of Pharmaceutical Investigation, 2014, 44, 493-504.	2.7	6

#	Article	IF	Citations
898	An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells. Oncogene, 2014, 33, 1198-1206.	2.6	15
899	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncology, 2014, 10, 1827-1841.	1.1	28
900	Anticancer and multidrug-resistance reversing potential of traditional medicinal plants and their bioactive compounds in leukemia cell lines. Chinese Journal of Natural Medicines, 2014, 12, 881-894.	0.7	21
901	mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2. Cancer Biology and Therapy, 2014, 15, 35-41.	1.5	50
902	MFS transporters required for multidrug/multixenobiotic (MD/MX) resistance in the model yeast: understanding their physiological function through post-genomic approaches. Frontiers in Physiology, 2014, 5, 180.	1.3	75
903	Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts. International Journal of Molecular Sciences, 2014, 15, 19265-19280.	1.8	9
904	Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells. Oncology Letters, 2014, 7, 1265-1269.	0.8	14
905	Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo. Oncology Letters, 2014, 8, 2806-2810.	0.8	29
906	Directed evolution of P-glycoprotein cysteines reveals site-specific, non-conservative substitutions that preserve multidrug resistance. Bioscience Reports, 2014, 34, .	1.1	12
907	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Frontiers in Physiology, 2014, 5, 141.	1.3	122
908	Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function. Frontiers in Oncology, 2014, 4, 41.	1.3	206
909	Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Frontiers in Pharmacology, 2014, 5, 257.	1.6	2
910	Dual Agent Loaded PLGA Nanoparticles Enhanced Antitumor Activity in a Multidrug-Resistant Breast Tumor Xenograft Model. International Journal of Molecular Sciences, 2014, 15, 2761-2772.	1.8	38
912	The RNA/DNAâ€binding protein PSF relocates to cell membrane and contributes cells' sensitivity to antitumor drug, doxorubicin. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 231-241.	1.1	10
913	Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation. Biochemical Pharmacology, 2014, 92, 558-566.	2.0	44
915	Novel Insights into Combating Cancer Chemotherapy Resistance Using a Plasmonic Nanocarrier: Enhancing Drug Sensitiveness and Accumulation Simultaneously with Localized Mild Photothermal Stimulus of Femtosecond Pulsed Laser. Advanced Functional Materials, 2014, 24, 4229-4239.	7.8	130
916	<scp>FTY720</scp> enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of <scp>P</scp>â€glycoprotein and multidrug resistance protein 1. Journal of Digestive Diseases, 2014, 15, 246-259.	0.7	24
917	Reversal of Lung Cancer Multidrug Resistance by pH-Responsive Micelleplexes Mediating Co-Delivery of siRNA and Paclitaxel. Macromolecular Bioscience, 2014, 14, 100-109.	2.1	61

#	Article	IF	Citations
918	pH-sensitive chitosan-folate nanogels crosslinked with biocompatible dicarboxylic acids. European Polymer Journal, 2014, 61, 215-225.	2.6	25
919	Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells. Investigational New Drugs, 2014, 32, 1053-1062.	1.2	85
920	Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells. Cancer Gene Therapy, 2014, 21, 275-282.	2.2	8
921	Understanding Cancer at the Genomic Level. , 2014, , 89-112.		0
922	Association between dietary intake of folate and MTHFR and MTR genotype with risk of breast cancer. Genetics and Molecular Research, 2014, 13, 8925-8931.	0.3	31
923	MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagnostic Pathology, 2014, 9, 143.	0.9	71
924	Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 57.	2.4	49
925	Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Anti-Cancer Drugs, 2014, 25, 255-269.	0.7	28
926	Multidrug resistance in fungi: regulation of transporter-encoding gene expression. Frontiers in Physiology, 2014, 5, 143.	1.3	112
927	ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy. Clinical Cancer Research, 2014, 20, 2703-2713.	3.2	105
928	ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition. Cancer Drug Discovery and Development, 2014, , 373-400.	0.2	8
929	Toxin-Based Cancer Gene Therapy. , 2014, , 107-122.		1
930	Schistosome ABC multidrug transporters: From pharmacology to physiology. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 301-309.	1.4	33
931	Efficient pH Dependent Drug Delivery to Target Cancer Cells by Gold Nanoparticles Capped with Carboxymethyl Chitosan. International Journal of Molecular Sciences, 2014, 15, 8216-8234.	1.8	132
932	Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10â€“Mediated Paclitaxel Resistance: A Preclinical Study. Molecular Cancer Therapeutics, 2014, 13, 714-723.	1.9	39
933	Attenuation of Carcinogenesis and the Mechanism Underlying by the Influence of Indole-3-carbinol and Its Metabolite 3,3â€²-Diindolylmethane: A Therapeutic Marvel. Advances in Pharmacological Sciences, 2014, 2014, 1-7.	3.7	47
934	The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment. BioMed Research International, 2014, 2014, 1-19.	0.9	53
935	Identification of the Distance between the Homologous Halves of P-glycoprotein That Triggers the High/Low ATPase Activity Switch. Journal of Biological Chemistry, 2014, 289, 8484-8492.	1.6	19

#	Article	IF	Citations
936	Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors. Journal of Chemical Information and Modeling, 2014, 54, 218-229.	2.5	95
937	Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3. Toxicology and Applied Pharmacology, 2014, 278, 238-248.	1.3	59
938	Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors. European Journal of Medicinal Chemistry, 2014, 81, 420-426.	2.6	18
939	Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance. Biomaterials, 2014, 35, 1227-1239.	5.7	123
940	Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochemical Pharmacology, 2014, 88, 58-65.	2.0	18
941	Facile preparation of hydroxyapatiteâ€“chondroitin sulfate hybrid mesoporous microrods for controlled and sustained release of antitumor drugs. Materials Letters, 2014, 125, 111-115.	1.3	10
942	Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomaterialia, 2014, 10, 1392-1402.	4.1	113
943	In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer. Experimental and Molecular Pathology, 2014, 97, 6-15.	0.9	31
944	Multifunctional nanomicellar systems for delivering anticancer drugs. Journal of Biomedical Materials Research - Part A, 2014, 102, 2024-2038.	2.1	30
945	Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnology Advances, 2014, 32, 789-803.	6.0	171
946	Triterpenoids as reversal agents for anticancer drug resistance treatment. Drug Discovery Today, 2014, 19, 482-488.	3.2	59
947	Inherited Disorders of Bilirubin Transport and Conjugation: New Insights Into Molecular Mechanisms and Consequences. Gastroenterology, 2014, 146, 1625-1638.	0.6	186
948	Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposomeâ€“microbubble complexes assisted by ultrasound. Journal of Controlled Release, 2014, 174, 109-116.	4.8	67
949	Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism. Drug Metabolism Reviews, 2014, 46, 261-282.	1.5	81
950	Euphorbia and Momordica metabolites for overcoming multidrug resistance. Phytochemistry Reviews, 2014, 13, 915-935.	3.1	34
951	Transferrin-Targeted Polymeric Micelles Co-loaded with Curcumin and Paclitaxel: Efficient Killing of Paclitaxel-Resistant Cancer Cells. Pharmaceutical Research, 2014, 31, 1938-1945.	1.7	55
952	Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer, 2014, 14, 37.	1.1	58
953	Establishment of Optimized MDCK Cell Lines for Reliable Efflux Transport Studies. Journal of Pharmaceutical Sciences, 2014, 103, 1298-1304.	1.6	44

#	Article	IF	Citations
954	Biomimetic RNAâ€Silencing Nanocomplexes: Overcoming Multidrug Resistance in Cancer Cells. Angewandte Chemie - International Edition, 2014, 53, 1997-2001.	7.2	55
955	Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: Implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 294-302.	1.1	42
956	The inhibitory and combinative mechanism of HZ08 with P-glycoprotein expressed on the membrane of Caco-2 cell line. Toxicology and Applied Pharmacology, 2014, 274, 232-239.	1.3	6
957	Discovery of Novel Pâ€Glycoproteinâ€Mediated Multidrug Resistance Inhibitors Bearing Triazole Core via Click Chemistry. Chemical Biology and Drug Design, 2014, 84, 182-191.	1.5	20
958	Alzheimerâ€™s and ABC transporters â€" new opportunities for diagnostics and treatment. Neurobiology of Disease, 2014, 72, 54-60.	2.1	66
959	Antimitotic and vascular disrupting agents: 2-Hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry, 2014, 77, 306-314.	2.6	8
960	Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. Biomaterials, 2014, 35, 2272-2282.	5.7	84
961	ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. Pharmaceutical Research, 2014, 31, 2237-2255.	1.7	48
962	Computational insights into the active site of human breast cancer resistance protein (BCRP/ABCG2): a similarity search approach. Medicinal Chemistry Research, 2014, 23, 4657-4668.	1.1	0
963	Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy. Biomacromolecules, 2014, 15, 1955-1969.	2.6	447
964	Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein. Biochemical and Biophysical Research Communications, 2014, 448, 430-436.	1.0	36
965	Symmetric Bis-chalcones as a New Type of Breast Cancer Resistance Protein Inhibitors with a Mechanism Different from That of Chromones. Journal of Medicinal Chemistry, 2014, 57, 2930-2941.	2.9	41
966	Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance. Chemical Reviews, 2014, 114, 5753-5774.	23.0	172
967	Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1. Leukemia Research, 2014, 38, 131-137.	0.4	8
968	Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomedicine and Pharmacotherapy, 2014, 68, 179-183.	2.5	44
969	Inorganic Nanoparticle-Based Drug Codelivery Nanosystems To Overcome the Multidrug Resistance of Cancer Cells. Molecular Pharmaceutics, 2014, 11, 2495-2510.	2.3	139
970	MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Letters, 2014, 343, 249-257.	3.2	138
971	The network of P-glycoprotein and microRNAs interactions. International Journal of Cancer, 2014, 135, 253-263.	2.3	52

#	Article	IF	Citations
972	Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drugâ€“gene co-delivery to cancer cells. Nanoscale, 2014, 6, 1567-1572.	2.8	101
973	Enhancing the Efficiency of Gold Nanoparticles Treatment of Cancer by Increasing Their Rate of Endocytosis and Cell Accumulation Using Rifampicin. Journal of the American Chemical Society, 2014, 136, 4464-4467.	6.6	101
974	Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorganic and Medicinal Chemistry, 2014, 22, 1148-1155.	1.4	30
975	Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. FÃ¬toterapÃ¬Ã¢, 2014, 92, 133-147.	1.1	243
976	The miR-106bâ^¼25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death and Differentiation, 2014, 21, 462-474.	5.0	75
977	miRNA expression patterns in chemoresistant breast cancer tissues. Biomedicine and Pharmacotherapy, 2014, 68, 935-942.	2.5	58
978	Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9. Nanoscale, 2014, 6, 14473-14483.	2.8	11
979	A metal-free and a solvent-free synthesis of thio-amides and amides: an efficient Friedelâ€“Crafts arylation of isothiocyanates and isocyanates. RSC Advances, 2014, 4, 60798-60807.	1.7	25
980	Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences, 2014, 103, 3810-3833.	1.6	30
981	Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents. Bioorganic and Medicinal Chemistry, 2014, 22, 6857-6866.	1.4	16
982	Natural daucane esters induces apoptosis in leukaemic cells through ROS production. Phytochemistry, 2014, 108, 147-156.	1.4	23
983	Transport in technicolor: Mapping ATPâ€binding cassette transporters in sea urchin embryos. Molecular Reproduction and Development, 2014, 81, 778-793.	1.0	25
984	The enriched fraction of Vernonia cinerea L. induces apoptosis and inhibits multi-drug resistance transporters in human epithelial cancer cells. Journal of Ethnopharmacology, 2014, 158, 33-42.	2.0	17
985	Design and synthesis of a mitochondria-targeting carrier for small molecule drugs. Organic and Biomolecular Chemistry, 2014, 12, 9793-9796.	1.5	14
986	Quantum Dots for Traceable Therapeutic Delivery. , 2014, , 393-417.		2
987	Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. British Journal of Cancer, 2014, 110, 2896-2904.	2.9	41
988	Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 599-616.	3.3	38
989	Selenorhodamine Photosensitizers for Photodynamic Therapy of P-Glycoprotein-Expressing Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 8622-8634.	2.9	53

#	Article	IF	Citations
990	Overcoming Cancer Multidrug Resistance by Codelivery of Doxorubicin and Verapamil with Hydrogel Nanoparticles. Macromolecular Bioscience, 2014, 14, 1106-1115.	2.1	49
991	Flexible membrane proteins: functional dynamics captured by mass spectrometry. Current Opinion in Structural Biology, 2014, 28, 122-130.	2.6	18
992	A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells. RSC Advances, 2014, 4, 44827-44836.	1.7	13
993	Flavonostilbenes from Sophora alopecuroides L. as multidrug resistance associated protein 1 (MRP1) inhibitors. Natural Product Research, 2014, 28, 2195-2198.	1.0	19
994	Functional Core/Shell Drug Nanoparticles for Highly Effective Synergistic Cancer Therapy. Advanced Healthcare Materials, 2014, 3, 1475-1485.	3.9	22
995	Thieno[2,3-b]pyridinesâ€"A new class of multidrug resistance (MDR) modulators. Bioorganic and Medicinal Chemistry, 2014, 22, 5860-5870.	1.4	34
996	Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-Î±-mediated signaling. Cell Death and Disease, 2014, 5, e1367-e1367.	2.7	134
997	Epigallocatechin-3-Gallate Potentiates the Effect of Curcumin in Inducing Growth Inhibition and Apoptosis of Resistant Breast Cancer Cells. The American Journal of Chinese Medicine, 2014, 42, 1279-1300.	1.5	49
998	Cell-Penetrating, Guanidinium-Rich Molecular Transporters for Overcoming Efflux-Mediated Multidrug Resistance. Molecular Pharmaceutics, 2014, 11, 2553-2565.	2.3	53
999	Trimethoxybenzanilide-Based P-Glycoprotein Modulators: An Interesting Case of Lipophilicity Tuning by Intramolecular Hydrogen Bonding. Journal of Medicinal Chemistry, 2014, 57, 6403-6418.	2.9	23
1000	Association of methylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B12 intakes. Tumor Biology, 2014, 35, 11895-11901.	0.8	54
1001	Activating transcription factor 4 mediates a multidrug resistance phenotype of esophageal squamous cell carcinoma cells through transactivation of STAT3 expression. Cancer Letters, 2014, 354, 142-152.	3.2	28
1002	Synthesis, Antimitotic and Antivascular Activity of 1-(3â€²,4â€²,5â€²-Trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles. Journal of Medicinal Chemistry, 2014, 57, 6795-6808.	2.9	52
1003	Total Synthesis of (â^')-4-Hydroxyzinowol. Journal of Organic Chemistry, 2014, 79, 8835-8849.	1.7	37
1004	Multilayer Spheroids To Quantify Drug Uptake and Diffusion in 3D. Molecular Pharmaceutics, 2014, 11, 2071-2081.	2.3	74
1005	Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells. Biomaterials, 2014, 35, 9495-9507.	5.7	67
1006	MicroRNAs and Drug Resistance in Prostate Cancers. Molecular Pharmaceutics, 2014, 11, 2539-2552.	2.3	63
1007	Translocation mechanism of P-glycoprotein and conformational changes occurring at drug-binding site: Insights from multi-targeted molecular dynamics. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2882-2898.	1.4	50

#	Article	IF	Citations
1008	Targeted theranostic prodrugs based on an aggregation-induced emission (AIE) luminogen for real-time dual-drug tracking. Chemical Communications, 2014, 50, 11465-11468.	2.2	83
1009	Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza. Phytomedicine, 2014, 21, 1264-1272.	2.3	82
1010	Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. Journal of Controlled Release, 2014, 192, 47-56.	4.8	93
1011	Caveolin-1 mediates chemoresistance in breast cancer stem cells via Î²-catenin/ABCG2 signaling pathway. Carcinogenesis, 2014, 35, 2346-2356.	1.3	75
1012	Self-Assembled Nanoparticles Based on PEGylated Conjugated Polyelectrolyte and Drug Molecules for Image-Guided Drug Delivery and Photodynamic Therapy. ACS Applied Materials & Interfaces, 2014, 6, 14903-14910.	4.0	55
1013	Bioengineering 3D environments for cancer models. Advanced Drug Delivery Reviews, 2014, 79-80, 40-49.	6.6	108
1014	Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation. International Journal of Pharmaceutics, 2014, 475, 372-384.	2.6	49
1015	MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer, 2014, 14, 611.	1.1	49
1016	Cyanogramide with a New Spiro[indolinone-pyrroloimidazole] Skeleton from Actinoalloteichus cyanogriseus. Organic Letters, 2014, 16, 3708-3711.	2.4	59
1017	Quantitative structure activity relationship and docking studies of imidazole-based derivatives as P-glycoprotein inhibitors. Medicinal Chemistry Research, 2014, 23, 4700-4712.	1.1	9
1018	Immune-related chemotactic factors were found in acute coronary syndromes by bioinformatics. Molecular Biology Reports, 2014, 41, 4389-4395.	1.0	3
1019	Structurally diverse MDM2â€“p53 antagonists act as modulators of MDR-1 function in neuroblastoma. British Journal of Cancer, 2014, 111, 716-725.	2.9	35
1020	Screening for natural anticancer agents using a fission yeast bioassay. Phytochemistry Letters, 2014, 8, 184-189.	0.6	5
1021	Understanding polyspecificity within the substrateâ€binding cavity of the human multidrug resistance Pâ€glycoprotein. FEBS Journal, 2014, 281, 673-682.	2.2	58
1022	Co-delivery of doxorubicin and RNA using pH-sensitive poly (Î²-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. Biomaterials, 2014, 35, 6047-6059.	5.7	113
1023	Targeted Therapeutic Nanotubes Influence the Viscoelasticity of Cancer Cells to Overcome Drug Resistance. ACS Nano, 2014, 8, 4177-4189.	7.3	68
1024	Structural basis for gating mechanisms of a eukaryotic P-glycoprotein homolog. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4049-4054.	3.3	163
1025	Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials, 2014, 35, 1643-1656.	5.7	113

#	Article	IF	Citations
1027	Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 371-378.	1.4	23
1028	Afatinib Enhances the Efficacy of Conventional Chemotherapeutic Agents by Eradicating Cancer Stemâ€“like Cells. Cancer Research, 2014, 74, 4431-4445.	0.4	50
1029	Electrochemical method to characterize multidrug resistance. Chemical Research in Chinese Universities, 2014, 30, 437-440.	1.3	1
1030	Molecular Vehicles for Mitochondrial Chemical Biology and Drug Delivery. ACS Chemical Biology, 2014, 9, 323-333.	1.6	128
1031	Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicology in Vitro, 2014, 28, 1498-1506.	1.1	34
1032	Importance of ABCC1 for cancer therapy and prognosis. Drug Metabolism Reviews, 2014, 46, 325-342.	1.5	46
1033	Drug Resistance Is Conferred on the Model Yeast Saccharomyces cerevisiae by Expression of Full-Length Melanoma-Associated Human ATP-Binding Cassette Transporter ABCB5. Molecular Pharmaceutics, 2014, 11, 3452-3462.	2.3	14
1034	Structural Modifications of Mitochondria-Targeted Chlorambucil Alter Cell Death Mechanism but Preserve MDR Evasion. Molecular Pharmaceutics, 2014, 11, 2675-2682.	2.3	21
1035	Synthesis and Biological Evaluation of Novel Millepachine Derivatives As a New Class of Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 7977-7989.	2.9	52
1036	Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via Î²-catenin/ABCG2 signaling. Carcinogenesis, 2014, 35, 2544-2554.	1.3	94
1038	DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo. Journal of Pharmacy and Pharmacology, 2014, 66, 398-407.	1.2	10
1039	CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Biochemical Pharmacology, 2014, 91, 144-156.	2.0	18
1040	Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Phytomedicine, 2014, 21, 315-322.	2.3	93
1041	Macrocyclic diterpenes resensitizing multidrug resistant phenotypes. Bioorganic and Medicinal Chemistry, 2014, 22, 3696-3702.	1.4	20
1042	Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives. European Journal of Medicinal Chemistry, 2014, 83, 409-418.	2.6	16
1043	Synthesis and antitumor activities of novel rhein Î±-aminophosphonates conjugates. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 501-507.	1.0	39
1044	Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicology and Applied Pharmacology, 2014, 274, 471-479.	1.3	38
1045	Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents. European Journal of Medicinal Chemistry, 2014, 81, 394-407.	2.6	17

#	Article	IF	Citations
1046	Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. Biomaterials, 2014, 35, 3005-3014.	5.7	126
1047	Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. International Journal of Pharmaceutics, 2014, 464, 178-184.	2.6	108
1048	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Letters, 2014, 350, 61-68.	3.2	35
1049	Recent advances in deep-sea natural products. Natural Product Reports, 2014, 31, 999-1025.	5.2	177
1050	Decreased Expression of miR216a Contributes to Nonâ€“Small-Cell Lung Cancer Progression. Clinical Cancer Research, 2014, 20, 4705-4716.	3.2	53
1051	Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux. Biochemical Pharmacology, 2014, 90, 235-245.	2.0	41
1052	Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncology, 2014, 10, 655-669.	1.1	34
1053	Uptake of Compounds That Selectively Kill Multidrug-Resistant Cells: The Copper Transporter SLC31A1 (CTR1) Increases Cellular Accumulation of the Thiosemicarbazone NSC73306. Molecular Pharmaceutics, 2014, 11, 2692-2702.	2.3	17
1054	Small Molecule Modulators of Proteinâ€“Protein Interactions: Selected Case Studies. Chemical Reviews, 2014, 114, 4640-4694.	23.0	71
1055	A high throughput flow cytometric assay platform targeting transporter inhibition. Drug Discovery Today: Technologies, 2014, 12, e95-e103.	4.0	20
1056	A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer. International Journal of Pharmaceutics, 2014, 471, 206-213.	2.6	73
1057	In vitro establishment of ivermectin-resistant Rhipicephalus microplus cell line and the contribution of ABC transporters on the resistance mechanism. Veterinary Parasitology, 2014, 204, 316-322.	0.7	27
1058	Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Materials Today, 2014, 17, 298-306.	8.3	128
1059	The pharmacological point of view of resistance to therapy in tumors. Cancer Treatment Reviews, 2014, 40, 909-916.	3.4	39
1060	Non-viral nanocarriers for siRNA delivery in breast cancer. Journal of Controlled Release, 2014, 190, 440-450.	4.8	75
1061	Quaternized starch-based carrier for siRNA delivery: From cellular uptake to gene silencing. Journal of Controlled Release, 2014, 185, 109-120.	4.8	50
1062	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharmaceutica Sinica B, 2014, 4, 105-111.	5.7	48
1063	Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chinese Journal of Cancer, 2014, 33, 223-230.	4.9	48

#	Article	IF	Citations
1064	The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance. Oncology Reports, 2014, 32, 1211-1217.	1.2	6
1066	Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line. Oncology Reports, 2014, 31, 2720-2726.	1.2	22
1067	Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. International Journal of Oncology, 2014, 44, 1634-1642.	1.4	28
1068	Mass Spectrometry Quantifies Protein Interactionsâ€"From Molecular Chaperones to Membrane Porins. Angewandte Chemie - International Edition, 2014, 53, 14002-14015.	7.2	53
1069	Role and mechanisms of microRNA-503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. Molecular Medicine Reports, 2014, 10, 3268-3274.	1.1	26
1070	Use of signaling pathways as therapeutic targets for blood cancer. International Journal of Hematologic Oncology, 2014, 3, 275-288.	0.7	0
1071	Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors. Molecular Pharmaceutics, 2015, 12, 3924-3934.	2.3	18
1072	Effect of Huaier on the proliferation and apoptosis of human gastric cancer cells through modulation of the PI3K/AKT signaling pathway. Experimental and Therapeutic Medicine, 2015, 10, 1212-1218.	0.8	33
1073	Capillary Electrophoresis with Laser-induced Fluorescence Detection for Application in Intracellular Investigation of Anthracyclines and Multidrug Resistance Proteins. Analytical Sciences, 2015, 31, 1121-1128.	0.8	6
1074	ABCB1 in children's brain tumours. Biochemical Society Transactions, 2015, 43, 1018-1022.	1.6	18
1075	Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Scientific Reports, 2015, 5, 8202.	1.6	68
1076	Photoacoustic â€œnanobombsâ€•fight against undesirable vesicular compartmentalization of anticancer drugs. Scientific Reports, 2015, 5, 15527.	1.6	13
1077	Effects of salinomycin and CGP37157 on head and neck squamous cell carcinoma cell lines in vitro. Molecular Medicine Reports, 2015, 12, 4455-4461.	1.1	8
1078	Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntingtonâ€™s disease R6/2 model. Scientific Reports, 2015, 5, 16887.	1.6	9
1079	Cytotoxicity of selected Cameroonian medicinal plants and Nauclea pobeguinii towards multi-factorial drug-resistant cancer cells. BMC Complementary and Alternative Medicine, 2015, 15, 309.	3.7	41
1080	Size Changeable Nanocarriers with Nuclear Targeting for Effectively Overcoming Multidrug Resistance in Cancer Therapy. Advanced Materials, 2015, 27, 6450-6456.	11.1	209
1081	Akt regulation of Aven contributes to the sensitivity of cancer cells to chemotherapeutic agents. Molecular Medicine Reports, 2015, 11, 3866-3871.	1.1	5
1082	Prussian Blue Derived Nanoporous Iron Oxides as Anticancer Drug Carriers for Magneticâ€Guided Chemotherapy. Chemistry - an Asian Journal, 2015, 10, 1457-1462.	1.7	61

#	Article	IF	Citations
1083	Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of <scp>P</scp>â€glycoprotein and enhancing apoptosis. International Journal of Cancer, 2015, 137, 2029-2039.	2.3	22
1084	Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy. Current Medicinal Chemistry, 2015, 23, 3-22.	1.2	29
1085	Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency. International Journal of Nanomedicine, 2015, 10, 3989.	3.3	10
1086	Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy. Current Gene Therapy, 2015, 15, 151-160.	0.9	8
1087	Smart Mesoporous Nanomaterials for Antitumor Therapy. Nanomaterials, 2015, 5, 1906-1937.	1.9	79
1088	Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway. Drug Design, Development and Therapy, 2015, 9, 5301.	2.0	4
1089	Perception and Resistance Mechanism of some Metal-drug Complexes and Their Roles as Antibacterial. , 0, , .		0
1090	Mechanisms of Drug Resistance in Veterinary Oncologyâ€" A Review with an Emphasis on Canine Lymphoma. Veterinary Sciences, 2015, 2, 150-184.	0.6	28
1091	Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma. Veterinary Sciences, 2015, 2, 185-205.	0.6	9
1092	Microchamber Device for Detection of Transporter Activity of Adherent Cells. Frontiers in Bioengineering and Biotechnology, 2015, 3, 32.	2.0	4
1093	Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Oncotarget, 2015, 6, 44643-44659.	0.8	39
1094	The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo. International Journal of Nanomedicine, 2015, 10, 2229.	3.3	35
1095	Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity. Current Topics in Medicinal Chemistry, 2015, 15, 37-42.	1.0	10
1096	Asymmetric Total Synthesis of (â^)-4-Hydroxyzinowol, a Highly Oxygenated Dihydro-Î²-Agarofuran. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2015, 73, 1081-1091.	0.0	2
1097	Synthesis and Evaluation of a Novel Adenosine-Ribose Probe for Global-Scale Profiling of Nucleoside and Nucleotide-Binding Proteins. PLoS ONE, 2015, 10, e0115644.	1.1	5
1098	A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design. PLoS ONE, 2015, 10, e0118977.	1.1	68
1099	A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects. Frontiers in Pharmacology, 2015, 6, 293.	1.6	15
1100	Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity. Drug Design, Development and Therapy, 2015, 9, 3481.	2.0	18

#	Article	IF	Citations
1101	African Flora Has the Potential to Fight Multidrug Resistance of Cancer. BioMed Research International, 2015, 2015, 1-24.	0.9	151
1102	Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. BioMed Research International, 2015, 2015, 1-21.	0.9	227
1103	The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer. BioMed Research International, 2015, 2015, 1-13.	0.9	40
1104	Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget, 2015, 6, 1143-1156.	0.8	171
1105	Natural paniceins from mediterranean sponge inhibit the multidrug resistance activity of Patched and increase chemotherapy efficiency on melanoma cells. Oncotarget, 2015, 6, 22282-22297.	0.8	24
1106	EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget, 2015, 6, 10697-10711.	0.8	408
1107	Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget, 2015, 6, 37135-37150.	0.8	57
1108	Linker Design for Antibodyâ€“Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 49-76.	0.2	1
1109	Sonic Hedgehog factor Gli1: As good as resistant. Molecular and Cellular Oncology, 2015, 2, e961827.	0.3	1
1110	Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharmaceutica Sinica B, 2015, 5, 169-175.	5.7	166
1111	Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 27-52.	0.1	10
1112	Enhance Cancer Cell Recognition and Overcome Drug Resistance Using Hyaluronic Acid and Î±-Tocopheryl Succinate Based Multifunctional Nanoparticles. Molecular Pharmaceutics, 2015, 12, 2189-2202.	2.3	76
1113	Site-Specific Drug-Releasing Polypeptide Nanocarriers Based on Dual-pH Response for Enhanced Therapeutic Efficacy against Drug-Resistant Tumors. Theranostics, 2015, 5, 890-904.	4.6	36
1114	Aliphatic acid-conjugated antimicrobial peptides â€“ potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability. Organic and Biomolecular Chemistry, 2015, 13, 7673-7680.	1.5	9
1115	The Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 209-244.	0.1	1
1116	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives. Journal of Medicinal Chemistry, 2015, 58, 4529-4549.	2.9	45
1117	AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation. Chemico-Biological Interactions, 2015, 236, 9-18.	1.7	12
1118	Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids and Surfaces B: Biointerfaces, 2015, 128, 419-426.	2.5	120

#	Article	IF	Citations
1119	Natural productsâ€"friends or foes?. Toxicology Letters, 2015, 236, 154-167.	0.4	57
1120	Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clinical Cancer Research, 2015, 21, 4133-4142.	3.2	57
1121	Synthesis of polysubstituted pyridines as potential multidrug resistance modulators. Heterocyclic Communications, 2015, 21, .	0.6	2
1122	Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2361-2370.	1.9	27
1123	Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD⁺/NADH Ratio and SIRT1. Journal of Medicinal Chemistry, 2015, 58, 9522-9534.	2.9	29
1124	Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells. ACS Applied Materials & Interfaces, 2015, 7, 26315-26325.	4.0	48
1125	Development of nordihydroguaiaretic acid derivatives as potential multidrug-resistant selective agents for cancer treatment. RSC Advances, 2015, 5, 107833-107838.	1.7	6
1126	Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility. Biochemical Journal, 2015, 471, 131-153.	1.7	111
1127	Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells. International Journal of Oncology, 2015, 46, 1849-1857.	1.4	22
1128	Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). International Journal of Oncology, 2015, 47, 840-848.	1.4	124
1129	Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line. International Journal of Oncology, 2015, 46, 2479-2487.	1.4	8
1130	Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. International Journal of Oncology, 2015, 47, 122-132.	1.4	34
1131	Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells. Oncology Letters, 2015, 10, 805-809.	0.8	9
1132	Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines. Experimental Cell Research, 2015, 331, 11-20.	1.2	12
1133	Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles. Acta Biomaterialia, 2015, 14, 115-124.	4.1	116
1134	Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in Childhood Nephrotic Syndrome: A longitudinal study. Cytokine, 2015, 72, 190-196.	1.4	50
1135	Natural Product Modulators to Overcome Multidrug Resistance In Cancer. Nutrition and Cancer, 2015, 67, 411-423.	0.9	46
1136	Design, Synthesis and In Vitro Antiproliferative Activity of Novel Isatinâ€Quinazoline Hybrids. Archiv Der Pharmazie, 2015, 348, 144-154.	2.1	46

#	Article	IF	Citations
1137	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. Advances in Cancer Research, 2015, 125, 217-243.	1.9	43
1138	ABC Transporters and Neuroblastoma. Advances in Cancer Research, 2015, 125, 139-170.	1.9	25
1139	Redundancy: A Critical Obstacle to Improving Cancer Therapy. Cancer Research, 2015, 75, 808-812.	0.4	50
1140	Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells. Journal of Materials Chemistry B, 2015, 3, 1204-1207.	2.9	34
1141	The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treatment Reviews, 2015, 41, 160-169.	3.4	83
1142	Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 947-958.	1.7	142
1143	Synthesis of CDDOâ€“Amino Acidâ€“Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer. Journal of Medicinal Chemistry, 2015, 58, 2452-2464.	2.9	65
1144	Using Hollow Carbon Nanospheres as a Light-Induced Free Radical Generator To Overcome Chemotherapy Resistance. Journal of the American Chemical Society, 2015, 137, 1947-1955.	6.6	182
1145	Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. Medical Oncology, 2015, 32, 470.	1.2	15
1146	Synthesis of New Steroidal Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance and Biological Evaluation on K562/R7 Erythroleukemia Cells. Journal of Medicinal Chemistry, 2015, 58, 1832-1845.	2.9	12
1147	Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Journal of Controlled Release, 2015, 205, 144-154.	4.8	250
1148	25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations. Molecular Pharmacology, 2015, 87, 766-775.	1.0	130
1149	Ten things you should know about protein kinases: <scp>IUPHAR R</scp>eview 14. British Journal of Pharmacology, 2015, 172, 2675-2700.	2.7	270
1150	Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line. RSC Advances, 2015, 5, 13972-13984.	1.7	25
1151	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Investigational New Drugs, 2015, 33, 300-309.	1.2	22
1152	Regulation of drug transporter expression and function in the placenta. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 533-555.	1.5	40
1153	Dual-pH Sensitive Charge-Reversal Polypeptide Micelles for Tumor-Triggered Targeting Uptake and Nuclear Drug Delivery. Small, 2015, 11, 2543-2554.	5.2	234
1154	Understanding cancer and the anticancer activities of naphthoquinones â€“ a review. RSC Advances, 2015, 5, 20309-20338.	1.7	240

#	Article	IF	Citations
1155	Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein. Biomedicine and Pharmacotherapy, 2015, 70, 140-145.	2.5	59
1156	Nanoparticle-Based Brachytherapy Spacers for Delivery of Localized Combined Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 91, 393-400.	0.4	23
1157	Intelligent nanoparticles for advanced drug delivery in cancer treatment. Current Opinion in Chemical Engineering, 2015, 7, 84-92.	3.8	90
1158	Self-Assembled Coreâ€“Shell Nanoparticles for Combined Chemotherapy and Photodynamic Therapy of Resistant Head and Neck Cancers. ACS Nano, 2015, 9, 991-1003.	7.3	247
1159	The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resistance Updates, 2015, 18, 1-17.	6.5	590
1160	Three- and four-class classification models for P-glycoprotein inhibitors using counter-propagation neural networks. SAR and QSAR in Environmental Research, 2015, 26, 139-163.	1.0	11
1161	Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials, 2015, 52, 126-139.	5.7	261
1162	Polymer nanoparticles with electrostatically loaded multicargo for combined cancer phototherapy. Journal of Materials Chemistry B, 2015, 3, 3001-3010.	2.9	18
1163	BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance. Cancer Research, 2015, 75, 732-741.	0.4	47
1164	Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. Journal of Antimicrobial Chemotherapy, 2015, 70, 1608-1621.	1.3	353
1165	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharmaceutical Research, 2015, 32, 37-46.	1.7	79
1166	XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. Mutagenesis, 2015, 30, 441-449.	1.0	28
1167	miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Research, 2015, 25, 477-495.	5.7	75
1168	Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors. Bulletin of Mathematical Biology, 2015, 77, 1-22.	0.9	96
1169	Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Investigational New Drugs, 2015, 33, 290-299.	1.2	33
1170	Prognostic value of circulating CD133⁺ cells in patients with gastric cancer. Cell Proliferation, 2015, 48, 311-317.	2.4	35
1171	Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance. Chemical Communications, 2015, 51, 11587-11590.	2.2	79
1172	Do adsorbed drugs onto P-glycoprotein influence its efflux capability?. Physical Chemistry Chemical Physics, 2015, 17, 22023-22034.	1.3	14

#	Article	IF	Citations
1173	A peptide-based pH-sensitive drug delivery system for targeted ablation of cancer cells. Chemical Communications, 2015, 51, 14454-14457.	2.2	28
1174	pH-Responsive supramolecular vesicles assembled by water-soluble pillar[5]arene and a BODIPY photosensitizer for chemo-photodynamic dual therapy. Chemical Communications, 2015, 51, 14381-14384.	2.2	122
1175	Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-Î²B signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Molecular and Cellular Biochemistry, 2015, 409, 33-43.	1.4	66
1176	Phosphodiesterase Type 5 as a Candidate Therapeutic Target in Cancers. Current Pathobiology Reports, 2015, 3, 193-201.	1.6	8
1177	Drug Transporters and Na⁺/H⁺ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins. Pharmacological Reviews, 2015, 67, 656-680.	7.1	17
1178	Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate. Journal of Controlled Release, 2015, 212, 94-102.	4.8	57
1179	The interplay between DNA repair and autophagy in cancer therapy. Cancer Biology and Therapy, 2015, 16, 1005-1013.	1.5	97
1180	Lentivirus-Mediated RNAi Silencing Targeting ERCC1 Reverses Cisplatin Resistance in Cisplatin-Resistant Ovarian Carcinoma Cell Line. DNA and Cell Biology, 2015, 34, 497-502.	0.9	9
1181	Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?. Clinical Radiology, 2015, 70, 1060-1082.	0.5	54
1182	Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. European Journal of Medicinal Chemistry, 2015, 101, 560-572.	2.6	45
1183	Intrinsic therapeutic and biocatalytic roles of ionic liquid mediated self-assembled platinumâ€“phytase nanospheres. RSC Advances, 2015, 5, 62871-62881.	1.7	13
1184	Effect of FosPegÂ® mediated photoactivation on P-gp / ABCB1 protein expression in human nasopharyngeal carcinoma cells. Journal of Photochemistry and Photobiology B: Biology, 2015, 148, 82-87.	1.7	9
1185	Tumor Cells Chronically Treated with a Trastuzumabâ€“Maytansinoid Antibodyâ€“Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments. Molecular Cancer Therapeutics, 2015, 14, 952-963.	1.9	158
1186	Antibodyâ€“Drug Conjugates and Small Moleculeâ€“Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents. Journal of Medicinal Chemistry, 2015, 58, 8751-8761.	2.9	141
1187	Discovery and Computer-Aided Drug Design Studies of the Anticancer Marine Triterpene Sipholanes as Novel P-gp and Brk Modulators. , 2015, , 547-569.		1
1188	Drugs That Modulate Resistance to Antitumor Agents. , 2015, , 655-700.		3
1189	HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). Journal of Medicinal Chemistry, 2015, 58, 3910-3921.	2.9	69
1190	A role for calcium in the regulation of ATP-binding cassette, sub-family C, member 3 (ABCC3) gene expression in a model of epidermal growth factor-mediated breast cancer epithelialâ€“mesenchymal transition. Biochemical and Biophysical Research Communications, 2015, 458, 509-514.	1.0	31

#	Article	IF	Citations
1191	Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity. Bioorganic and Medicinal Chemistry, 2015, 23, 3337-3350.	1.4	29
1192	Recent progress in biomedical applications of Pluronic (PF127): Pharmaceutical perspectives. Journal of Controlled Release, 2015, 209, 120-138.	4.8	267
1193	NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecologic Oncology, 2015, 137, 134-142.	0.6	10
1194	Doxorubicin-loaded NaYF4:Yb/Tmâ€“TiO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers. Biomaterials, 2015, 57, 93-106.	5.7	154
1195	Role of the N-terminal transmembrane domain in the endo-lysosomal targeting and function of the human ABCB6 protein. Biochemical Journal, 2015, 467, 127-139.	1.7	36
1196	A conjugate of the lytic peptide Hecate and gallic acid: structure, activity against cervical cancer, and toxicity. Amino Acids, 2015, 47, 1433-1443.	1.2	22
1197	Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development. Digestive Diseases and Sciences, 2015, 60, 2373-2383.	1.1	28
1198	Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases. Pharmaceutical Research, 2015, 32, 2060-2071.	1.7	27
1199	Molecular Imaging of Membrane Transportersâ€™ Activity in Cancer: a Picture is Worth a Thousand Tubes. AAPS Journal, 2015, 17, 788-801.	2.2	21
1200	Gold nanorods and curcumin-loaded nanomicelles for efficient in vivo photothermal therapy of Barrett's esophagus. Nanomedicine, 2015, 10, 1723-1733.	1.7	28
1201	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	298
1202	Hybrid Nanoparticles for Cancer Imaging and Therapy. Cancer Treatment and Research, 2015, 166, 173-192.	0.2	10
1203	Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemotherapy and Pharmacology, 2015, 76, 105-116.	1.1	28
1204	MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Scientific Reports, 2015, 5, 8509.	1.6	109
1205	Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 27-36.	2.0	143
1206	Selective targeting of FAKâ€“Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells. Cancer Letters, 2015, 362, 25-35.	3.2	28
1207	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Letters, 2015, 361, 112-120.	3.2	24
1208	Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1197-1205.	1.1	16

#	Article	IF	Citations
1209	In vitro and in vivo Anticancer Effects of a Novel 9-Phenyldibenzo[a,c]phenazin-9-ium Cation and Its Ligands. Chemotherapy, 2015, 60, 261-266.	0.8	0
1210	Human Transport Protein Carrier for Controlled Photoactivation of Antitumor Prodrug and Real-Time Intracellular Tumor Imaging. Bioconjugate Chemistry, 2015, 26, 955-961.	1.8	47
1211	Construction of a cancer-targeted nanosystem as a payload of iron complexes to reverse cancer multidrug resistance. Journal of Materials Chemistry B, 2015, 3, 4345-4354.	2.9	24
1212	Marine Natural Products as Breast Cancer Resistance Protein Inhibitors. Marine Drugs, 2015, 13, 2010-2029.	2.2	41
1213	Induction of Human UDP-Glucuronosyltransferase 2B7 Gene Expression by Cytotoxic Anticancer Drugs in Liver Cancer HepG2 Cells. Drug Metabolism and Disposition, 2015, 43, 660-668.	1.7	25
1214	Highly efficient ablation of metastatic breast cancer using ammonium-tungsten-bronze nanocube as a novel 1064Ânm-laser-driven photothermal agent. Biomaterials, 2015, 52, 407-416.	5.7	107
1215	Antiproliferative effect of Dendrobium catenatum Lindley polypeptides against human liver, gastric and breast cancer cell lines. Food and Function, 2015, 6, 1489-1495.	2.1	37
1216	Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurgical Focus, 2015, 38, E9.	1.0	96
1217	Mechanisms and therapeutic potential of inhibiting drug efflux transporters. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 907-920.	1.5	21
1218	Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models. Cancer Research, 2015, 75, 4573-4581.	0.4	23
1219	Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60). Biomedicine and Pharmacotherapy, 2015, 75, 100-104.	2.5	27
1220	Self-assembled multifunctional DNA nanoflowers for the circumvention of multidrug resistance in targeted anticancer drug delivery. Nano Research, 2015, 8, 3447-3460.	5.8	95
1221	Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). Biochemistry, 2015, 54, 6195-6206.	1.2	24
1222	Synthesis of aqueous AgInS/ZnS@PEI as a self-indicating nonviral vector for plasmid DNA self-tracking delivery. Journal of Materials Chemistry B, 2015, 3, 8518-8527.	2.9	12
1223	Architecture of Chimeric Spheroids Controls Drug Transport. Cancer Microenvironment, 2015, 8, 101-109.	3.1	13
1224	Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics, 2015, 12, 3885-3895.	2.3	31
1225	Modulators of the human ABCC2: hope from natural sources?. Future Medicinal Chemistry, 2015, 7, 2041-2063.	1.1	17
1226	Chronic-Leptin Attenuates Cisplatin Cytotoxicity in MCF-7 Breast Cancer Cell Line. Cellular Physiology and Biochemistry, 2015, 36, 221-232.	1.1	17

#	Article	IF	Citations
1227	Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine, 2015, 10, 2199-2228.	1.7	52
1228	The Pharmacological and Physiological Role of Multidrug-Resistant Protein 4. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 358-375.	1.3	65
1229	Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: A potential target for â€˜two-in-oneâ€™ cancer chemoimmunotherapeutics. Cancer Letters, 2015, 369, 9-19.	3.2	13
1230	Cellular Uptake Behavior of Doxorubicinâ€Conjugated Nanodiamond Clusters for Efficient Cancer Therapy. Macromolecular Bioscience, 2015, 15, 1469-1475.	2.1	25
1231	Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacological Research, 2015, 102, 123-131.	3.1	51
1232	Sustained Epigenetic Drug Delivery Depletes Cholesterolâ€“Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids. Langmuir, 2015, 31, 11564-11573.	1.6	17
1233	Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 5566-5573.	1.4	14
1234	A novel peptide-based recognition probe for the sensitive detection ofÂCD44 on breast cancer stem cells. Molecular and Cellular Probes, 2015, 29, 492-499.	0.9	15
1235	Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44+/Musashi-1+ gastric cancer stem cells. Cancer Letters, 2015, 369, 124-133.	3.2	57
1236	Inhibition of ABCB1 Overcomes Cancer Stem Cellâ€“like Properties and Acquired Resistance to MET Inhibitors in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 2433-2440.	1.9	51
1237	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. Molecular Pharmaceutics, 2015, 12, 3556-3568.	2.3	15
1238	Co-delivery of doxorubicin hydrochloride and verapamil hydrochloride by pH-sensitive polymersomes for the reversal of multidrug resistance. RSC Advances, 2015, 5, 77986-77995.	1.7	36
1239	Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations. Molecular Pharmaceutics, 2015, 12, 4026-4037.	2.3	27
1240	Nanoparticle approaches to combating drug resistance. Future Medicinal Chemistry, 2015, 7, 1503-1510.	1.1	24
1241	Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 2015, 33, 941-951.	9.4	4,868
1242	Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice. International Journal of Pharmaceutics, 2015, 495, 329-335.	2.6	42
1244	In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas. Molecular Pharmaceutics, 2015, 12, 4247-4258.	2.3	69
1245	Novel isatin derivatives of podophyllotoxin: synthesis and cytotoxic evaluation against human leukaemia cancer cells as potent anti-MDR agents. RSC Advances, 2015, 5, 97816-97823.	1.7	26

#	Article	IF	Citations
1246	Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents. Bioorganic and Medicinal Chemistry, 2015, 23, 839-848.	1.4	51
1247	Functional vesicles formed by anticancer drug assembly. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 188-191.	1.0	5
1248	Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives. Journal of Inorganic Biochemistry, 2015, 144, 18-30.	1.5	25
1249	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. , 2015, 147, 12-21.		187
1250	P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. , 2015, , 593-619.		0
1251	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. , 2015, 149, 1-123.		275
1252	Zinc Finger Nucleaseâ€“Mediated Gene Knockout Results in Loss of Transport Activity for P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells. Drug Metabolism and Disposition, 2015, 43, 199-207.	1.7	32
1253	Fragment-Based Strategy for Investigating and Suppressing the Efflux of Bioactive Small Molecules. ACS Infectious Diseases, 2015, 1, 53-58.	1.8	11
1254	Oct-3/4 promotes tumor angiogenesis through VEGF production in glioblastoma. Brain Tumor Pathology, 2015, 32, 31-40.	1.1	9
1255	TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. Biomaterials, 2015, 40, 107-116.	5.7	172
1256	Reduction-Responsive Coreâ€“Shellâ€“Corona Micelles Based on Triblock Copolymers: Novel Synthetic Strategy, Characterization, and Application As a Tumor Microenvironment-Responsive Drug Delivery System. ACS Applied Materials & Interfaces, 2015, 7, 166-174.	4.0	108
1257	The effect of multidrug resistance modulator HZ08 on pharmacodynamics and pharmacokinetics of adriamycin in xenograft-nude mice. European Journal of Pharmaceutical Sciences, 2015, 66, 109-117.	1.9	3
1258	Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells. Journal of Biomedical Materials Research - Part A, 2015, 103, 1476-1484.	2.1	55
1259	Cancer Stem Cells â€” Perspectives and How to Target Them. , 0, , .		0
1260	Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer. Chinese Medical Journal, 2016, 129, 456-463.	0.9	38
1261	New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is). Current Medicinal Chemistry, 2016, 23, 1239-1249.	1.2	34
1262	Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers. Yonsei Medical Journal, 2016, 57, 50.	0.9	10
1263	Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. PLoS ONE, 2016, 11, e0161427.	1.1	2

#	Article	IF	Citations
1264	Effect of Molecular Structure, Substrate and Docking Scores on the Prediction of the Inhibition Constants of P-glycoprotein Inhibitors. Journal of Drug Metabolism & Toxicology, 2016, 07, .	0.1	0
1265	Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Oncotarget, 2016, 7, 83451-83461.	0.8	11
1266	miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget, 2016, 7, 24510-24526.	0.8	83
1267	The use of Brazilian vegetable oils in nanoemulsions: an update on preparation and biological applications. Brazilian Journal of Pharmaceutical Sciences, 2016, 52, 347-363.	1.2	43
1268	Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. Oncotarget, 2016, 7, 27158-27175.	0.8	49
1269	Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer. Oncotarget, 2016, 7, 36755-36766.	0.8	12
1270	Evaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma models. International Journal of Nanomedicine, 2016, Volume 11, 6703-6712.	3.3	11
1271	Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo. International Journal of Nanomedicine, 2016, Volume 11, 5429-5442.	3.3	19
1272	Novel N-Substituted 2-(2-(Adamantan-1-yl)-1H-Indol-3-yl)-2-Oxoacetamide Derivatives: Synthesis and Biological Evaluation. Molecules, 2016, 21, 530.	1.7	2
1273	Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget, 2016, 7, 73347-73369.	0.8	31
1274	Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World Journal of Gastroenterology, 2016, 22, 6876.	1.4	289
1275	Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance. Journal of Stem Cell Research & Therapy, 2016, 06, .	0.3	89
1276	Biomolecular Network-Based Synergistic Drug Combination Discovery. BioMed Research International, 2016, 2016, 1-11.	0.9	22
1277	Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer Agents. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-15.	1.9	115
1278	Cellular inactivation of nitric oxide induces p53-dependent apoptosis in human melanoma cells. Tropical Journal of Pharmaceutical Research, 2016, 15, 1595.	0.2	0
1279	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules, 2016, 21, 1236.	1.7	37
1280	Inorganic nanoflotillas as engineered particles for drug and gene delivery. , 2016, , 429-483.		5
1281	Molecular Mechanisms and Potential Clinical Applications of Campylobacter jejuni Cytolethal Distending Toxin. Frontiers in Cellular and Infection Microbiology, 2016, 6, 9.	1.8	44

#	Article	IF	Citations
1282	Antibodyâ€“Drug Conjugates for Cancer Therapy. Biomedicines, 2016, 4, 14.	1.4	77
1283	Identification of Long Nonâ€Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors. Genes, 2016, 7, 84.	1.0	15
1284	Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer. International Journal of Molecular Sciences, 2016, 17, 424.	1.8	96
1285	Activated Charge-Reversal Polymeric Nano-System: The Promising Strategy in Drug Delivery for Cancer Therapy. Polymers, 2016, 8, 99.	2.0	36
1286	Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates. PLoS ONE, 2016, 11, e0160042.	1.1	22
1287	Nanostructured Lipid Carriers: A Novel Platform for Chemotherapeutics. Current Drug Delivery, 2016, 13, 4-26.	0.8	65
1288	Plant mediated green synthesis of metallic nanoparticles. , 2016, , 149-177.		8
1289	Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors. Frontiers in Pharmacology, 2016, 7, 426.	1.6	4
1290	Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. Frontiers in Pharmacology, 2016, 7, 518.	1.6	93
1291	The anticancer properties of phytochemical extracts from Salvia plants. Botanics: Targets and Therapy, 2016, , 25.	0.3	3
1292	Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. Oncotarget, 2016, 7, 8850-8865.	0.8	32
1293	Substrate Specificity of Aglaia loheri Active Isolate towards P-glycoprotein in Multidrug-Resistant Cancer Cells. Natural Product Communications, 2016, 11, 1934578X1601101.	0.2	1
1294	Design, synthesis, biological evaluation, <scp>NMR</scp> and <scp>DFT</scp> studies of structurally simplified trimethoxy benzamides as selective Pâ€glycoprotein inhibitors: the role of molecular flatness. Chemical Biology and Drug Design, 2016, 88, 820-831.	1.5	3
1295	Simotinib as a modulator of P-glycoprotein. Anti-Cancer Drugs, 2016, 27, 300-311.	0.7	3
1296	Molecular Assembly of Polysaccharideâ€Based Microcapsules and Their Biomedical Applications. Chemical Record, 2016, 16, 1991-2004.	2.9	16
1297	Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells. Anti-Cancer Drugs, 2016, 27, 183-191.	0.7	8
1298	RNA binding protein RBM3 increases Î²â€catenin signaling to increase stem cell characteristics in colorectal cancer cells. Molecular Carcinogenesis, 2016, 55, 1503-1516.	1.3	44
1299	How can nanomedicines overcome cellular-based anticancer drug resistance?. Journal of Materials Chemistry B, 2016, 4, 5078-5100.	2.9	32

#	Article	IF	Citations
1300	Mixed Micelles for Targeted and Efficient Doxorubicin Delivery to Multidrugâ€Resistant Breast Cancer Cells. Macromolecular Bioscience, 2016, 16, 748-758.	2.1	17
1301	Genetic variants in <scp>ABCG</scp>1 are associated with survival of nonsmallâ€cell lung cancer patients. International Journal of Cancer, 2016, 138, 2592-2601.	2.3	41
1302	A Potent and Selective Pâ€gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. ChemMedChem, 2016, 11, 374-376.	1.6	13
1303	Predicting chemotherapeutic drug combinations through gene network profiling. Scientific Reports, 2016, 6, 18658.	1.6	24
1304	A single active catalytic site is sufficient to promote transport in P-glycoprotein. Scientific Reports, 2016, 6, 24810.	1.6	42
1305	The transport activity of P-glycoprotein upon a change of the redox balance in lymphocytes of patients with chronic B-lymphocytic leukemia. Biophysics (Russian Federation), 2016, 61, 971-978.	0.2	0
1306	Isoalantolactone induces autophagic cell death in SKOV3 human ovarian carcinoma cells via upregulation of PEA-15. Oncology Reports, 2016, 35, 833-840.	1.2	13
1307	MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. Cancer Cell International, 2016, 16, 64.	1.8	39
1308	RECQL4 Modulates MDR1 Expression and Chemoresistanceâ€”Letter. Cancer Research, 2016, 76, 7290-7290.	0.4	1
1309	Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption. Scientific Reports, 2016, 6, 22847.	1.6	34
1310	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2). European Journal of Medicinal Chemistry, 2016, 117, 212-229.	2.6	52
1311	Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance. European Journal of Medicinal Chemistry, 2016, 117, 335-354.	2.6	79
1312	ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resistance Updates, 2016, 26, 1-9.	6.5	316
1313	CellMiner Companion: an interactive web application to explore CellMiner NCI-60 data. Bioinformatics, 2016, 32, 2399-2401.	1.8	15
1314	Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein. Canadian Journal of Physiology and Pharmacology, 2016, 94, 929-935.	0.7	21
1315	Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. Molecular and Cellular Biology, 2016, 36, 2078-2088.	1.1	17
1316	The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. Sexual Medicine Reviews, 2016, 4, 74-84.	1.5	40
1317	Pancreatic Tumor Progression Associated With CD133 Overexpression. Pancreas, 2016, 45, 443-457.	0.5	19

#	Article	IF	Citations
1318	Active targeting co-delivery system based on pH-sensitive methoxy-poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 747 Td (glycol)2 Colloid and Interface Science, 2016, 472, 90-98.	5.0	25
1319	Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clinical and Experimental Metastasis, 2016, 33, 521-550.	1.7	30
1320	Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer. Expert Review of Molecular Diagnostics, 2016, 16, 769-782.	1.5	9
1321	Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy. Biomaterials, 2016, 97, 110-121.	5.7	39
1322	Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro. Molecular Pharmaceutics, 2016, 13, 2117-2125.	2.3	42
1323	Nanotechnology for cancer therapy. , 2016, , 395-470.		2
1324	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo. Molecular Cancer Therapeutics, 2016, 15, 1845-1858.	1.9	43
1325	Cell Cycle as an Object of Control. , 2016, , 9-54.		19
1326	Co-Delivery of Cisplatin Prodrug and Chlorin e6 by Mesoporous Silica Nanoparticles for Chemo-Photodynamic Combination Therapy to Combat Drug Resistance. ACS Applied Materials & Interfaces, 2016, 8, 13332-13340.	4.0	167
1327	TPGS modified reduced bovine serum albumin nanoparticles as a lipophilic anticancer drug carrier for overcoming multidrug resistance. Journal of Materials Chemistry B, 2016, 4, 3959-3968.	2.9	22
1328	Combining ABCG2 Inhibitors with IMMU-132, an Antiâ€“Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Molecular Cancer Therapeutics, 2016, 15, 1910-1919.	1.9	30
1329	Stimuli-responsive poly(N -isopropyl acrylamide)-co-tyrosine@gadolinium: Iron oxide nanoparticle-based nanotheranostic for cancer diagnosis and treatment. Colloids and Surfaces B: Biointerfaces, 2016, 142, 248-258.	2.5	44
1330	Design, synthesis and biological evaluation of novel triazole-core reversal agents against P-glycoprotein-mediated multidrug resistance. RSC Advances, 2016, 6, 25819-25828.	1.7	13
1331	Good's buffer derived highly emissive carbon quantum dots: excellent biocompatible anticancer drug carrier. Journal of Materials Chemistry B, 2016, 4, 2412-2420.	2.9	28
1332	pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells. Journal of Controlled Release, 2016, 232, 9-19.	4.8	119
1333	Combinatorial effects of geopropolis produced by Melipona fasciculata Smith with anticancer drugs against human laryngeal epidermoid carcinoma (HEp-2) cells. Biomedicine and Pharmacotherapy, 2016, 81, 48-55.	2.5	22
1334	Zinc Oxide Nanoparticles as Adjuvant To Facilitate Doxorubicin Intracellular Accumulation and Visualize pH-Responsive Release for Overcoming Drug Resistance. Molecular Pharmaceutics, 2016, 13, 1723-1730.	2.3	61
1335	Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Xenobiotica, 2016, 46, 416-423.	0.5	1

#	Article	IF	Citations
1336	Mechanism study of PEGylated polyester and Î²-cyclodextrin integrated micelles on drug resistance reversal in MRP1-overexpressed HL60/ADR cells. Colloids and Surfaces B: Biointerfaces, 2016, 144, 203-213.	2.5	13
1337	Cancer chemoresistance; biochemical and molecular aspects: a brief overview. European Journal of Pharmaceutical Sciences, 2016, 89, 20-30.	1.9	123
1338	Long-term exposure to irinotecan reduces cell migration in glioma cells. Journal of Neuro-Oncology, 2016, 127, 455-462.	1.4	1
1339	An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials, 2016, 97, 34-50.	5.7	117
1340	Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 633-644.	1.5	39
1341	Improving Viral Protease Inhibitors to Counter Drug Resistance. Trends in Microbiology, 2016, 24, 547-557.	3.5	81
1342	Development of efflux pump inhibitors in antituberculosis therapy. International Journal of Antimicrobial Agents, 2016, 47, 421-429.	1.1	41
1343	How plausible is the use of dietary n-3 PUFA in the adjuvant therapy of cancer?. Nutrition Research Reviews, 2016, 29, 102-125.	2.1	28
1344	Carrier-Free, Chemophotodynamic Dual Nanodrugs via Self-Assembly for Synergistic Antitumor Therapy. ACS Applied Materials & Interfaces, 2016, 8, 13262-13269.	4.0	281
1346	Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators. ChemMedChem, 2016, 11, 2422-2435.	1.6	15
1347	STAT3 Inhibitors in Cancer: A Comprehensive Update. Cancer Drug Discovery and Development, 2016, , 95-161.	0.2	11
1348	Machine learning-, rule- and pharmacophore-based classification on the inhibition of P-glycoprotein and NorA. SAR and QSAR in Environmental Research, 2016, 27, 747-780.	1.0	8
1349	Systematic identification of novel biomarker signatures associated with acquired erlotinib resistance in cancer cells. Molecular and Cellular Toxicology, 2016, 12, 139-148.	0.8	3
1350	Cisplatin and doxorubicin dual-loaded mesoporous silica nanoparticles for controlled drug delivery. RSC Advances, 2016, 6, 94160-94169.	1.7	42
1351	Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy. Journal of Materials Chemistry B, 2016, 4, 6856-6864.	2.9	38
1352	Codelivery of a Ï€â€“Ï€ Stacked Dual Anticancer Drug Combination with Nanocarriers for Overcoming Multidrug Resistance and Tumor Metastasis. Advanced Functional Materials, 2016, 26, 8266-8280.	7.8	123
1353	In Vitro Evaluation of pH-Responsive Nanoscale Hydrogels for the Oral Delivery of Hydrophobic Therapeutics. Industrial & Engineering Chemistry Research, 2016, 55, 10576-10590.	1.8	16
1354	Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts. Molecular Cancer Therapeutics, 2016, 15, 2853-2862.	1.9	18

#	Article	IF	Citations
1355	Targeting NF-Î²B RelA/p65 phosphorylation overcomes RITA resistance. Cancer Letters, 2016, 383, 261-271.	3.2	22
1356	Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems. International Journal of Pharmaceutics, 2016, 515, 132-164.	2.6	83
1357	Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics. Advanced Science, 2016, 3, 1600134.	5.6	107
1359	Osthole Induces Cell Cycle Arrest and Inhibits Migration and Invasion via PTEN/Akt Pathways in Osteosarcoma. Cellular Physiology and Biochemistry, 2016, 38, 2173-2182.	1.1	55
1360	Overcoming ABCG2-mediated multidrug resistance by a mineralized hyaluronanâ€“drug nanocomplex. Journal of Materials Chemistry B, 2016, 4, 6652-6661.	2.9	4
1361	The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-Î²B and PPARÎ³ in multidrug-resistant cancer cells. Food and Chemical Toxicology, 2016, 96, 35-42.	1.8	16
1362	Method to Screen Multidrug Transport Inhibitors Using Yeast Overexpressing a Human MDR Transporter. Methods in Molecular Biology, 2016, 1432, 303-318.	0.4	6
1363	Emissive nanoparticles from pyridinium-substituted tetraphenylethylene salts: imaging and selective cytotoxicity towards cancer cells in vitro and in vivo by varying counter anions. Chemical Science, 2016, 7, 7013-7019.	3.7	65
1364	Antibody-drug conjugates: Current status and future perspectives. , 2016, 167, 48-59.		51
1365	Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1. Journal of Natural Products, 2016, 79, 2135-2142.	1.5	22
1366	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1419-1432.	1.5	46
1367	Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Molecular Cancer Therapeutics, 2016, 15, 2282-2293.	1.9	57
1368	Stereoselective Modulation of Pâ€Glycoprotein by Chiral Small Molecules. ChemMedChem, 2016, 11, 93-101.	1.6	10
1369	Spica prunellae and its marker compound rosmarinic acid induced the expression of efflux transporters through activation of Nrf2-mediated signaling pathway in HepG2 cells. Journal of Ethnopharmacology, 2016, 193, 1-11.	2.0	31
1370	A H⁺-triggered bubble-generating nanosystem for killing cancer cells. Chemical Communications, 2016, 52, 10838-10841.	2.2	13
1371	Solution Binding and Structural Analyses Reveal Potential Multidrug Resistance Functions for SAV2435 and CTR107 and Other GyrI-like Proteins. Biochemistry, 2016, 55, 4850-4863.	1.2	11
1372	Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates, 2016, 28, 65-81.	6.5	147
1373	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4466-4471.	1.0	18

#	Article	IF	Citations
1374	Computational insights into the destabilization of Î±-helical conformations formed by leucine zipper peptides in response to temperature. Physical Chemistry Chemical Physics, 2016, 18, 25465-25473.	1.3	8
1375	Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. Drug Metabolism Reviews, 2016, 48, 502-540.	1.5	18
1377	Structureâ€“Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance. Journal of Medicinal Chemistry, 2016, 59, 8601-8620.	2.9	82
1378	Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis. BMC Cancer, 2016, 16, 906.	1.1	17
1379	Magnetic Tandem Apoptosis for Overcoming Multidrug-Resistant Cancer. Nano Letters, 2016, 16, 7455-7460.	4.5	41
1380	Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Scientific Reports, 2016, 6, 23269.	1.6	90
1381	Resin Glycosides from Ipomoea alba Seeds as Potential Chemosensitizers in Breast Carcinoma Cells. Journal of Natural Products, 2016, 79, 3093-3104.	1.5	22
1382	Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis. Tumor Biology, 2016, 37, 14745-14755.	0.8	12
1383	Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Molecular and Cellular Biochemistry, 2016, 422, 161-170.	1.4	57
1384	Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Therapy, 2016, 23, 821-828.	2.3	25
1385	Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter. European Journal of Medicinal Chemistry, 2016, 124, 881-895.	2.6	16
1386	Polydopamineâ€Functionalized Graphene Oxide Loaded with Gold Nanostars and Doxorubicin for Combined Photothermal and Chemotherapy of Metastatic Breast Cancer. Advanced Healthcare Materials, 2016, 5, 2227-2236.	3.9	54
1387	Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds. Molecular Diversity, 2016, 20, 945-961.	2.1	43
1388	Biotinylated carboxymethyl chitosan/CaCO3 hybrid nanoparticles for targeted drug delivery to overcome tumor drug resistance. RSC Advances, 2016, 6, 69083-69093.	1.7	25
1389	External-stimuli responsive systems for cancer theranostic. Asian Journal of Pharmaceutical Sciences, 2016, 11, 585-595.	4.3	116
1390	Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Scientific Reports, 2016, 6, 31009.	1.6	33
1391	Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. International Journal of Pharmaceutics, 2016, 514, 24-40.	2.6	51
1392	Induction of P-glycoprotein expression and activity by Aconitum alkaloids: Implication for clinical drugâ€“drug interactions. Scientific Reports, 2016, 6, 25343.	1.6	35

#	Article	IF	Citations
1393	Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. Scientific Reports, 2016, 6, 25659.	1.6	14
1394	Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion. Tumor Biology, 2016, 37, 16249-16258.	0.8	6
1395	Thermoresponsive Delivery of Paclitaxel by Î²-Cyclodextrin-Based Poly(N-isopropylacrylamide) Star Polymer via Inclusion Complexation. Biomacromolecules, 2016, 17, 3957-3963.	2.6	68
1396	A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy. Scientific Reports, 2016, 6, 32363.	1.6	23
1397	Mechanisms of Resistance to Antibodyâ€“Drug Conjugates. Molecular Cancer Therapeutics, 2016, 15, 2825-2834.	1.9	119
1398	Exceedingly Higher co-loading of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent Synergistic Anticancer Treatment. Scientific Reports, 2016, 6, 32808.	1.6	84
1399	Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10774-10780.	2.9	6
1400	Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates. ChemMedChem, 2016, 11, 2547-2558.	1.6	13
1401	Crystal Structure of Eukaryotic P-glycoprotein Homolog from <i>Cyanidioschyzon merolae</i>. Seibutsu Butsuri, 2016, 56, 315-318.	0.0	0
1402	Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. Molecular Cytogenetics, 2016, 9, 52.	0.4	25
1403	The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. Drug Discovery Today: Disease Models, 2016, 21, 23-32.	1.2	8
1404	Synthesis and Investigation of Tetrahydro-Î²-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2). Journal of Medicinal Chemistry, 2016, 59, 6121-6135.	2.9	57
1405	Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy. Journal of Controlled Release, 2016, 240, 454-464.	4.8	46
1406	Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1021-1033.	1.5	43
1407	Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Cellular Oncology (Dordrecht), 2016, 39, 411-433.	2.1	36
1408	Chinese Ginseng. , 2016, , 693-705.		7
1409	Synthesis of 6-alkylsulfanyl-1,4-dihydropyridines as potential multidrug resistance modulators. Heterocyclic Communications, 2016, 22, 157-160.	0.6	4
1410	Investigation of the apoptotic pathway induced by benzimidazoleâ€“oxindole conjugates against human breast cancer cells MCF-7. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3313-3317.	1.0	13

#	Article	IF	Citations
1411	Jatrophane diterpenes and cancer multidrug resistance â€“ ABCB1 efflux modulation and selective cell death induction. Phytomedicine, 2016, 23, 968-978.	2.3	41
1412	Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. Journal of Pharmaceutical Sciences, 2016, 105, 484-496.	1.6	24
1413	All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complementary and Alternative Medicine, 2016, 16, 113.	3.7	49
1414	High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. Molecular Cancer Therapeutics, 2016, 15, 1998-2008.	1.9	13
1415	Nuclear Transcription Factor Kappa B Downregulation Reduces Chemoresistance in Bone Marrow-derived Cells Through P-glycoprotein Modulation. Archives of Medical Research, 2016, 47, 78-88.	1.5	6
1416	Supramolecular Drug Delivery Systems Based on Water-Soluble Pillar[n]arenes. Chemical Record, 2016, 16, 1216-1227.	2.9	66
1417	Efficacy of traditional Chinese medicine in treating cancer. Biomedical Reports, 2016, 4, 3-14.	0.9	92
1418	Ambra1 in autophagy and apoptosis: Implications for cell survival and chemotherapy resistance. Oncology Letters, 2016, 12, 367-374.	0.8	27
1419	Design, synthesis and biological evaluation of rhein derivatives as anticancer agents. MedChemComm, 2016, 7, 1812-1818.	3.5	7
1420	Invited review: Architectures and mechanisms of ATP binding cassette proteins. Biopolymers, 2016, 105, 492-504.	1.2	62
1421	NVPâ€TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting Pâ€glycoprotein (PGP1) function. British Journal of Pharmacology, 2016, 173, 613-626.	2.7	26
1422	Nanocarriers for cancer-targeted drug delivery. Journal of Drug Targeting, 2016, 24, 179-191.	2.1	423
1423	Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/Î²-catenin signalling pathway via suppression of activator protein 2Î±. Gut, 2016, 65, 1494-1504.	6.1	284
1424	Lung cancer stem cells: The root of resistance. Cancer Letters, 2016, 372, 147-156.	3.2	130
1425	The role of glucuronidation in drug resistance. , 2016, 159, 35-55.		75
1426	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. Molecular Pharmaceutics, 2016, 13, 784-794.	2.3	29
1427	Lysosomes as mediators of drug resistance in cancer. Drug Resistance Updates, 2016, 24, 23-33.	6.5	330
1428	Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene, 2016, 578, 232-241.	1.0	52

#	Article	IF	Citations
1429	Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opinion on Drug Delivery, 2016, 13, 401-419.	2.4	40
1430	Chondroitin sulfate coated gold nanoparticles: a new strategy to resolve multidrug resistance and thromboinflammation. Chemical Communications, 2016, 52, 966-969.	2.2	40
1431	Anticancer and Cancer Prevention Effects of Piperine-Free Piper nigrum Extract on N-nitrosomethylurea-Induced Mammary Tumorigenesis in Rats. Cancer Prevention Research, 2016, 9, 74-82.	0.7	42
1432	Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III Î²-tubulin in drug-resistant breast cancers. Acta Biomaterialia, 2016, 31, 197-210.	4.1	72
1433	Detection of MDR1 mRNA expression with optimized gold nanoparticle beacon. Proceedings of SPIE, 2016, , .	0.8	1
1434	Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. Drug Metabolism and Disposition, 2016, 44, 180-188.	1.7	5
1435	Pyrimido[1â€³,2â€³:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Letters, 2016, 376, 118-126.	3.2	28
1436	Anticancer efficacy of a nitric oxideâ€modified derivative of bifendate against multidrugâ€resistant cancer cells. Journal of Cellular and Molecular Medicine, 2016, 20, 1095-1105.	1.6	30
1437	Cancer stem cells and chemoresistance: The smartest survives the raid. , 2016, 160, 145-158.		360
1438	Toward a unifying strategy for the structure-based prediction of toxicological endpoints. Archives of Toxicology, 2016, 90, 2445-2460.	1.9	9
1439	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	1.0	21
1440	Regulation of drug-metabolizing enzymes and efflux transporters by Astragali radix decoction and its main bioactive compounds: Implication for clinical drugâ€“drug interactions. Journal of Ethnopharmacology, 2016, 180, 104-113.	2.0	29
1441	Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chemical Reviews, 2016, 116, 2602-2663.	23.0	2,018
1442	Tumor metabolism, cancer cell transporters, and microenvironmental resistance. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 859-866.	2.5	60
1443	N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines. Heliyon, 2016, 2, e00060.	1.4	18
1444	Total Synthesis and Biological Evaluation of Natural and Designed Tubulysins. Journal of the American Chemical Society, 2016, 138, 1698-1708.	6.6	78
1445	Î²-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function. Phytomedicine, 2016, 23, 316-323.	2.3	48
1446	Uptake and Permeability Studies to Delineate the Role of Efflux Transporters. Methods in Molecular Biology, 2016, 1395, 69-74.	0.4	0

#	Article	IF	Citations
1447	Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter. Methods in Molecular Biology, 2016, 1395, 87-103.	0.4	9
1448	Organocatalytic Anticancer Drug Loading of Degradable Polymeric Mixed Micelles via a Biomimetic Mechanism. Macromolecules, 2016, 49, 2013-2021.	2.2	38
1449	Topoisomerase IIÎ± mediates TCF-dependent epithelialâ€“mesenchymal transition in colon cancer. Oncogene, 2016, 35, 4990-4999.	2.6	23
1450	Inborn Errors of the Cellular Expression and Localization of ABCG2 and ABCB6. A Database for ABC Transporter Mutations. , 2016, , 341-355.		0
1451	Molecular basis of polyspecificity of the Small Multidrug Resistance Efflux Pump AbeS from Acinetobacter baumannii. Journal of Molecular Biology, 2016, 428, 644-657.	2.0	24
1452	PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumor Biology, 2016, 37, 8799-8809.	0.8	8
1453	Potential anti-MDR agents based on the podophyllotoxin scaffold: synthesis and antiproliferative activity evaluation against chronic myeloid leukemia cells by activating MAPK signaling pathways. RSC Advances, 2016, 6, 2895-2903.	1.7	20
1454	Vitamin E derivative-based multifunctional nanoemulsions for overcoming multidrug resistance in cancer. Journal of Drug Targeting, 2016, 24, 663-669.	2.1	21
1455	Targeting CD133+ laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles. Tumor Biology, 2016, 37, 2209-2217.	0.8	32
1456	p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. Cancer Chemotherapy and Pharmacology, 2016, 77, 349-356.	1.1	37
1457	Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Research, 2016, 76, 1066-1077.	0.4	104
1458	Polymer assembly: Promising carriers as co-delivery systems for cancer therapy. Progress in Polymer Science, 2016, 58, 1-26.	11.8	86
1459	â€œComboâ€•nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 3-18.	6.6	399
1460	Combination Treatment of Murine Colon Cancer with Doxorubicin and Redox Nanoparticles. Molecular Pharmaceutics, 2016, 13, 449-455.	2.3	41
1461	Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells. Archives of Toxicology, 2016, 90, 2275-2286.	1.9	30
1462	Pharmacokinetics and tissue distribution of 5,7-dimethoxyflavone in mice following single dose oral administration. Journal of Pharmaceutical and Biomedical Analysis, 2016, 119, 65-70.	1.4	18
1463	The role of hypoxia in pancreatic cancer: a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 301-316.	1.4	114
1464	Phototherapeutic Release of Nitric Oxide with Engineered Nanoconstructs. Topics in Current Chemistry, 2016, 370, 225-257.	4.0	26

#	Article	IF	Citations
1465	Gd-based upconversion nanocarriers with yolkâ€“shell structure for dual-modal imaging and enhanced chemotherapy to overcome multidrug resistance in breast cancer. Nanoscale, 2016, 8, 878-888.	2.8	47
1466	Dietary Factors May Influence the Clinical Outcome of Chemotherapy in Cancer Multidrug Resistance. , 2016, , 307-319.		1
1467	Sonoporation: Applications for Cancer Therapy. Advances in Experimental Medicine and Biology, 2016, 880, 263-291.	0.8	43
1468	Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 19-29.	1.9	43
1469	Monodistearoylphosphatidylethanolamine-hyaluronic acid functionalization of single-walled carbon nanotubes for targeting intracellular drug delivery to overcome multidrug resistance of cancer cells. Carbon, 2016, 96, 362-376.	5.4	39
1470	Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis. Tumor Biology, 2016, 37, 2285-2297.	0.8	11
1471	MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN. Tumor Biology, 2016, 37, 3215-3225.	0.8	70
1472	MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumor Biology, 2016, 37, 1197-1204.	0.8	38
1473	Methotrexate-conjugated quantum dots: synthesis, characterisation and cytotoxicity in drug resistant cancer cells. Journal of Drug Targeting, 2016, 24, 120-133.	2.1	45
1474	Altered GABA_A receptor density and unaltered bloodâ€“brain barrier [¹¹C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 97-105.	2.4	8
1475	Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma. Journal of Oncology Pharmacy Practice, 2017, 23, 43-55.	0.5	6
1476	Cell cycle kinetics, apoptosis rates and gene expressions of <scp>MDR</scp>â€1, <scp>TP53</scp>, <scp>BCL</scp>â€2 and <scp>BAX</scp> in transmissible venereal tumour cells and their association with therapy response. Veterinary and Comparative Oncology, 2017, 15, 793-807.	0.8	24
1477	Anticancer activity of baicalein and luteolin studied in colorectal adenocarcinoma LoVo cells and in drug-resistant LoVo/Dx cells. Biomedicine and Pharmacotherapy, 2017, 88, 232-241.	2.5	52
1478	Downregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil. Oncology Letters, 2017, 13, 483-487.	0.8	16
1479	Dual aptamer modified dendrigraft poly-<scp>l</scp>-lysine nanoparticles for overcoming multi-drug resistance through mitochondrial targeting. Journal of Materials Chemistry B, 2017, 5, 972-979.	2.9	28
1480	Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors. SAR and QSAR in Environmental Research, 2017, 28, 1-16.	1.0	18
1481	Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharmaceutica Sinica B, 2017, 7, 38-51.	5.7	159
1482	Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo. Journal of Medicinal Chemistry, 2017, 60, 928-940.	2.9	32

#	Article	IF	Citations
1483	Stimulusâ€Responsive Short Peptide Nanogels for Controlled Intracellular Drug Release and for Overcoming Tumor Resistance. Chemistry - an Asian Journal, 2017, 12, 744-752.	1.7	18
1484	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. ACS Medicinal Chemistry Letters, 2017, 8, 361-365.	1.3	39
1485	Fewâ€Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients. Angewandte Chemie - International Edition, 2017, 56, 3014-3019.	7.2	59
1486	Redoxâ€Activatable ATPâ€Depleting Micelles with Dual Modulation Characteristics for Multidrugâ€Resistant Cancer Therapy. Advanced Healthcare Materials, 2017, 6, 1601293.	3.9	43
1487	TAT-Modified Gold Nanoparticle Carrier with Enhanced Anticancer Activity and Size Effect on Overcoming Multidrug Resistance. ACS Applied Materials & Interfaces, 2017, 9, 5828-5837.	4.0	49
1488	Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties. Journal of Controlled Release, 2017, 251, 49-67.	4.8	104
1489	Synthesis and Cytostatic and Antiviral Profiling of Thieno-Fused 7-Deazapurine Ribonucleosides. Journal of Medicinal Chemistry, 2017, 60, 2411-2424.	2.9	33
1490	Molecular markers in glioma. Journal of Neuro-Oncology, 2017, 134, 505-512.	1.4	279
1491	In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1460.	3.3	66
1492	pH-sensitive micelles for the intracellular co-delivery of curcumin and Pluronic L61 unimers for synergistic reversal effect of multidrug resistance. Scientific Reports, 2017, 7, 42465.	1.6	37
1493	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. Molecular Cancer Therapeutics, 2017, 16, 1021-1030.	1.9	30
1495	Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss. Cellular Oncology (Dordrecht), 2017, 40, 209-218.	2.1	30
1496	Synthesis and evaluation of pH-sensitive, self-assembled chitosan-based nanoparticles as efficient doxorubicin carriers. Journal of Biomaterials Applications, 2017, 31, 1182-1195.	1.2	27
1497	Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers. Topics in Current Chemistry, 2017, 375, 24.	3.0	22
1498	Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells. European Journal of Medicinal Chemistry, 2017, 128, 247-257.	2.6	30
1499	Comparative solution equilibrium studies of antitumor ruthenium(Î·⁶-p-cymene) and rhodium(Î·⁵-C₅Me₅) complexes of 8-hydroxyquinolines. Dalton Transactions, 2017, 46, 4382-4396.	1.6	39
1500	Fewâ€Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients. Angewandte Chemie, 2017, 129, 3060-3065.	1.6	9
1501	Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of Î±-tocopheryl succinate-based polyphosphoester copolymers. Acta Pharmacologica Sinica, 2017, 38, 859-873.	2.8	27

#	Article	IF	Citations
1502	Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line. Oncology Reports, 2017, 37, 219-226.	1.2	8
1503	Importance of Drug Pharmacokinetics at the Site of Action. Clinical and Translational Science, 2017, 10, 133-142.	1.5	86
1504	Structure and biological properties of mixed-ligand Cu(II) Schiff base complexes as potential anticancer agents. European Journal of Medicinal Chemistry, 2017, 134, 207-217.	2.6	90
1505	MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. Experimental Biology and Medicine, 2017, 242, 1299-1305.	1.1	30
1506	Synthesis and SAR Study of Anticancer Protoflavone Derivatives: Investigation of Cytotoxicity and Interaction with ABCB1 and ABCG2 Multidrug Efflux Transporters. ChemMedChem, 2017, 12, 850-859.	1.6	11
1507	P-gp modulatory acetyl-11-keto-Î²-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel. Colloids and Surfaces B: Biointerfaces, 2017, 155, 276-286.	2.5	22
1508	Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. Biomacromolecules, 2017, 18, 1855-1865.	2.6	21
1509	Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-ÎºB pathway. Biomedicine and Pharmacotherapy, 2017, 90, 677-685.	2.5	146
1510	Core-shell hierarchical mesostructured silica nanoparticles for gene/chemo-synergetic stepwise therapy of multidrug-resistant cancer. Biomaterials, 2017, 133, 219-228.	5.7	114
1511	Exploring Jolkinol D Derivatives To Overcome Multidrug Resistance in Cancer. Journal of Natural Products, 2017, 80, 1411-1420.	1.5	24
1512	Coordinating Biointeraction and Bioreaction of a Nanocarrier Material and an Anticancer Drug to Overcome Membrane Rigidity and Target Mitochondria in Multidrugâ€Resistant Cancer Cells. Advanced Functional Materials, 2017, 27, 1700804.	7.8	29
1513	Diospyros , an under-utilized, multi-purpose plant genus: A review. Biomedicine and Pharmacotherapy, 2017, 91, 714-730.	2.5	45
1514	Unidirectional Transport Mechanism in an ATP Dependent Exporter. ACS Central Science, 2017, 3, 250-258.	5.3	19
1515	Stimuli-responsive liposome and control release drug. , 2017, , 887-917.		3
1516	Mitochondria-Targeting Polydopamine Nanoparticles To Deliver Doxorubicin for Overcoming Drug Resistance. ACS Applied Materials & Interfaces, 2017, 9, 16793-16802.	4.0	135
1517	MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncology Letters, 2017, 13, 1451-1455.	0.8	14
1518	Effects of a novel photoactivated photosensitizer on MDR1 over-expressing human breast cancer cells. Journal of Photochemistry and Photobiology B: Biology, 2017, 171, 67-74.	1.7	9
1519	AP-2Î± reverses vincristine-induced multidrug resistance of SGC7901 gastric cancer cells by inhibiting the Notch pathway. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 933-941.	2.2	21

#	Article	IF	Citations
1520	Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells. Journal of Pharmacy and Pharmacology, 2017, 69, 834-843.	1.2	14
1521	Pluronic-PEI Micelles Reverse Multidrug Resistance by Depleting ATP and Inhibiting P-Glycoprotein for Colon Cancer Therapy. Materials Science Forum, 0, 886, 111-116.	0.3	2
1522	Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs. Advanced Drug Delivery Reviews, 2017, 115, 82-97.	6.6	64
1523	Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy. ACS Applied Materials & Interfaces, 2017, 9, 18450-18461.	4.0	24
1524	The role of membrane transporters in ovarian cancer chemoresistance and prognosis. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 741-753.	1.5	8
1525	Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. Scientific Reports, 2017, 7, 3182.	1.6	55
1526	Photothermal gold nanocages filled with temperature sensitive tetradecanol and encapsulated with glutathione responsive polycurcumin for controlled DOX delivery to maximize anti-MDR tumor effects. Journal of Materials Chemistry B, 2017, 5, 5464-5472.	2.9	25
1527	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Reports, 2017, 19, 1669-1684.	2.9	82
1528	PARP inhibitors as precision medicine for cancer treatment. National Science Review, 2017, 4, 576-592.	4.6	12
1529	Cadmium exposure exerts neurotoxic effects in peacock blennies Salaria pavo. Ecotoxicology and Environmental Safety, 2017, 143, 217-227.	2.9	14
1530	Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer Journal, 2017, 7, e565-e565.	2.8	41
1531	Multifunctional Molecular Beacon Micelles for Intracellular mRNA Imaging and Synergistic Therapy in Multidrugâ€Resistant Cancer Cells. Advanced Functional Materials, 2017, 27, 1701027.	7.8	45
1532	Mesoporous polydopamine nanoparticles with co-delivery function for overcoming multidrug resistance via synergistic chemo-photothermal therapy. Nanoscale, 2017, 9, 8781-8790.	2.8	180
1533	Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resistance Updates, 2017, 31, 15-30.	6.5	242
1534	Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Research, 2017, 77, 3908-3921.	0.4	56
1535	Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy. AAPS Journal, 2017, 19, 973-988.	2.2	64
1536	Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells. Oncology Letters, 2017, 13, 4974-4978.	0.8	58
1537	Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 251-260.	1.1	4

#	Article	IF	Citations
1538	Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. Molecular Pharmaceutics, 2017, 14, 2368-2377.	2.3	11
1539	Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicology in Vitro, 2017, 43, 87-91.	1.1	12
1540	Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncology Letters, 2017, 13, 4785-4793.	0.8	15
1541	Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4194-4202.	1.4	9
1542	Advances in antibodyâ€“drug conjugates: A new era of targeted cancer therapy. Drug Discovery Today, 2017, 22, 1547-1556.	3.2	139
1543	Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance. DNA Repair, 2017, 54, 13-21.	1.3	69
1544	Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. Journal of Ethnopharmacology, 2017, 203, 110-119.	2.0	38
1545	Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms. , 2017, , 15-65.		4
1546	PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 1187-1198.	1.9	37
1547	Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm. Handbook of Experimental Pharmacology, 2017, 249, 1-12.	0.9	18
1548	The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opinion on Therapeutic Targets, 2017, 21, 511-530.	1.5	101
1549	Can a nanoparticle that mimics Salmonella effectively combat tumor chemotherapy resistance?. Nanomedicine, 2017, 12, 705-710.	1.7	2
1550	Nitroxide radical-containing nanoparticles as potential candidates for overcoming drug resistance in epidermoid cancers. Polymer, 2017, 116, 429-438.	1.8	22
1551	Diterpenes and Their Derivatives as Potential Anticancer Agents. Phytotherapy Research, 2017, 31, 691-712.	2.8	56
1552	Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene. Molecular Therapy - Nucleic Acids, 2017, 6, 209-220.	2.3	64
1553	Salinomycin: A new paradigm in cancer therapy. Tumor Biology, 2017, 39, 101042831769503.	0.8	102
1554	Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017, 36, 35.	4.9	63
1555	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells. European Journal of Medicinal Chemistry, 2017, 131, 81-91.	2.6	28

#	Article	IF	Citations
1556	Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy. Journal of Controlled Release, 2017, 253, 110-121.	4.8	43
1557	Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model. Scientific Reports, 2017, 7, 43961.	1.6	18
1558	Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy. Biomaterials, 2017, 129, 83-97.	5.7	37
1559	Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60, 2930-2943.	2.9	36
1560	Design, Synthesis, and Cytotoxic Evaluation of Certain 7â€Chloroâ€4â€(piperazinâ€1â€yl)quinoline Derivatives as VEGFRâ€I Inhibitors. Archiv Der Pharmazie, 2017, 350, 1600377.	2.1	10
1561	Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Experimental and Molecular Medicine, 2017, 49, e303-e303.	3.2	37
1562	Mixed poly(vinyl pyrrolidone)-based drug-loaded nanomicelles shows enhanced efficacy against pancreatic cancer cell lines. European Journal of Pharmaceutical Sciences, 2017, 102, 250-260.	1.9	18
1563	An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis. Leukemia and Lymphoma, 2017, 58, 1922-1930.	0.6	12
1564	Sulfonic acid functionalized boron nitride nano materials as a microwave-assisted efficient and highly biologically active one-pot synthesis of piperazinyl-quinolinyl fused Benzo[c]acridine derivatives. Materials Chemistry and Physics, 2017, 188, 154-167.	2.0	17
1565	Tumor-Specific Multiple Stimuli-Activated Dendrimeric Nanoassemblies with Metabolic Blockade Surmount Chemotherapy Resistance. ACS Nano, 2017, 11, 416-429.	7.3	118
1566	MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomedicine and Pharmacotherapy, 2017, 86, 450-456.	2.5	82
1567	Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro. Oncology Letters, 2017, 13, 389-395.	0.8	51
1568	Modulation of cell death in human colorectal and breast cancer cells through a manganese chelate by involving GSH with intracellular p53 status. Molecular and Cellular Biochemistry, 2017, 427, 35-58.	1.4	1
1569	Multifunctional Metalâ€“Organic Framework Nanoprobe for Cathepsin B-Activated Cancer Cell Imaging and Chemo-Photodynamic Therapy. ACS Applied Materials & Interfaces, 2017, 9, 2150-2158.	4.0	118
1570	MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. Cancer Biomarkers, 2017, 18, 1-9.	0.8	36
1571	Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy. Drug Delivery and Translational Research, 2017, 7, 346-358.	3.0	26
1572	Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors. Journal of Pharmaceutical Investigation, 2017, 47, 37-49.	2.7	43
1573	Oneâ€Step Microfluidic Synthesis of Nanocomplex with Tunable Rigidity and Acidâ€Switchable Surface Charge for Overcoming Drug Resistance. Small, 2017, 13, 1603109.	5.2	56

#	Article	IF	Citations
1574	Safe and Effective Reversal of Cancer Multidrug Resistance Using Sericinâ€Coated Mesoporous Silica Nanoparticles for Lysosomeâ€Targeting Delivery in Mice. Small, 2017, 13, 1602567.	5.2	50
1575	The role of nanoparticles in the albumin-cytarabine and albumin-methotrexate interactions. Materials Science and Engineering C, 2017, 73, 388-397.	3.8	12
1576	FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells. Oncology Reports, 2017, 38, 2205-2210.	1.2	16
1577	Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resistance Updates, 2017, 32, 23-46.	6.5	109
1578	A Multifunctional Nanoplatform against Multidrug Resistant Cancer: Merging the Best of Targeted Chemo/Gene/Photothermal Therapy. Advanced Functional Materials, 2017, 27, 1704135.	7.8	260
1579	The design of peptide-grafted graphene oxide targeting the actin cytoskeleton for efficient cancer therapy. Chemical Communications, 2017, 53, 11433-11436.	2.2	16
1580	Targeted H+-Triggered Bubble-Generating Nanosystems for Effective Therapy in Cancer Cells. Colloids and Surfaces B: Biointerfaces, 2017, 160, 207-214.	2.5	8
1581	Nanotechnology for Multimodal Synergistic Cancer Therapy. Chemical Reviews, 2017, 117, 13566-13638.	23.0	1,392
1582	Lawsone derivatives target the Wnt/Î²-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells. Biochemical Pharmacology, 2017, 146, 63-73.	2.0	26
1583	Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. Journal of Visualized Experiments, 2017, , .	0.2	4
1584	Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma. Laboratory Investigation, 2017, 97, 1400-1411.	1.7	8
1585	H₂Sâ€Activable MOF Nanoparticle Photosensitizer for Effective Photodynamic Therapy against Cancer with Controllable Singletâ€Oxygen Release. Angewandte Chemie - International Edition, 2017, 56, 13752-13756.	7.2	283
1586	Tumor-homing, pH- and ultrasound-responsive polypeptide-doxorubicin nanoconjugates overcome doxorubicin resistance in cancer therapy. Journal of Controlled Release, 2017, 264, 66-75.	4.8	58
1587	Synthesis and in vitro biological evaluation of thiosulfinate derivatives for the treatment of human multidrug-resistant breast cancer. Acta Pharmacologica Sinica, 2017, 38, 1353-1368.	2.8	28
1588	Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 196-210.	1.3	20
1589	Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. European Journal of Pharmaceutical Sciences, 2017, 109, 631-637.	1.9	17
1590	Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer. Biomaterials Science, 2017, 5, 2268-2275.	2.6	22
1591	H₂Sâ€Activable MOF Nanoparticle Photosensitizer for Effective Photodynamic Therapy against Cancer with Controllable Singletâ€Oxygen Release. Angewandte Chemie, 2017, 129, 13940-13944.	1.6	59

#	Article	IF	Citations
1592	Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2017, 409, 56-65.	3.2	18
1593	Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression. Bioscience Reports, 2017, 37, .	1.1	13
1594	Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses. Npj Systems Biology and Applications, 2017, 3, 23.	1.4	15
1595	Polyphyllin I suppresses human osteosarcoma growth by inactivation of Wnt/Î²-catenin pathway in vitro and in vivo. Scientific Reports, 2017, 7, 7605.	1.6	34
1596	Prophetic medicine as potential functional food elements in the intervention of cancer: A review. Biomedicine and Pharmacotherapy, 2017, 95, 614-648.	2.5	32
1597	Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy. Nanoscale, 2017, 9, 13879-13904.	2.8	38
1598	Antibiotic That Inhibits the ATPase Activity of an ATP-Binding Cassette Transporter by Binding to a Remote Extracellular Site. Journal of the American Chemical Society, 2017, 139, 10597-10600.	6.6	18
1599	Lapatinib potentiates cytotoxicity of ÂYM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Scientific Reports, 2017, 7, 3091.	1.6	35
1600	Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents. European Journal of Medicinal Chemistry, 2017, 138, 1114-1125.	2.6	28
1601	AIE Luminogens for Bioimaging and Theranostics: From Organelles to Animals. CheM, 2017, 3, 56-91.	5.8	465
1602	Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma. European Journal of Medicinal Chemistry, 2017, 138, 602-615.	2.6	6
1603	Graphene Quantum Dots Downregulate Multiple Multidrugâ€Resistant Genes via Interacting with Their Câ€Rich Promoters. Advanced Healthcare Materials, 2017, 6, 1700328.	3.9	30
1604	Visfatin mediates doxorubicin resistance in human nonâ€“smallâ€cell lung cancer via Aktâ€mediated upâ€regulation of <scp>ABCC</scp>1. Cell Proliferation, 2017, 50, .	2.4	21
1605	Mixed micelles based on a pH-sensitive prodrug and TPGS for enhancing drug efficacy against multidrug-resistant cancer cells. Colloids and Surfaces B: Biointerfaces, 2017, 159, 419-426.	2.5	10
1606	Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells. Phytomedicine, 2017, 33, 62-68.	2.3	66
1607	Modulation of P-glycoprotein by Stemona alkaloids in human multidrug resistance leukemic cells and structural relationships. Phytomedicine, 2017, 34, 182-190.	2.3	27
1608	Redox sensitive cationic pullulan for efficient gene transfection and drug retention in C6 glioma cells. International Journal of Pharmaceutics, 2017, 530, 401-414.	2.6	20
1609	Dioxomorpholines and Derivatives from a Marine-Facultative Aspergillus Species. Journal of Natural Products, 2017, 80, 2311-2318.	1.5	29

#	Article	IF	Citations
1610	Hydrazone cross-linked micelles based on redox degradable block copolymer for enhanced stability and controlled drug release. Reactive and Functional Polymers, 2017, 119, 64-74.	2.0	16
1611	Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe. Molecular Pharmaceutics, 2017, 14, 3391-3398.	2.3	18
1612	Smart activatable and traceable dual-prodrug for image-guided combination photodynamic and chemo-therapy. Biomaterials, 2017, 144, 53-59.	5.7	73
1613	A novel delocalized lipophilic cation-chlorambucil conjugate inhibits P-glycoprotein in HepG2/ADM cells. Bioorganic and Medicinal Chemistry, 2017, 25, 5461-5467.	1.4	8
1614	Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-<scp>d</scp>-aspartate (NMDA) Receptor Antagonist. Journal of Medicinal Chemistry, 2017, 60, 9885-9904.	2.9	27
1615	Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines. Oncology Reports, 2018, 39, 160-172.	1.2	19
1616	A Small Molecule Nanodrug by Self-Assembly of Dual Anticancer Drugs and Photosensitizer for Synergistic near-Infrared Cancer Theranostics. ACS Applied Materials & Interfaces, 2017, 9, 43508-43519.	4.0	107
1617	Antiproliferative activities of alkaloid-like compounds. MedChemComm, 2017, 8, 2105-2114.	3.5	5
1618	CuS-Based Theranostic Micelles for NIR-Controlled Combination Chemotherapy and Photothermal Therapy and Photoacoustic Imaging. ACS Applied Materials & Interfaces, 2017, 9, 41700-41711.	4.0	67
1619	Transport of drugs from blood vessels to tumour tissue. Nature Reviews Cancer, 2017, 17, 738-750.	12.8	499
1620	Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncology Reports, 2017, 38, 3376-3386.	1.2	29
1621	ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells. Toxicology and Applied Pharmacology, 2017, 337, 22-29.	1.3	29
1622	EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment. Pharmaceutical Research, 2017, 34, 2891-2900.	1.7	32
1623	Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. Molecular Pharmaceutics, 2017, 14, 2805-2814.	2.3	24
1624	Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. Journal of Controlled Release, 2017, 261, 287-296.	4.8	70
1625	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	4.0	74
1626	Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance. ACS Applied Materials & Interfaces, 2017, 9, 25152-25163.	4.0	87
1627	Prognostic significance of ABCB1 in stage I lung adenocarcinoma. Oncology Letters, 2017, 14, 313-321.	0.8	10

#	Article	IF	Citations
1629	Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 110, 76-84.	2.0	46
1630	Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Clinical and Translational Oncology, 2017, 19, 587-592.	1.2	17
1631	SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity. Molecular and Cellular Biochemistry, 2017, 426, 1-8.	1.4	21
1632	Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. Biomaterials, 2017, 115, 65-80.	5.7	43
1633	A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells. Bioorganic and Medicinal Chemistry, 2017, 25, 581-596.	1.4	45
1634	Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1311-1315.	1.0	14
1635	Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm, 2017, 8, 53-66.	3.5	12
1636	Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Lineâ€“Specific Effects from P-Glycoproteinâ€“Induced Toxicity. Molecular Cancer Therapeutics, 2017, 16, 45-56.	1.9	34
1637	MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 143-155.	1.9	31
1638	Comparative Study of Different Nano-Formulations of Curcumin for Reversal of Doxorubicin Resistance in K562R Cells. Pharmaceutical Research, 2017, 34, 279-289.	1.7	3
1639	Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 391-401.	1.7	56
1640	Chemophototherapy: An Emerging Treatment Option for Solid Tumors. Advanced Science, 2017, 4, 1600106.	5.6	344
1641	Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells. Journal of Liposome Research, 2017, 27, 293-301.	1.5	12
1642	Extending the structureâ^'activity relationship study of marine natural ningalin B analogues as P-glycoprotein inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 795-806.	2.6	16
1643	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 183-192.	1.5	29
1644	Presence of an Immune System Increases Antiâ€Tumor Effect of Ag Nanoparticle Treated Mice. Advanced Healthcare Materials, 2017, 6, 1601099.	3.9	22
1645	Targeted Tumor Therapy Based on Nanodiamonds Decorated with Doxorubicin and Folic Acid. Macromolecular Bioscience, 2017, 17, 1600180.	2.1	21
1646	TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters. Biomedicine and Pharmacotherapy, 2017, 96, 371-377.	2.5	42

#	Article	IF	Citations
1647	The effect of Nullomer-derived peptides 9R, 9S1R and 124R on the NCI-60 panel and normal cell lines. BMC Cancer, 2017, 17, 533.	1.1	15
1648	Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway. Molecular Medicine Reports, 2017, 15, 1869-1876.	1.1	31
1649	Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells. Cancer Letters, 2017, 408, 1-9.	3.2	11
1650	Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a Derivative. Frontiers in Pharmacology, 2017, 8, 205.	1.6	28
1651	Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia. Frontiers in Physiology, 2017, 8, 98.	1.3	4
1652	Real-time kinetic binding studies at attomolar concentrations in solution phase using a single-stage opto-biosensing platform based upon infrared surface plasmons. Optics Express, 2017, 25, 39.	1.7	13
1653	Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget, 2017, 8, 84559-84571.	0.8	142
1654	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
1655	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncology Letters, 2017, 14, 3185-3192.	0.8	6
1656	Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. International Journal of Molecular Sciences, 2017, 18, 2171.	1.8	83
1658	CLIC1 Induces Drug Resistance in Human Choriocarcinoma Through Positive Regulation of MRP1. Oncology Research, 2017, 25, 863-871.	0.6	22
1659	Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers, 2017, 9, 157.	1.7	316
1660	Nanoparticles: A Novel Approach to Target Tumors. , 2017, , 113-129.		7
1661	Mathematical Simulation of Transport Kinetics of Tumor-Imaging Radiopharmaceutical99mTc-MIBI. Computational and Mathematical Methods in Medicine, 2017, 2017, 1-12.	0.7	4
1662	Brain and the Drug Transporters. , 2017, , 35-67.		1
1663	Nanoparticle System for Anticancer Drug Delivery: Targeting to Overcome Multidrug Resistance. , 2017, , 159-169.		7
1664	Nitric-Oxide-Mediated Chemosensitization: Gene Therapy Versus Exogenous Introduction of NO Donors. , 2017, , 1-14.		0
1665	Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance. Oncotarget, 2017, 8, 111281-111294.	0.8	12

#	Article	IF	Citations
1666	Nanoparticle-based drug delivery systems: What can they really do in vivo?. F1000Research, 2017, 6, 681.	0.8	47
1667	Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-Î²B signaling. International Journal of Molecular Medicine, 2017, 39, 993-1000.	1.8	35
1668	Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. International Journal of Oncology, 2017, 51, 257-268.	1.4	22
1669	Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biology and Medicine, 2017, 14, 212.	1.4	98
1670	Chemotherapy resistance mechanisms in advanced skin cancer. Oncology Reviews, 2017, 11, 326.	0.8	83
1671	Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy. Oncotarget, 2017, 8, 24337-24353.	0.8	73
1672	Synergistic Activities of Nitric Oxide and Various Drugs. , 2017, , 293-312.		3
1673	YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget, 2017, 8, 4096-4109.	0.8	43
1674	Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme. Current Medicinal Chemistry, 2017, 24, 2781-2795.	1.2	24
1675	Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling. Oncotarget, 2017, 8, 101965-101983.	0.8	20
1676	Enhanced Photodynamic Therapy by Reduced Levels of Intracellular Glutathione Obtained By Employing a Nanoâ€MOF with Cu^{II} as the Active Center. Angewandte Chemie, 2018, 130, 4985-4990.	1.6	70
1677	H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicology and Applied Pharmacology, 2018, 341, 98-105.	1.3	82
1678	BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells. Neoplasia, 2018, 20, 263-279.	2.3	71
1679	Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells. Scientific Reports, 2018, 8, 3446.	1.6	29
1681	Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide. Investigational New Drugs, 2018, 36, 797-809.	1.2	6
1682	Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 546-557.	2.5	42
1683	Co-administration of a charge-conversional dendrimer enhances antitumor efficacy of conventional chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 371-377.	2.0	17
1684	Design, Synthesis, and Docking Studies of Novel Dimethyl Triazene Incorporated Thiazolyl Pyrazolines for Anticancer Activity. Journal of Heterocyclic Chemistry, 2018, 55, 1313-1323.	1.4	13

#	Article	IF	Citations
1685	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochemical Pharmacology, 2018, 154, 10-17.	2.0	41
1686	CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1441-1454.	1.7	53
1687	A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity. Acta Biomaterialia, 2018, 73, 388-399.	4.1	40
1688	Imaging techniques to study drug transporter function in vivo. , 2018, 189, 104-122.		57
1689	Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. Gynecologic Oncology, 2018, 150, 143-150.	0.6	27
1690	Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Chemico-Biological Interactions, 2018, 288, 32-37.	1.7	17
1691	Reversing Multidrug Resistance by Multiplexed Gene Silencing for Enhanced Breast Cancer Chemotherapy. ACS Applied Materials & Interfaces, 2018, 10, 15461-15466.	4.0	55
1692	Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial. ACS Central Science, 2018, 4, 567-581.	5.3	49
1693	Methotrexate-conjugated to polymer quantum dot for cytotoxicity effect improved against MCF-7 and Hela cells. Medicinal Chemistry Research, 2018, 27, 1578-1588.	1.1	6
1694	Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell. European Journal of Medicinal Chemistry, 2018, 151, 546-556.	2.6	32
1695	2â€²,4â€²-Dihydroxy-6â€²-methoxy-3â€²,5â€²-dimethylchalcone, a potent Nrf2/ARE pathway inhibitor, reverses drug resistance by decreasing glutathione synthesis and drug efflux in BEL-7402/5-FU cells. Food and Chemical Toxicology, 2018, 119, 252-259.	1.8	17
1696	Chemical Design of Nuclearâ€Targeting Mesoporous Silica Nanoparticles for Intraâ€nuclear Drug Delivery. Chinese Journal of Chemistry, 2018, 36, 481-486.	2.6	9
1697	Quercetin reversed MDR in breast cancer cells through downâ€regulating Pâ€gp expression and eliminating cancer stem cells mediated by YBâ€1 nuclear translocation. Phytotherapy Research, 2018, 32, 1530-1536.	2.8	89
1698	Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 2018, 18, 452-464.	12.8	1,181
1699	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1817-1824.	1.0	28
1700	Enhanced Photodynamic Therapy by Reduced Levels of Intracellular Glutathione Obtained By Employing a Nanoâ€MOF with Cu^{II} as the Active Center. Angewandte Chemie - International Edition, 2018, 57, 4891-4896.	7.2	259
1701	Discovery of 18Î²-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance. Bioorganic and Medicinal Chemistry, 2018, 26, 1759-1775.	1.4	20
1702	Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomedicine and Pharmacotherapy, 2018, 100, 335-348.	2.5	156

#	Article	IF	Citations
1703	A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy. Biomaterials, 2018, 178, 706-719.	5.7	130
1704	Nanomaterial-assisted sensitization of oncotherapy. Nano Research, 2018, 11, 2932-2950.	5.8	19
1705	Co-loading of photothermal agents and anticancer drugs into porous silicon nanoparticles with enhanced chemo-photothermal therapeutic efficacy to kill multidrug-resistant cancer cells. Colloids and Surfaces B: Biointerfaces, 2018, 164, 291-298.	2.5	28
1706	Cytotoxicity of Î·-areneruthenium-based molecules to glioblastoma cells and their recognition by multidrug ABC transporters. European Journal of Medicinal Chemistry, 2018, 148, 165-177.	2.6	5
1707	Fabrication of dual stimuli-responsive multicompartmental drug carriers for tumor-selective drug release. Lab on A Chip, 2018, 18, 754-764.	3.1	19
1708	Crossâ€Linking of Thiolated Paclitaxelâ€“Oligo(pâ€phenylene vinylene) Conjugates Aggregates inside Tumor Cells Leads to â€œChemical Locksâ€•That Increase Drug Efficacy. Advanced Materials, 2018, 30, 1704888.	11.1	61
1709	Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. International Journal of Cancer, 2018, 143, 199-211.	2.3	21
1710	Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance. Nature Communications, 2018, 9, 562.	5.8	242
1711	Coarse-grained molecular dynamics simulations reveal lipid access pathways in P-glycoprotein. Journal of General Physiology, 2018, 150, 417-429.	0.9	31
1712	NK-18, a promising antimicrobial peptide: anti-multidrug resistant leukemia cells and LPS neutralizing properties. Biochimie, 2018, 147, 143-152.	1.3	9
1713	Efflux inhibition by IWR-1-endo confers sensitivity to doxorubicin effects in osteosarcoma cells. Biochemical Pharmacology, 2018, 150, 141-149.	2.0	3
1714	Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Scientific Reports, 2018, 8, 967.	1.6	189
1715	Enhancement of antitumor activity by using 5-ALAâ€“mediated sonodynamic therapy to induce apoptosis in malignant gliomas: significance of high-intensity focused ultrasound on 5-ALA-SDT in a mouse glioma model. Journal of Neurosurgery, 2018, 129, 1416-1428.	0.9	57
1716	Multifunctional Shellâ€“Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma. Advanced Functional Materials, 2018, 28, 1706124.	7.8	51
1717	A d-Peptide Ligand of Integrins for Simultaneously Targeting Angiogenic Blood Vasculature and Glioma Cells. Molecular Pharmaceutics, 2018, 15, 592-601.	2.3	14
1718	pH-responsive gold nanoclusters-based nanoprobes for lung cancer targeted near-infrared fluorescence imaging and chemo-photodynamic therapy. Acta Biomaterialia, 2018, 68, 308-319.	4.1	78
1719	Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. Journal of Medicinal Chemistry, 2018, 61, 834-864.	2.9	25
1720	Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. Journal of Medicinal Chemistry, 2018, 61, 5108-5121.	2.9	260

#	Article	IF	Citations
1721	Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 1389-1401.	3.2	43
1722	Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target. Scientific Reports, 2018, 8, 397.	1.6	16
1723	pHâ€Responsive PEGâ€“Doxorubicinâ€Encapsulated Azaâ€BODIPY Nanotheranostic Agent for Imagingâ€Guided Synergistic Cancer Therapy. Advanced Healthcare Materials, 2018, 7, e1701272.	3.9	100
1724	Augmented Anticancer Efficacy by si-RNA Complexed Drug-Loaded Mesoporous Silica Nanoparticles in Lung Cancer Therapy. ACS Applied Nano Materials, 2018, 1, 730-740.	2.4	35
1725	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine, 2018, 24, 203-212.	15.2	178
1726	Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. Critical Reviews in Oncology/Hematology, 2018, 122, 30-51.	2.0	119
1727	A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance. Small, 2018, 14, e1703321.	5.2	70
1728	Novel Metal Polyphenol Framework for MR Imaging-Guided Photothermal Therapy. ACS Applied Materials & Interfaces, 2018, 10, 3295-3304.	4.0	78
1729	Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery. Biomaterials Science, 2018, 6, 1457-1468.	2.6	51
1730	Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. Journal of Experimental and Clinical Cancer Research, 2018, 37, 31.	3.5	22
1731	Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. Cancer & Metabolism, 2018, 6, 1.	2.4	29
1732	Reversal Effects of Bound Polyphenol from Foxtail Millet Bran on Multidrug Resistance in Human HCT-8/Fu Colorectal Cancer Cell. Journal of Agricultural and Food Chemistry, 2018, 66, 5190-5199.	2.4	36
1733	Star-shaped polymer of Î²â€˜cyclodextrin-g-vitamin E TPGS for doxorubicin delivery and multidrug resistance inhibition. Colloids and Surfaces B: Biointerfaces, 2018, 169, 10-19.	2.5	20
1734	Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 867-878.	2.5	47
1735	Porphyrinâ€“Gold Nanomaterial for Efficient Drug Delivery to Cancerous Cells. ACS Omega, 2018, 3, 4602-4619.	1.6	53
1736	Mirâ€1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Thoracic Cancer, 2018, 9, 676-683.	0.8	26
1737	Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. Molecular Cancer Therapeutics, 2018, 17, 1441-1453.	1.9	120
1738	Use of ultrasound with magnetic field for enhanced in vitro drug delivery in colon cancer treatment. Journal of Materials Research, 2018, 33, 625-637.	1.2	6

#	Article	IF	Citations
1739	Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging. Materials Science and Engineering C, 2018, 89, 106-118.	3.8	25
1740	Pro-survival autophagy and cancer cell resistance to therapy. Cancer and Metastasis Reviews, 2018, 37, 749-766.	2.7	116
1741	A Nonquiescent â€œIdlingâ€•Population State in Drug-Treated, BRAF-Mutated Melanoma. Biophysical Journal, 2018, 114, 1499-1511.	0.2	34
1742	Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncology Letters, 2018, 15, 4585-4591.	0.8	23
1743	An Enzyme-Directed Imidazoquinoline Activated by Drug Resistance. Biochemistry, 2018, 57, 2184-2188.	1.2	14
1744	Application of Combination Highâ€Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Productâ€Based Combination Drugs. Medicinal Research Reviews, 2018, 38, 504-524.	5.0	55
1745	Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). Molecular Cancer Therapeutics, 2018, 17, 243-253.	1.9	117
1746	Comparison of mechanistic transport cycle models of ABC exporters. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 818-832.	1.4	88
1747	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2018, 143, 1535-1542.	2.6	41
1748	Two sides to supramolecular drug delivery systems. Supramolecular Chemistry, 2018, 30, 664-666.	1.5	5
1749	Improved photodynamic efficiency for methylene blue from silica-methylene blue@tannic acid-Fe(III) ions complexes in aqueous solutions. Advanced Powder Technology, 2018, 29, 341-348.	2.0	14
1750	Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical Applications. Advanced Healthcare Materials, 2018, 7, 1700831.	3.9	415
1751	Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFRâ€2 inhibitors. Archiv Der Pharmazie, 2018, 351, 1700234.	2.1	16
1752	Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. Journal of Cellular Physiology, 2018, 233, 5034-5043.	2.0	28
1753	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Seminars in Cancer Biology, 2018, 52, 53-65.	4.3	58
1754	Synthetically lethal nanoparticles for treatment of endometrial cancer. Nature Nanotechnology, 2018, 13, 72-81.	15.6	53
1755	Monoterpene indole alkaloid azine derivatives as MDR reversal agents. Bioorganic and Medicinal Chemistry, 2018, 26, 421-434.	1.4	25
1756	Tetrandrine and cancer â€“ An overview on the molecular approach. Biomedicine and Pharmacotherapy, 2018, 97, 624-632.	2.5	84

#	Article	IF	Citations
1757	Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells. European Journal of Medicinal Chemistry, 2018, 143, 1919-1930.	2.6	21
1758	Accurate prediction and elucidation of drug resistance based on the robust and reproducible chemoresponse communities. International Journal of Cancer, 2018, 142, 1427-1439.	2.3	3
1759	Internalization kinetics and cytoplasmic localization of functionalized diatomite nanoparticles in cancer cells by Raman imaging. Journal of Biophotonics, 2018, 11, e201700207.	1.1	41
1760	ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo. Pharmacological Research, 2018, 129, 388-399.	3.1	10
1761	Synthesis, crystal structure, vibrational profiling, DFT studies and molecular docking of N-(4-chloro-2-{[2-(1H-indol-2-ylcarbonyl) hydrazinyl](oxo)acetyl}phenyl)acetamide.DMSO: A new antiproliferative agent. Journal of Molecular Structure, 2018, 1155, 457-468.	1.8	10
1762	Screening of novel RGD peptides to modify nanoparticles for targeted cancer therapy. Biomaterials Science, 2018, 6, 125-135.	2.6	33
1763	Downregulation of high mobility group protein boxâ€'1 resensitizes ovarian cancer cells to carboplatin. Oncology Letters, 2018, 16, 4586-4592.	0.8	6
1764	P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomaterials Science, 2018, 6, 3063-3074.	2.6	11
1765	Thermo/pH dual-responsive coreâ€"shell particles for apatinib/doxorubicin controlled release: preparation, characterization and biodistribution. Journal of Materials Chemistry B, 2018, 6, 7621-7633.	2.9	13
1766	Design, synthesis and biological evaluation of novel nitric oxide-donating podophyllotoxin derivatives as potential antiproliferative agents against multi-drug resistant leukemia cells. RSC Advances, 2018, 8, 34266-34274.	1.7	6
1767	NIR organic dyes based on phenazine-cyanine for photoacoustic imaging-guided photothermal therapy. Journal of Materials Chemistry B, 2018, 6, 7420-7426.	2.9	31
1768	Knockdown of miRâ€'935 increases paclitaxel sensitivity via regulation of SOX7 in nonâ€'smallâ€'cell lung cancer. Molecular Medicine Reports, 2018, 18, 3397-3402.	1.1	13
1769	Acquired and Intrinsic Resistance to Colorectal Cancer Treatment. , 2018, , .		6
1770	Cucurbitacin D exhibits its anti-cancer effect in human breast cancer cells by inhibiting Stat3 and Akt signaling. European Journal of Inflammation, 2018, 16, 1721727X1775180.	0.2	10
1771	Anticancer effects of curcumin on nude mice bearing lung cancer A549 cell subsets SP and NSP cells. Oncology Letters, 2018, 16, 6756-6762.	0.8	28
1772	Synthesis and characterisation of liposomal doxorubicin with loaded gold nanoparticles. IET Nanobiotechnology, 2018, 12, 846-849.	1.9	23
1773	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. Frontiers in Pharmacology, 2018, 9, 1236.	1.6	41
1774	Reversal of Multidrug Resistance in Human Colon Cancer and Human Leukemia Cells by Three Plant Extracts and Their Major Secondary Metabolites. Medicines (Basel, Switzerland), 2018, 5, 123.	0.7	22

#	Article	IF	Citations
1775	Ovarian hormones modulate multidrug resistance transporters in the ovary. Contraception and Reproductive Medicine, 2018, 3, 26.	0.7	9
1776	miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Research and Therapy, 2018, 9, 327.	2.4	58
1777	Boosted feature selectors: a case study on prediction P-gp inhibitors and substrates. Journal of Computer-Aided Molecular Design, 2018, 32, 1273-1294.	1.3	11
1778	Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance. International Journal of Pharmaceutics, 2018, 553, 349-362.	2.6	10
1779	Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients. Cancers, 2018, 10, 511.	1.7	14
1780	A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor. International Journal of Nanomedicine, 2018, Volume 13, 8411-8427.	3.3	19
1781	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers, 2018, 10, 503.	1.7	44
1782	P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of pRb and pH2AX in Highly Drug-resistant KBV20C Cells. Anticancer Research, 2018, 38, 5685-5692.	0.5	16
1783	Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes. Molecular Cancer Therapeutics, 2018, 17, 2575-2585.	1.9	14
1784	A Tailored DNA Nanoplatform for Synergistic RNAiâ€/Chemotherapy of Multidrugâ€Resistant Tumors. Angewandte Chemie, 2018, 130, 15712-15716.	1.6	29
1785	Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells. Drug Metabolism and Disposition, 2018, 46, 1856-1866.	1.7	18
1786	The effects of ultrasound exposure on P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Journal of Experimental and Clinical Cancer Research, 2018, 37, 232.	3.5	18
1787	Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin. Phytomedicine, 2018, 50, 213-222.	2.3	55
1788	Recent progress in macrocyclic amphiphiles and macrocyclic host-based supra-amphiphiles. Materials Chemistry Frontiers, 2018, 2, 2152-2174.	3.2	102
1789	Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides. Journal of Medicinal Chemistry, 2018, 61, 9347-9359.	2.9	24
1790	A Tailored DNA Nanoplatform for Synergistic RNAiâ€/Chemotherapy of Multidrugâ€Resistant Tumors. Angewandte Chemie - International Edition, 2018, 57, 15486-15490.	7.2	157
1791	Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. Journal of Controlled Release, 2018, 290, 75-87.	4.8	35
1792	Dual-Stimuli Responsive Bismuth Nanoraspberries for Multimodal Imaging and Combined Cancer Therapy. Nano Letters, 2018, 18, 6778-6788.	4.5	116

#	Article	IF	Citations
1793	Mannoseâ€Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications. Chemistry - an Asian Journal, 2018, 13, 3448-3459.	1.7	43
1794	Discovery of traditional Chinese medicine monomers and theirÂsynthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance. European Journal of Medicinal Chemistry, 2018, 159, 381-392.	2.6	38
1795	Gut Microbiota-Mediated Bile Acid Transformations Alter the Cellular Response to Multidrug Resistant Transporter Substrates in Vitro: Focus on P-glycoprotein. Molecular Pharmaceutics, 2018, 15, 5711-5727.	2.3	13
1796	Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway. Cancer Management and Research, 2018, Volume 10, 4371-4380.	0.9	30
1797	Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. Pharmaceutics, 2018, 10, 180.	2.0	10
1798	Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p. Biomedicine and Pharmacotherapy, 2018, 108, 1070-1080.	2.5	36
1799	On-Demand Versatile Prodrug Nanomicelle for Tumor-Specific Bioimaging and Photothermal-Chemo Synergistic Cancer Therapy. ACS Applied Materials & Interfaces, 2018, 10, 38700-38714.	4.0	40
1800	A discrete organoplatinum(II) metallacage as a multimodality theranostic platform for cancer photochemotherapy. Nature Communications, 2018, 9, 4335.	5.8	197
1801	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochemical Pharmacology, 2018, 158, 274-285.	2.0	47
1802	Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-Î²1-induced EMT and confers paclitaxel resistance in ovarian cancer. Cell Death and Disease, 2018, 9, 1102.	2.7	92
1803	Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment. Science and Technology of Advanced Materials, 2018, 19, 771-790.	2.8	49
1804	Arminin 1a-C, a novel antimicrobial peptide from ancient metazoan Hydra, shows potent antileukemia activity against drug-sensitive and drug-resistant leukemia cells. Drug Design, Development and Therapy, 2018, Volume 12, 3691-3703.	2.0	6
1805	Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2018, 15, 5371-5376.	0.8	22
1806	MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer. Cell Death and Disease, 2018, 9, 1070.	2.7	80
1807	Mesoporous silica-coated bismuth nanohybrids as a new platform for photoacoustic/computed tomography imaging and synergistic chemophotothermal therapy. Nanomedicine, 2018, 13, 2283-2300.	1.7	18
1808	Bioinstructive microparticles for self-assembly of mesenchymal stem Cell-3D tumor spheroids. Biomaterials, 2018, 185, 155-173.	5.7	58
1809	Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells. Cancer Cell International, 2018, 18, 128.	1.8	50
1810	Inactivation of nuclear factor κB by MIP-based drug combinations augments cell death of breast cancer cells. Drug Design, Development and Therapy, 2018, Volume 12, 1053-1063.	2.0	7

#	Article	IF	Citations
1811	The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors. Frontiers in Immunology, 2018, 9, 1914.	2.2	26
1812	Molecular pathways involved in microRNA-mediated regulation of multidrug resistance. Molecular Biology Reports, 2018, 45, 2913-2923.	1.0	10
1813	Development of cholate conjugated hybrid polymeric micelles for FXR receptor mediated effective site-specific delivery of paclitaxel. New Journal of Chemistry, 2018, 42, 17021-17032.	1.4	22
1814	Using LC–MS/MS-based targeted proteomics to monitor the pattern of ABC transporters expression in the development of drug resistance. Cancer Management and Research, 2018, Volume 10, 2859-2870.	0.9	7
1815	Mitochondriaâ€and Lysosomesâ€Targeted Synergistic Chemoâ€Photodynamic Therapy Associated with Selfâ€Monitoring by Dual Lightâ€Up Fluorescence. Advanced Functional Materials, 2018, 28, 1804362.	7.8	101
1816	Thermo-Sensitive Vesicles in Controlled Drug Delivery for Chemotherapy. Pharmaceutics, 2018, 10, 150.	2.0	46
1817	Terpenoids from Euphorbia pedroi as Multidrug-Resistance Reversers. Journal of Natural Products, 2018, 81, 2032-2040.	1.5	37
1818	Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms. Anticancer Research, 2018, 38, 5149-5157.	0.5	21
1819	Bio-nano: Theranostic at Cellular Level. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 85-170.	0.2	1
1820	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 842.	1.6	5
1821	Functional evaluation of doxorubicin decorated polymeric liposomal curcumin: a surface tailored therapeutic platform for combination chemotherapy. New Journal of Chemistry, 2018, 42, 16608-16619.	1.4	10
1822	A New Class of 1â€Arylâ€5,6â€dihydropyrrolo[2,1â€a]isoquinoline Derivatives as Reversers of Pâ€Glycoproteinâ€Mediated Multidrug Resistance in Tumor Cells. ChemMedChem, 2018, 13, 1588-1596.	1.6	19
1823	Nanoformulations of doxorubicin: how far have we come and where do we go from here?. Nanotechnology, 2018, 29, 332002.	1.3	26
1824	Ultrasound Doppler as an Imaging Modality for Selection of Murine 4T1 Breast Tumors for Combination Radiofrequency Hyperthermia and Chemotherapy. Translational Oncology, 2018, 11, 864-872.	1.7	7
1825	Current advances in screening for bioactive components from medicinal plants by affinity ultrafiltration mass spectrometry. Phytochemical Analysis, 2018, 29, 375-386.	1.2	42
1826	The challenge of drugÂresistance in cancer treatment: a current overview. Clinical and Experimental Metastasis, 2018, 35, 309-318.	1.7	354
1827	The inhibitory effect of kokusaginine on the growth of human breast cancer cells and MDR-resistant cells is mediated by the inhibition of tubulin assembly. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2490-2492.	1.0	9
1828	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. Journal of Medicinal Chemistry, 2018, 61, 5988-6001.	2.9	53

#	Article	IF	Citations
1829	Multifunctional Electrospun Nanofibers for Enhancing Localized Cancer Treatment. Small, 2018, 14, e1801183.	5.2	52
1830	Beyond the Bloodâ€“Brain Barrier. , 2018, , 397-437.		6
1831	Cytotoxic Activity of Extracts from Plants of Central Argentina on Sensitive and Multidrug-Resistant Leukemia Cells: Isolation of an Active Principle from Gaillardia megapotamica. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-13.	0.5	20
1832	ABCB6 Resides in Melanosomes and Regulates Early Steps of Melanogenesis Required for PMEL Amyloid Matrix Formation. Journal of Molecular Biology, 2018, 430, 3802-3818.	2.0	17
1833	Solid Lipid Nanoparticles for Targeted Brain Drug Delivery. , 2018, , 191-244.		11
1834	The LncRNA H19/miRâ€193aâ€3p axis modifies the radioâ€resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1. Journal of Cellular Biochemistry, 2018, 119, 8325-8335.	1.2	57
1835	SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling. Experimental Cell Research, 2018, 370, 283-291.	1.2	18
1836	Synergized Multimodal Therapy for Safe and Effective Reversal of Cancer Multidrug Resistance Based on Lowâ€Level Photothermal and Photodynamic Effects. Small, 2018, 14, e1800785.	5.2	27
1837	Cancer cell nucleus-targeting nanocomposites for advanced tumor therapeutics. Chemical Society Reviews, 2018, 47, 6930-6946.	18.7	191
1838	Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN. Oncology Research, 2018, 26, 901-911.	0.6	40
1839	Poly(Ethylene Glycol)â€“Polylactide Micelles for Cancer Therapy. Frontiers in Pharmacology, 2018, 9, 202.	1.6	100
1840	Bio-Inspired Protein-Based Nanoformulations for Cancer Theranostics. Frontiers in Pharmacology, 2018, 9, 421.	1.6	68
1841	Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway. Oncology Letters, 2018, 16, 1634-1640.	0.8	7
1842	The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget, 2018, 9, 10164-10174.	0.8	86
1843	The impact of pharmacokinetic gene profiles across human cancers. BMC Cancer, 2018, 18, 577.	1.1	3
1844	Chemotherapeutic resistance: a nano-mechanical point of view. Biological Chemistry, 2018, 399, 1433-1446.	1.2	18
1845	P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. Journal of Controlled Release, 2018, 286, 289-300.	4.8	18
1846	On the design principles of peptideâ€“drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein Journal of Organic Chemistry, 2018, 14, 930-954.	1.3	110

#	Article	IF	Citations
1847	Synthesis and Biological Evaluation of Certain new Cyclohexane-1-carboxamides as Apoptosis Inducers. Oriental Journal of Chemistry, 2018, 34, 825-833.	0.1	5
1848	Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers, 2018, 10, 14.	1.7	26
1849	Remedy of Targeting Cancer and Cancer Stem Cells with Botanicals. , 2018, , 289-320.		0
1850	Endophytic Microbes as a Novel Source for Producing Anticancer Compounds as Multidrug Resistance Modulators. , 2018, , 343-381.		1
1851	Fumitremorgins and Relatives â€“ From Tremorgenic Compounds to Valuable Anti-Cancer Drugs. Current Medicinal Chemistry, 2018, 25, 123-140.	1.2	7
1852	Role of Galectins in Tumors and in Clinical Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 430.	1.8	182
1853	Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-Î± in Hormone-Resistant Breast Cancers. International Journal of Molecular Sciences, 2018, 19, 579.	1.8	9
1854	Capsaicin and Piperine Can Overcome Multidrug Resistance in Cancer Cells to Doxorubicin. Molecules, 2018, 23, 557.	1.7	61
1855	SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2018, 433, 259-272.	3.2	19
1856	Pluripotent Stem Cell Platforms for Drug Discovery. Trends in Molecular Medicine, 2018, 24, 805-820.	3.5	33
1857	Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cellular Physiology and Biochemistry, 2018, 48, 16-28.	1.1	70
1858	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochemical Pharmacology, 2018, 155, 316-325.	2.0	16
1859	The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. Cancer Letters, 2018, 434, 81-90.	3.2	7
1860	Deciphering the roles of lncRNAs in breast development and disease. Oncotarget, 2018, 9, 20179-20212.	0.8	42
1861	Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation. World Journal of Surgical Oncology, 2018, 16, 76.	0.8	27
1862	Haploid genetic screens identify genetic vulnerabilities to microtubuleâ€targeting agents. Molecular Oncology, 2018, 12, 953-971.	2.1	12
1863	Folateâ€Conjugated and Dual Stimuliâ€Responsive Mixed Micelles Loading Indocyanine Green for Photothermal and Photodynamic Therapy. Macromolecular Bioscience, 2018, 18, e1700409.	2.1	17
1864	pH-Controlled Liposomes for Enhanced Cell Penetration in Tumor Environment. ACS Applied Materials & Interfaces, 2018, 10, 17646-17661.	4.0	30

#	Article	IF	Citations
1865	Light-Activated ROS-Responsive Nanoplatform Codelivering Apatinib and Doxorubicin for Enhanced Chemo-Photodynamic Therapy of Multidrug-Resistant Tumors. ACS Applied Materials & Interfaces, 2018, 10, 17672-17684.	4.0	98
1866	Discovery of novel Î²-carboline/acylhydrazone hybrids as potent antitumor agents and overcome drug resistance. European Journal of Medicinal Chemistry, 2018, 152, 516-526.	2.6	17
1867	PCI29732, a Brutonâ€™s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. Cellular Physiology and Biochemistry, 2018, 48, 2302-2317.	1.1	8
1868	Millepachine showed novel antitumor effects in cisplatinâ€resistant human ovarian cancer through inhibiting drug efflux function of <scp>ATP</scp>â€binding cassette transporters. Phytotherapy Research, 2018, 32, 2428-2435.	2.8	11
1869	Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. Journal of Drug Delivery Science and Technology, 2018, 48, 106-117.	1.4	16
1870	In silico analysis of nsSNPs in ABCB1 gene affecting breast cancer associated protein P-glycoprotein (P-gp). Computational Biology and Chemistry, 2018, 77, 430-441.	1.1	10
1871	A chloroquine-loaded Prussian blue platform with controllable autophagy inhibition for enhanced photothermal therapy. Journal of Materials Chemistry B, 2018, 6, 5854-5859.	2.9	33
1872	Mannoside and 1,2-mannobioside Î²-cyclodextrin-scaffolded NO-photodonors for targeting antibiotic resistant bacteria. Carbohydrate Polymers, 2018, 199, 649-660.	5.1	10
1873	TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1- NF-ÎºB and - AP-1 pathways. Molecular Immunology, 2018, 101, 471-478.	1.0	20
1874	Engineering Anticancer Amphipathic Peptide-Dendronized Compounds for Highly-Efficient Plasma/Organelle Membrane Perturbation and Multidrug Resistance Reversal. ACS Applied Materials & Interfaces, 2018, 10, 30952-30962.	4.0	22
1875	Let There be Light: Polymeric Micelles with Upper Critical Solution Temperature as Lightâ€Triggered Heat Nanogenerators for Combating Drugâ€Resistant Cancer. Small, 2018, 14, e1802420.	5.2	63
1876	Cytotoxicity of abietane diterpenoids from Salvia multicaulis towards multidrug-resistant cancer cells. FÃ¬toterapÃ¬Ã¢, 2018, 130, 54-60.	1.1	18
1877	Update on the effects of the sodium pump Î±1 subunit on human glioblastoma: from the laboratory to the clinic. Expert Opinion on Investigational Drugs, 2018, 27, 753-763.	1.9	6
1878	Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects. Journal of Controlled Release, 2018, 283, 190-199.	4.8	85
1879	Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities. Journal of Medicinal Chemistry, 2018, 61, 5424-5434.	2.9	31
1880	Glucuronide-Linked Antibodyâ€“Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models. Molecular Cancer Therapeutics, 2018, 17, 1752-1760.	1.9	17
1881	Role of Resveratrol in Chemosensitization of Cancer. , 2018, , 61-76.		4
1882	The Enhanced Cytotoxic Effects of the p28-Apoptin Chimeric Protein As A Novel Anti-Cancer Agent on Breast Cancer Cell Lines. Drug Research, 2019, 69, 144-150.	0.7	11

#	Article	IF	Citations
1883	Pien Tze Huang (ç‰‡ä»”ç™€) Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells. Chinese Journal of Integrative Medicine, 2019, 25, 598-603.	0.7	8
1884	Combined approach of homology modeling, molecular dynamics, and docking: computer-aided drug discovery. Physical Sciences Reviews, 2019, 4, .	0.8	2
1885	Danazol mediates collateral sensitivity via STAT3/Myc related pathway in multidrug-resistant cancer cells. Scientific Reports, 2019, 9, 11628.	1.6	7
1886	Synthesis and anticancer cytotoxicity with structural context of an Î±-hydroxyphosphonate based compound library derived from substituted benzaldehydes. New Journal of Chemistry, 2019, 43, 14028-14035.	1.4	15
1887	Reductive responsive micelle overcoming multidrug resistance of breast cancer by co-delivery of DOX and specific antibiotic. Journal of Materials Chemistry B, 2019, 7, 6075-6086.	2.9	24
1888	Multi-Modulation of Doxorubicin Resistance in Breast Cancer Cells by Poly(l-histidine)-Based Multifunctional Micelles. Pharmaceutics, 2019, 11, 385.	2.0	10
1889	A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma. Scientific Reports, 2019, 9, 10290.	1.6	13
1890	miR-203 Inhibits the Invasion and EMT of Gastric Cancer Cells by Directly Targeting Annexin A4. Oncology Research, 2019, 27, 789-799.	0.6	18
1891	Novel bio compactable silver nanowires and nanocubes: An effective treatment against carbapenem and vancomycin resistant strains isolated from cancer patients. Journal of Saudi Chemical Society, 2019, 23, 1090-1101.	2.4	6
1892	YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell International, 2019, 19, 179.	1.8	85
1893	Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition. Anticancer Research, 2019, 39, 3757-3765.	0.5	14
1894	Role of protein kinase CK2 in antitumor drug resistance. Journal of Experimental and Clinical Cancer Research, 2019, 38, 287.	3.5	74
1895	Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor. Acta Biomaterialia, 2019, 97, 461-473.	4.1	15
1896	Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.. Journal of Clinical Medicine, 2019, 8, 912.	1.0	36
1897	Drug-Impregnated Polymer Delivery. , 2019, , 275-296.		0
1898	Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells. Critical Reviews in Microbiology, 2019, 45, 334-353.	2.7	41
1899	Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids. Frontiers in Oncology, 2019, 9, 487.	1.3	108
1900	Intravenous and Intravascular Drug Delivery. , 2019, , 165-191.		0

#	Article	IF	Citations
1901	Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. Anticancer Research, 2019, 39, 3785-3793.	0.5	16
1902	Histamine Receptor Antagonists, Loratadine and Azelastine, Sensitize P-gp-overexpressing Antimitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms. Anticancer Research, 2019, 39, 3767-3775.	0.5	18
1903	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Frontiers in Oncology, 2019, 9, 514.	1.3	29
1904	Catalaseâ€Functionalized Iron Oxide Nanoparticles Reverse Hypoxiaâ€Induced Chemotherapeutic Resistance. Advanced Healthcare Materials, 2019, 8, e1900826.	3.9	26
1905	STS-NLSP: A Network-Based Label Space Partition Method for Predicting the Specificity of Membrane Transporter Substrates Using a Hybrid Feature of Structural and Semantic Similarity. Frontiers in Bioengineering and Biotechnology, 2019, 7, 306.	2.0	17
1906	Incorporation of Chloramphenicol Loaded Hydroxyapatite Nanoparticles into Polylactide. International Journal of Molecular Sciences, 2019, 20, 5056.	1.8	11
1907	Interaction Effects between Doxorubicin and Hernandezine on the Pharmacokinetics by Liquid Chromatography Coupled with Mass Spectrometry. Molecules, 2019, 24, 3622.	1.7	4
1908	Achillin Increases Chemosensitivity to Paclitaxel, Overcoming Resistance and Enhancing Apoptosis in Human Hepatocellular Carcinoma Cell Line Resistant to Paclitaxel (Hep3B/PTX). Pharmaceutics, 2019, 11, 512.	2.0	10
1909	Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 182, 111668.	2.6	11
1910	Gold Nanorods Functionalized with Cathepsin B Targeting Peptide and Doxorubicin for Combinatorial Therapy against Multidrug Resistance. ACS Applied Bio Materials, 2019, 2, 5697-5706.	2.3	9
1911	Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy. Theranostics, 2019, 9, 7033-7050.	4.6	38
1912	Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship. Pharmaceutics, 2019, 11, 579.	2.0	12
1913	Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-8.	0.5	8
1914	Aptamer-Based Erythrocyte-Derived Mimic Vesicles Loaded with siRNA and Doxorubicin for the Targeted Treatment of Multidrug-Resistant Tumors. ACS Applied Materials & Interfaces, 2019, 11, 45455-45466.	4.0	41
1915	Functional Biodegradable Nitric Oxide Donor-Containing Polycarbonate-Based Micelles for Reduction-Triggered Drug Release and Overcoming Multidrug Resistance. ACS Macro Letters, 2019, 8, 1552-1558.	2.3	37
1916	In Vitro 3D Cultures to Reproduce the Bone Marrow Niche. JBMR Plus, 2019, 3, e10228.	1.3	9
1917	Present Scenario of Bioconjugates in Cancer Therapy: A Review. International Journal of Molecular Sciences, 2019, 20, 5243.	1.8	37
1918	Enhanced generation efficiency of singlet oxygen for methylene blue released from hydroxyapatite-MB@tannic acid-Fe(III) ions. Pigment and Resin Technology, 2019, 48, 185-196.	0.5	4

#	Article	IF	Citations
1919	Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. Pharmaceuticals, 2019, 12, 124.	1.7	9
1920	Induction of Mitochondrial Cell Death and Reversal of Anticancer Drug Resistance via Nanocarriers Composed of a Triphenylphosphonium Derivative of Tocopheryl Polyethylene Glycol Succinate. Molecular Pharmaceutics, 2019, 16, 3744-3759.	2.3	10
1921	Multifunctional Molecular Beacons-Modified Gold Nanoparticle as a Nanocarrier for Synergistic Inhibition and in Situ Imaging of Drug-Resistant-Related mRNAs in Living Cells. ACS Applied Materials & Interfaces, 2019, 11, 35548-35555.	4.0	15
1922	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. European Journal of Pharmacology, 2019, 863, 172611.	1.7	22
1923	Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo. Cell Communication and Signaling, 2019, 17, 110.	2.7	8
1924	Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 2019, 8, 1013.	1.8	51
1925	Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. Biomaterials, 2019, 223, 119486.	5.7	159
1926	Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. Beilstein Journal of Nanotechnology, 2019, 10, 1707-1715.	1.5	48
1927	Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment. Theranostics, 2019, 9, 5755-5768.	4.6	43
1928	Programmed degradation of a hierarchical nanoparticle with redox and light responsivity for self-activated photo-chemical enhanced chemodynamic therapy. Biomaterials, 2019, 224, 119498.	5.7	99
1929	Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins. International Journal of Molecular Sciences, 2019, 20, 4647.	1.8	32
1930	Multi-target ABC transporter modulators: what next and where to go?. Future Medicinal Chemistry, 2019, 11, 2353-2358.	1.1	42
1931	Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species. Biomaterials Science, 2019, 7, 4782-4789.	2.6	28
1932	Saikosaponin-d Inhibits the Hepatoma Cells and Enhances Chemosensitivity Through SENP5-Dependent Inhibition of Gli1 SUMOylation Under Hypoxia. Frontiers in Pharmacology, 2019, 10, 1039.	1.6	35
1933	Polydopamine-Based â€œFour-in-Oneâ€•Versatile Nanoplatforms for Targeted Dual Chemo and Photothermal Synergistic Cancer Therapy. Pharmaceutics, 2019, 11, 507.	2.0	36
1934	Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells, 2019, 8, 1102.	1.8	150
1935	Acid-breakable TPGS-functionalized and diallyl disulfide-crosslinked nanogels for enhanced inhibition of MCF-7/ADR solid tumours. Journal of Materials Chemistry B, 2019, 7, 240-250.	2.9	16
1936	Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2â€“p53 interaction. Bioorganic Chemistry, 2019, 86, 598-608.	2.0	52

#	Article	IF	Citations
1937	Inhibition of ABCB1 and ABCG2 at the Mouse Bloodâ€“Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [¹¹C]erlotinib. Molecular Pharmaceutics, 2019, 16, 1282-1293.	2.3	20
1938	Suppressing the secretion of exosomal miR-19b by gw4869 could regulate oxaliplatin sensitivity in colorectal cancer. Neoplasma, 2019, 66, 39-45.	0.7	26
1939	Upregulated microRNAâ€193aâ€3p is responsible for cisplatin resistance in <scp>CD</scp>44(+) gastric cancer cells. Cancer Science, 2019, 110, 662-673.	1.7	41
1940	Programmable Codelivery of Doxorubicin and Apatinib Using an Implantable Hierarchicalâ€Structured Fiber Device for Overcoming Cancer Multidrug Resistance. Small, 2019, 15, e1804397.	5.2	47
1941	Synthesis of Polyfunctionalized Fused Pyrazoloâ€Pyridines: Characterization, Anticancer Activity, Protein Binding and Molecular Docking Studies. ChemistrySelect, 2019, 4, 285-297.	0.7	11
1942	Scutellarin inhibits the metastasis and cisplatin resistance in glioma cells. OncoTargets and Therapy, 2019, Volume 12, 587-598.	1.0	9
1943	Oxygen-rich chemotherapyviamodified Abraxane to inhibit the growth and metastasis of triple-negative breast cancer. Biomaterials Science, 2019, 7, 168-177.	2.6	22
1944	Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function. Cancers, 2019, 11, 697.	1.7	21
1945	Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer. Pharmaceutics, 2019, 11, 216.	2.0	17
1946	Multifunctional DNA Origami Nanoplatforms for Drug Delivery. Chemistry - an Asian Journal, 2019, 14, 2193-2202.	1.7	36
1947	Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. Journal of Hematology and Oncology, 2019, 12, 51.	6.9	155
1948	Teratogenic jervine increases the activity of doxorubicin in MCF-7/ADR cells by inhibiting ABCB1. Biomedicine and Pharmacotherapy, 2019, 117, 109059.	2.5	7
1949	Tumor-Microenvironment-Induced All-in-One Nanoplatform for Multimodal Imaging-Guided Chemical and Photothermal Therapy of Cancer. ACS Applied Materials & Interfaces, 2019, 11, 25043-25053.	4.0	57
1950	Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian Journal of Pharmaceutical Sciences, 2019, 14, 581-594.	4.3	97
1951	An insight into the therapeutic potential of piperazine-based anticancer agents. Turkish Journal of Chemistry, 2019, 43, 1-23.	0.5	26
1952	Superparamagnetic iron oxide nanoparticulate system: synthesis, targeting, drug delivery and therapy in cancer. Dalton Transactions, 2019, 48, 9490-9515.	1.6	159
1953	Androgen receptor plasticity and its implications for prostate cancer therapy. Cancer Treatment Reviews, 2019, 81, 101871.	3.4	40
1954	Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors. ACS Omega, 2019, 4, 9784-9799.	1.6	16

#	Article	IF	Citations
1955	Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT. Cancer Letters, 2019, 459, 15-29.	3.2	13
1956	Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model. Frontiers in Oncology, 2019, 9, 353.	1.3	15
1957	Avapritinib: A Selective Inhibitor of KIT and PDGFRÎ± that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Molecular Pharmaceutics, 2019, 16, 3040-3052.	2.3	49
1958	Arginyl-glycyl-aspartic acid (RGD) containing nanostructured lipid carrier co-loaded with doxorubicin and sildenafil citrate enhanced anti-cancer effects and overcomes drug resistance. Process Biochemistry, 2019, 84, 172-179.	1.8	28
1959	Tumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 19, 71-80.	1.7	50
1960	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2019, 166, 120-127.	2.0	52
1961	Natural products as multidrug resistance modulators in cancer. European Journal of Medicinal Chemistry, 2019, 176, 268-291.	2.6	225
1962	Identification of a small-molecule compound that inhibits homodimerization of oncogenic NAC1 protein and sensitizes cancer cells to anticancer agents. Journal of Biological Chemistry, 2019, 294, 10006-10017.	1.6	15
1963	Bioinspired Multivalent Peptide Nanotubes for Sialic Acid Targeting and Imagingâ€Guided Treatment of Metastatic Melanoma. Small, 2019, 15, e1900157.	5.2	30
1964	Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5. Frontiers in Pharmacology, 2019, 10, 400.	1.6	16
1965	Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer. Molecular Pharmaceutics, 2019, 16, 2502-2510.	2.3	26
1966	A Versatile Carbon Monoxide Nanogenerator for Enhanced Tumor Therapy and Anti-Inflammation. ACS Nano, 2019, 13, 5523-5532.	7.3	89
1967	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Molecular Pharmacology, 2019, 96, 73-89.	1.0	23
1968	Integrated InÂVitro and In Silico Modeling Delineates the Molecular Effects of a Synbiotic Regimen on Colorectal-Cancer-Derived Cells. Cell Reports, 2019, 27, 1621-1632.e9.	2.9	59
1969	The role of photodynamic therapy on multidrug resistant breast cancer. Cancer Cell International, 2019, 19, 91.	1.8	70
1970	An artificially engineered â€œtumor bio-magnetâ€•for collecting blood-circulating nanoparticles and magnetic hyperthermia. Biomaterials Science, 2019, 7, 1815-1824.	2.6	10
1971	Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review). International Journal of Oncology, 2019, 54, 1511-1524.	1.4	21
1972	Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment . OncoTargets and Therapy, 2019, Volume 12, 1539-1552.	1.0	59

#	Article	IF	Citations
1973	Hostâ^'guest complexation-mediated codelivery of anticancer drug and photosensitizer for cancer photochemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6618-6623.	3.3	111
1974	Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation. Leukemia Research, 2019, 79, 45-51.	0.4	17
1975	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology, 2019, 163, 290-298.	2.0	9
1976	Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy. Current Medicinal Chemistry, 2019, 25, 5128-5141.	1.2	43
1977	Inhibition of PINK1/Parkin-dependent mitophagy sensitizes multidrug-resistant cancer cells to B5G1, a new betulinic acid analog. Cell Death and Disease, 2019, 10, 232.	2.7	87
1978	Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling. Cancers, 2019, 11, 338.	1.7	71
1979	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 13-27.		0
1980	Characterization of Lipidâ€"Protein Interactions and Lipid-Mediated Modulation of Membrane Protein Function through Molecular Simulation. Chemical Reviews, 2019, 119, 6086-6161.	23.0	176
1981	The effect of medicinal plants on multiple drug resistance through autophagy: A review of in vitro studies. European Journal of Pharmacology, 2019, 852, 244-253.	1.7	26
1982	Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. , 2019, , 169-185.		1
1983	Mitochondrial Surface Engineering for Multidrug Resistance Reversal. Nano Letters, 2019, 19, 2905-2913.	4.5	44
1984	An ATG5 knockout promotes paclitaxel resistance in v-Ha-ras-transformed NIH 3T3 cells. Biochemical and Biophysical Research Communications, 2019, 513, 234-241.	1.0	9
1985	Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Molecular Cancer, 2019, 18, 75.	7.9	853
1986	ncRNAs associated with drug resistance and the therapy of digestive system neoplasms. Journal of Cellular Physiology, 2019, 234, 19143-19157.	2.0	12
1987	Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer. Phytotherapy Research, 2019, 33, 1658-1669.	2.8	47
1988	Extracellular and intracellular microRNAs in pancreatic cancer: from early diagnosis to reducing chemoresistance. ExRNA, 2019, 1, .	1.0	4
1989	Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Molecular Cancer, 2019, 18, 82.	7.9	146
1990	Boron Dipyrromethene Nanoâ€Photosensitizers for Anticancer Phototherapies. Small, 2019, 15, e1804927.	5.2	135

#	Article	IF	Citations
1991	Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. Journal of Thoracic Oncology, 2019, 14, 358-376.	0.5	11
1992	Smart internal and external stimuli-responsive nanocarriers for image-guided drug delivery and therapy. , 2019, , 197-217.		0
1993	The basics of epithelialâ€“mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective. Journal of Cellular Physiology, 2019, 234, 14535-14555.	2.0	159
1994	Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biology, 2019, 22, 101131.	3.9	45
1995	Application of 3-D Microfluidic Models for Studying Mass Transport Properties of the Tumor Interstitial Matrix. Frontiers in Bioengineering and Biotechnology, 2019, 7, 6.	2.0	26
1996	Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. British Journal of Cancer, 2019, 120, 407-423.	2.9	28
1997	Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Medicinal Research Reviews, 2019, 39, 1398-1426.	5.0	98
1998	Oncogenic PITX2 facilitates tumor cell drug resistance by inverse regulation of hOCT3/SLC22A3 and ABC drug transporters in colon and kidney cancers. Cancer Letters, 2019, 449, 237-251.	3.2	18
1999	Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death and Disease, 2019, 10, 204.	2.7	16
2000	MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer. Scientific Reports, 2019, 9, 3008.	1.6	25
2001	An ROS-responsive and self-accelerating drug release nanoplatform for overcoming multidrug resistance. Chemical Communications, 2019, 55, 3383-3386.	2.2	28
2002	The inhibitive effect of sh-HIF1A-AS2 on the proliferation, invasion, and pathological damage of breast cancer via targeting miR-548c-3p through regulating HIF-1α/VEGF pathway in vitro and vivo . OncoTargets and Therapy, 2019, Volume 12, 825-834.	1.0	22
2003	Graphene nano-ribbon based high potential and efficiency for DNA, cancer therapy and drug delivery applications. Drug Metabolism Reviews, 2019, 51, 91-104.	1.5	44
2004	Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects. Theranostics, 2019, 9, 747-760.	4.6	24
2005	Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 109-124.		2
2006	EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression . OncoTargets and Therapy, 2019, Volume 12, 9627-9637.	1.0	22
2007	Combinational delivery therapies of nucleic acids for cancer treatment. , 2019, , 257-291.		0
2008	Stepwise dual stimuli triggered dual drug release by a single naphthalene based two-photon chromophore to reverse MDR for alkylating agents with dual surveillance in uncaging steps. Chemical Communications, 2019, 55, 13140-13143.	2.2	15

#	Article	IF	Citations
2009	Zhankuic Acids A, B and C from Taiwanofungus camphoratus Act as Cytotoxicity Enhancers by Regulating P-Glycoprotein in Multi-Drug Resistant Cancer Cells. Biomolecules, 2019, 9, 759.	1.8	7
2010	The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid. Nature Communications, 2019, 10, 5433.	5.8	44
2011	Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics. Stem Cells International, 2019, 2019, 1-15.	1.2	44
2012	Anticancer Molecule Discovery via C2-Substituent Promoted Oxidative Coupling of Indole and Enolate. IScience, 2019, 22, 214-228.	1.9	9
2013	A Model-System to Address the Impact of Phenotypic Heterogeneity and Plasticity on the Development of Cancer Therapies. Frontiers in Oncology, 2019, 9, 842.	1.3	6
2014	Maackia amurensis agglutinin induces apoptosis in cultured drug resistant human non-small cell lung cancer cells. Glycoconjugate Journal, 2019, 36, 473-485.	1.4	6
2015	Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer. , 2019, , 325-367.		2
2016	Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology. Future Oncology, 2019, 15, 3861-3876.	1.1	13
2017	Anticandidal agent for multiple targets: the next paradigm in the discovery of proficient therapeutics/overcoming drug resistance. Future Medicinal Chemistry, 2019, 11, 2955-2974.	1.1	8
2018	The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway. EBioMedicine, 2019, 49, 55-71.	2.7	30
2019	Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy. Nature Materials, 2019, 18, 1376-1383.	13.3	164
2020	Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review. Anticancer Research, 2019, 39, 6443-6455.	0.5	22
2021	Drug Concentration Asymmetry in Tissues and Plasma for Small Moleculeâ€“Related Therapeutic Modalities. Drug Metabolism and Disposition, 2019, 47, 1122-1135.	1.7	79
2022	Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment. European Journal of Medicinal Chemistry, 2019, 163, 883-895.	2.6	115
2023	The inhibitory effects of mitragynine on P-glycoprotein in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 481-496.	1.4	23
2024	The multikinase inhibitor ECâ€70124 synergistically increased the antitumor activity of doxorubicin in sarcomas. International Journal of Cancer, 2019, 145, 254-266.	2.3	12
2025	Conjugated Polymer Nanoparticles for Imaging, Cell Activity Regulation, and Therapy. Advanced Functional Materials, 2019, 29, 1806818.	7.8	204
2026	miRâ€381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biology International, 2019, 43, 12-21.	1.4	42

#	Article	IF	Citations
2027	Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs. Journal of Controlled Release, 2019, 293, 84-93.	4.8	17
2028	Cytotoxicity of 40 Egyptian plant extracts targeting mechanisms of drug-resistant cancer cells. Phytomedicine, 2019, 59, 152771.	2.3	36
2029	Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel. Cancers, 2019, 11, 77.	1.7	22
2030	Development of Photo-Activated ROS-Responsive Nanoplatform as a Dual-Functional Drug Carrier in Combinational Chemo-Photodynamic Therapy. Frontiers in Chemistry, 2018, 6, 647.	1.8	12
2031	The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters, 2019, 445, 34-44.	3.2	28
2032	Inward- and outward-facing X-ray crystal structures of homodimeric P-glycoprotein CmABCB1. Nature Communications, 2019, 10, 88.	5.8	52
2033	5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells. Toxicology and Applied Pharmacology, 2019, 362, 136-149.	1.3	38
2034	Recent advances in magnetic fluid hyperthermia for cancer therapy. Colloids and Surfaces B: Biointerfaces, 2019, 174, 42-55.	2.5	233
2035	The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer. European Journal of Medicinal Chemistry, 2019, 162, 423-434.	2.6	30
2036	CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression. Journal of Cellular Physiology, 2019, 234, 9297-9307.	2.0	18
2037	Identification of Smac mimetics as novel substrates for p-glycoprotein. Cancer Letters, 2019, 440-441, 126-134.	3.2	8
2038	Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 161, 118-130.	2.6	27
2039	Delivery of docetaxel using pH-sensitive liposomes based on D-Î±-tocopheryl poly(2-ethyl-2-oxazoline) succinate: Comparison with PEGylated liposomes. Asian Journal of Pharmaceutical Sciences, 2019, 14, 391-404.	4.3	18
2040	Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1). Toxicology, 2019, 411, 81-92.	2.0	7
2041	Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents. European Journal of Medicinal Chemistry, 2019, 161, 364-377.	2.6	15
2042	1,2,3,4-Tetrahydroisoquinoline/2H-chromen-2-one conjugates as nanomolar P-glycoprotein inhibitors: Molecular determinants for affinity and selectivity over multidrug resistance associated protein 1. European Journal of Medicinal Chemistry, 2019, 161, 433-444.	2.6	13
2043	Peptide-Guided System with Programmable Subcellular Translocation for Targeted Therapy and Bypassing Multidrug Resistance. Analytical Chemistry, 2019, 91, 1880-1886.	3.2	14
2044	Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology, 2019, 83, 399-410.	1.1	12

#	Article	IF	Citations
2045	Proteins Regulating Microvesicle Biogenesis and Multidrug Resistance in Cancer. Proteomics, 2019, 19, e1800165.	1.3	37
2046	Pluronics: Intelligent building units for targeted cancer therapy and molecular imaging. International Journal of Pharmaceutics, 2019, 556, 30-44.	2.6	38
2047	Design, synthesis, and biological evaluation of indole carboxylic acid esters of podophyllotoxin as antiproliferative agents. Medicinal Chemistry Research, 2019, 28, 81-94.	1.1	9
2048	Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. Acta Pharmaceutica Sinica B, 2019, 9, 615-625.	5.7	61
2049	Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opinion on Drug Delivery, 2019, 16, 69-78.	2.4	364
2050	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters, 2019, 440-441, 82-93.	3.2	83
2051	Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment. Antioxidants and Redox Signaling, 2019, 30, 1096-1123.	2.5	21
2052	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxidants and Redox Signaling, 2019, 30, 1062-1082.	2.5	137
2053	New pyrazolyl-dibenzo[b,e][1,4]diazepinones: room temperature one-pot synthesis and biological evaluation. Molecular Diversity, 2020, 24, 355-377.	2.1	13
2054	Potential drugs used in the antibodyâ€“drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology, 2020, 235, 31-64.	2.0	97
2055	AIE-based cancer theranostics. Coordination Chemistry Reviews, 2020, 402, 213076.	9.5	127
2056	A Case of Hashimotoâ€™s Thyroiditis with Multiple Drug Resistance and High Expression of Efflux Transporters. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 399-406.	1.8	3
2057	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. Abdominal Radiology, 2020, 45, 828-841.	1.0	2
2058	Role of ATP-binding cassette transporters in cancer initiation and progression. Seminars in Cancer Biology, 2020, 60, 72-95.	4.3	55
2059	Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells. Nutrition and Cancer, 2020, 72, 522-527.	0.9	6
2060	Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy. Progress in Materials Science, 2020, 107, 100599.	16.0	138
2061	In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2026-2035.	3.3	3
2062	Efflux transporters in cancer resistance: Molecular and functional characterization of P-glycoprotein. , 2020, , 1-30.		3

#	Article	IF	Citations
2063	Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein. , 2020, , 67-96.		1
2064	Molecular imaging of membrane drug efflux transporters activity in cancer. , 2020, , 97-120.		0
2065	ABC-transporters and drug efflux in hematologic cancers. , 2020, , 149-195.		2
2066	Influence of transporters in treating cancers in the CNS. , 2020, , 277-301.		2
2067	Overcoming efflux transporter-mediated resistance in cancer by using nanomedicines. , 2020, , 337-369.		2
2068	Probing cholesterol binding and translocation in P-glycoprotein. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183090.	1.4	18
2069	Mitochondrion-Targeting Peptides and Peptidomimetics: Recent Progress and Design Principles. Biochemistry, 2020, 59, 270-284.	1.2	37
2070	Co-delivery of Poria cocos extract and doxorubicin as an â€˜all-in-oneâ€™ nanocarrier to combat breast cancer multidrug resistance during chemotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 23, 102095.	1.7	31
2071	Nanotechnology platforms for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1590.	3.3	82
2073	The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences, 2020, 21, 238.	1.8	10
2074	Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways. Computational and Structural Biotechnology Journal, 2020, 18, 125-136.	1.9	22
2075	Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells. European Journal of Pharmacology, 2020, 868, 172883.	1.7	6
2076	lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer. Molecular Therapy - Nucleic Acids, 2020, 19, 643-653.	2.3	75
2077	FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. Cancer Letters, 2020, 470, 29-42.	3.2	48
2078	Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine. Journal of Controlled Release, 2020, 319, 46-62.	4.8	84
2079	Knockdown of TMEM45A overcomes multidrug resistance and epithelialâ€“mesenchymal transition in human colorectal cancer cells through inhibition of TGFâ€²² signalling pathway. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 503-516.	0.9	10
2080	Piper anisum as a promising new source of bioactive metabolites. Chemical Papers, 2020, 74, 1505-1515.	1.0	12
2081	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2020, 206, 107447.		449

#	Article	IF	Citations
2082	A Marine Collagen-Based Biomimetic Hydrogel Recapitulates Cancer Stem Cell Niche and Enhances Progression and Chemoresistance in Human Ovarian Cancer. Marine Drugs, 2020, 18, 498.	2.2	9
2083	Magnetically switchable mechano-chemotherapy for enhancing the death of tumour cells by overcoming drug-resistance. Nano Today, 2020, 35, 100967.	6.2	16
2084	Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Reports, 2022, 5, e1291.	0.6	56
2085	Nanoenabled Intracellular Calcium Bursting for Safe and Efficient Reversal of Drug Resistance in Tumor Cells. Nano Letters, 2020, 20, 8102-8111.	4.5	64
2086	Study of the controversial resveratrol that interact with the endogenous glutathione thiyl radical in cancer cells. Free Radical Research, 2020, 54, 687-693.	1.5	1
2087	Blood-brain-barrier penetrable thiolated paclitaxel-oligo (p-phenylene vinylene) nanomedicine with increased drug efficiency for glioblastoma treatment. Nano Today, 2020, 35, 100969.	6.2	20
2088	Complete inhibition of ABCB1 and ABCG2 at the bloodâ€“brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹C]erlotinib. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1634-1646.	2.4	17
2089	Cancer stem cells and strategies for targeted drug delivery. Drug Delivery and Translational Research, 2021, 11, 1779-1805.	3.0	6
2090	Metformin reverses the drug resistance of cisplatin in irradiated CNE-1 human nasopharyngeal carcinoma cells through PECAM-1 mediated MRPs down-regulation. International Journal of Medical Sciences, 2020, 17, 2416-2426.	1.1	12
2091	Barriers for Tumor Drug Delivery. , 2020, , 5-26.		1
2092	Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today, 2020, 25, 2227-2244.	3.2	71
2093	Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. International Journal of Pharmaceutics, 2020, 590, 119915.	2.6	43
2094	Synthesis and Biological Profiling of Pyrazolo-Fused 7-Deazapurine Nucleosides. Journal of Organic Chemistry, 2020, 85, 10539-10551.	1.7	7
2095	In silico studies of fluorinated chalcone and pyrazoline analogues as inhibitors for cervical cancer. AIP Conference Proceedings, 2020, , .	0.3	2
2096	Carrierâ€Free Delivery of Precise Drugâ€“Chemogene Conjugates for Synergistic Treatment of Drugâ€Resistant Cancer. Angewandte Chemie, 2020, 132, 18100-18106.	1.6	10
2097	CPPF, A Novel Microtubule Targeting Anticancer Agent, Inhibits the Growth of a Wide Variety of Cancers. International Journal of Molecular Sciences, 2020, 21, 4800.	1.8	3
2098	Influence of Ultrasound and Magnetic Field Treatment Time on Carcinoma Cell Inhibition with Drug Carriers: An in Vitro Study. Ultrasound in Medicine and Biology, 2020, 46, 2752-2764.	0.7	4
2099	The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes. Phytomedicine, 2020, 77, 153280.	2.3	31

#	Article	IF	Citations
2100	Particulate Matter (PM2.5) from Biomass Combustion Induces an Anti-Oxidative Response and Cancer Drug Resistance in Human Bronchial Epithelial BEAS-2B Cells. International Journal of Environmental Research and Public Health, 2020, 17, 8193.	1.2	17
2101	Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer. Drug Delivery and Translational Research, 2021, 11, 2052-2071.	3.0	19
2102	Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance. International Journal of Molecular Sciences, 2020, 21, 8991.	1.8	40
2103	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. Journal of Medicinal Chemistry, 2020, 63, 15979-15996.	2.9	25
2104	New Series of Double-Modified Colchicine Derivatives: Synthesis, Cytotoxic Effect and Molecular Docking. Molecules, 2020, 25, 3540.	1.7	8
2105	Design, Synthesis, and Biological Evaluation of Novel 7H-[1,2,4]Triazolo[3,4-b][1,3,4]thiadiazine Inhibitors as Antitumor Agents. ACS Omega, 2020, 5, 20170-20186.	1.6	16
2106	Co-delivery of IR-768 and daunorubicin using mPEG-b-PLGA micelles for synergistic enhancement of combination therapy of melanoma. Journal of Photochemistry and Photobiology B: Biology, 2020, 211, 111981.	1.7	14
2107	Impact of Galectins in Resistance to Anticancer Therapies. Clinical Cancer Research, 2020, 26, 6086-6101.	3.2	40
2108	Delivery of Platinum(IV) Prodrugs via Bi₂Te₃ Nanoparticles for Photothermalâ€“Chemotherapy and Photothermal/Photoacoustic Imaging. Molecular Pharmaceutics, 2020, 17, 3403-3411.	2.3	15
2109	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. Frontiers in Oncology, 2020, 10, 1219.	1.3	11
2110	pH/redox sequentially responsive nanoparticles with size shrinkage properties achieve deep tumor penetration and reversal of multidrug resistance. Biomaterials Science, 2020, 8, 4767-4778.	2.6	21
2111	Adjudin-loaded redox-sensitive paclitaxel-prodrug micelles for overcoming multidrug resistance with efficient targeted Colon cancer therapy. Drug Delivery, 2020, 27, 1094-1105.	2.5	15
2112	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 5510.	1.8	83
2113	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates, 2020, 50, 100682.	6.5	160
2114	Metal-polyphenol-network coated CaCO3 as pH-responsive nanocarriers to enable effective intratumoral penetration and reversal of multidrug resistance for augmented cancer treatments. Nano Research, 2020, 13, 3057-3067.	5.8	40
2115	Repurposing of Drugs for Antibacterial Activities on Selected ESKAPE Bacteria Staphylococcus aureus and Pseudomonas aeruginosa. International Journal of Microbiology, 2020, 2020, 1-9.	0.9	15
2116	Design and Characterization of Glyceryl Monooleate-Nanostructures Containing Doxorubicin Hydrochloride. Pharmaceutics, 2020, 12, 1017.	2.0	27
2117	Autophagy-mediating microRNAs in cancer chemoresistance. Cell Biology and Toxicology, 2020, 36, 517-536.	2.4	22

#	Article	IF	Citations
2118	Enhancing Chemotherapy by RNA Interference. BIO Integration, 2020, 1, .	0.9	11
2119	A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance. ACS Applied Materials & Interfaces, 2020, 12, 54343-54355.	4.0	15
2120	YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells. Toxicology in Vitro, 2020, 69, 104971.	1.1	7
2121	Deciphering the chemical instability of sphaeropsidin A under physiological conditions â€“ degradation studies and structural elucidation of the major metabolite. Organic and Biomolecular Chemistry, 2020, 18, 8147-8160.	1.5	0
2122	Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
2123	The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype. PLoS ONE, 2020, 15, e0226450.	1.1	15
2124	Increase in Toxicity of Anticancer Drugs by PMTPV, a Claudin-1-Binding Peptide, Mediated via Down-Regulation of Claudin-1 in Human Lung Adenocarcinoma A549 Cells. International Journal of Molecular Sciences, 2020, 21, 5909.	1.8	6
2125	The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacology and Translational Science, 2020, 3, 835-843.	2.5	15
2126	Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. Frontiers in Oncology, 2020, 10, 561936.	1.3	68
2127	A Compressive Review about TaxolÂ®: History and Future Challenges. Molecules, 2020, 25, 5986.	1.7	148
2128	Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response. International Journal of Molecular Sciences, 2020, 21, 9556.	1.8	14
2129	Methods to Scale Down Graphene Oxide Size and Size Implication in Anti-cancer Applications. Frontiers in Bioengineering and Biotechnology, 2020, 8, 613280.	2.0	14
2130	Computational Insights into Allosteric Conformational Modulation of P-Glycoprotein by Substrate and Inhibitor Binding. Molecules, 2020, 25, 6006.	1.7	9
2131	Study on reversal of ABCB1 mediated multidrug resistance in Colon cancer by acetogenins: An in-silico approach. Journal of Biomolecular Structure and Dynamics, 2022, 40, 4273-4284.	2.0	11
2132	Review of Curcumin Physicochemical Targeting Delivery System . International Journal of Nanomedicine, 2020, Volume 15, 9799-9821.	3.3	30
2133	Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. Cancers, 2020, 12, 3249.	1.7	19
2134	Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells. Cellular Signalling, 2020, 75, 109742.	1.7	6
2135	Improving Treatment Efficacy of In Situ Forming Implants via Concurrent Delivery of Chemotherapeutic and Chemosensitizer. Scientific Reports, 2020, 10, 6587.	1.6	6

#	Article	IF	Citations
2136	Leonurine Promotes Cisplatin Sensitivity in Human Cervical Cancer Cells Through Increasing Apoptosis and Inhibiting Drug-Resistant Proteins . Drug Design, Development and Therapy, 2020, Volume 14, 1885-1895.	2.0	12
2137	Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer. Clinical Breast Cancer, 2020, 20, 275-282.	1.1	4
2138	An Artemisininâ€Derivativeâ€“(NHC)Gold(I) Hybrid with Enhanced Cytotoxicity through Inhibition of NRF2 Transcriptional Activity. Angewandte Chemie, 2020, 132, 12160-12166.	1.6	7
2139	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Frontiers in Oncology, 2020, 10, 674.	1.3	18
2140	M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. Cells, 2020, 9, 1224.	1.8	24
2141	Combined pH-responsive chemotherapy and glutathione-triggered photosensitization to overcome drug-resistant hepatocellular carcinoma â€” a SPP/JPP Young Investigator Award paper. Journal of Porphyrins and Phthalocyanines, 2020, 24, 1387-1401.	0.4	3
2142	In vitro photodynamic treatment of cancer cells induced by aza-BODIPYs. Photochemical and Photobiological Sciences, 2020, 19, 790-799.	1.6	5
2143	The Progress and Prospect of Zeolitic Imidazolate Frameworks in Cancer Therapy, Antibacterial Activity, and Biomineralization. Advanced Healthcare Materials, 2020, 9, e2000248.	3.9	99
2144	ABCG2 transports anticancer drugs via a closed-to-open switch. Nature Communications, 2020, 11, 2264.	5.8	142
2145	All-in-One Molecular Aggregation-Induced Emission Theranostics: Fluorescence Image Guided and Mitochondria Targeted Chemo- and Photodynamic Cancer Cell Ablation. Chemistry of Materials, 2020, 32, 4681-4691.	3.2	73
2146	MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor. International Journal of Molecular Sciences, 2020, 21, 3333.	1.8	15
2147	Light-Switchable Yolkâ€“Mesoporous Shell UCNPs@MgSiO₃ for Nitric Oxide-Evoked Multidrug Resistance Reversal in Cancer Therapy. ACS Applied Materials & Interfaces, 2020, 12, 30066-30076.	4.0	45
2148	In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. Journal of Controlled Release, 2020, 324, 146-155.	4.8	9
2149	Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers, 2020, 12, 1366.	1.7	23
2150	Collective Locomotion of Human Cells, Wound Healing and Their Control by Extracts and Isolated Compounds from Marine Invertebrates. Molecules, 2020, 25, 2471.	1.7	21
2151	TME-activatable theranostic nanoplatform with ATP burning capability for tumor sensitization and synergistic therapy. Theranostics, 2020, 10, 6987-7001.	4.6	35
2152	Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. International Journal of Pharmaceutics, 2020, 585, 119513.	2.6	36
2153	Doxorubicin-loading core-shell pectin nanocell: A novel nanovehicle for anticancer agent delivery with multidrug resistance reversal. PLoS ONE, 2020, 15, e0235090.	1.1	11

#	Article	IF	Citations
2154	Chick embryo chorioallantoic membrane as a suitable in vivo model to evaluate drug delivery systems for cancer treatment: A review. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 273-284.	2.0	30
2155	A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance. PLoS ONE, 2020, 15, e0233993.	1.1	13
2156	Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. Biochemical Pharmacology, 2020, 178, 114061.	2.0	16
2157	Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity. Molecular Pharmaceutics, 2020, 17, 2398-2410.	2.3	12
2158	Epithelialâ€“Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. Molecular Cancer Research, 2020, 18, 1257-1270.	1.5	86
2159	LncRNA TTN-AS1 Regulates miR-524-5p and RRM2 to Promote Breast Cancer Progression . OncoTargets and Therapy, 2020, Volume 13, 4799-4811.	1.0	15
2160	Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis. Nature Communications, 2020, 11, 3062.	5.8	33
2161	New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188382.	3.3	54
2162	Substituted 4,5â€²-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIÎ±. Journal of Chemical Information and Modeling, 2020, 60, 3662-3678.	2.5	19
2163	Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro. Frontiers in Oncology, 2020, 10, 696.	1.3	14
2164	Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. Frontiers in Oncology, 2020, 10, 764.	1.3	70
2165	Schistosoma mansoni sarco/endoplasmic reticulum Ca2+ ATPases (SERCA): role in reduced sensitivity to praziquantel. Journal of Bioenergetics and Biomembranes, 2020, 52, 397-408.	1.0	6
2166	FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 399-409.	1.9	59
2167	Metabolism and pharmacokinetics characterization of metarrestin in multiple species. Cancer Chemotherapy and Pharmacology, 2020, 85, 805-816.	1.1	6
2168	The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP. Cells, 2020, 9, 613.	1.8	13
2169	Polyphosphazene-Based Drug Self-Framed Delivery System as a Universal Intelligent Platform for Combination Therapy against Multidrug-Resistant Tumors. ACS Applied Bio Materials, 2020, 3, 2284-2294.	2.3	20
2170	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs in R and D, 2020, 20, 55-73.	1.1	84
2171	Mitochondrial targeted strategies and their application for cancer and other diseases treatment. Journal of Pharmaceutical Investigation, 2020, 50, 271-293.	2.7	34

#	Article	IF	Citations
2172	Reversal of ABCB1-related multidrug resistance by ERK5-IN-1. Journal of Experimental and Clinical Cancer Research, 2020, 39, 50.	3.5	14
2173	Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol through the Modulation of EGFR and CSC Signaling Pathways. Cells, 2020, 9, 681.	1.8	23
2174	miRNAâ€765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells. FEBS Open Bio, 2020, 10, 1021-1030.	1.0	15
2175	Î²-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53â€“MDM2 Interaction in Colorectal Cancer. Journal of Agricultural and Food Chemistry, 2020, 68, 3850-3858.	2.4	50
2176	Dihydroartemisinin-Loaded Magnetic Nanoparticles for Enhanced Chemodynamic Therapy. Frontiers in Pharmacology, 2020, 11, 226.	1.6	38
2177	Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoproteinâ€“Expressing Cells. Cancer Research, 2020, 80, 663-674.	0.4	21
2178	PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation. Theranostics, 2020, 10, 3767-3778.	4.6	50
2179	pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Communications Biology, 2020, 3, 95.	2.0	163
2180	Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. Frontiers in Oncology, 2020, 10, 932.	1.3	8
2181	Drug transporters in the development of multidrug resistance in colorectal cancer. , 2020, , 35-55.		4
2182	Bone interface modulates drug resistance in breast cancer bone metastasis. Colloids and Surfaces B: Biointerfaces, 2020, 195, 111224.	2.5	14
2183	Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. Expert Opinion on Drug Delivery, 2020, 17, 1361-1376.	2.4	31
2184	Disulfide based prodrugs for cancer therapy. RSC Advances, 2020, 10, 24397-24409.	1.7	43
2185	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2020, 10, 955.	1.3	31
2186	Importance of efflux pumps in subjugating antibiotic resistance. , 2020, , 273-299.		3
2187	Smart Hydrogels â€“ Synthetic Stimuli-Responsive Antitumor Drug Release Systems . International Journal of Nanomedicine, 2020, Volume 15, 4541-4572.	3.3	106
2188	Carrierâ€Free Delivery of Precise Drugâ€“Chemogene Conjugates for Synergistic Treatment of Drugâ€Resistant Cancer. Angewandte Chemie - International Edition, 2020, 59, 17944-17950.	7.2	73
2189	Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology, 2020, 180, 114137.	2.0	19

#	Article	IF	Citations
2190	Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chemical Biology, 2020, 27, 1359-1370.e8.	2.5	13
2191	Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 43-49.	2.0	31
2192	Nanoemulsions for intravenous drug delivery. , 2020, , 581-601.		4
2193	Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia. Annals of Hematology, 2020, 99, 2173-2180.	0.8	12
2194	Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2020, 79, 266-276.	0.9	17
2195	Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells. Scientific Reports, 2020, 10, 1970.	1.6	28
2197	Wnt-mediated endothelial transformation into mesenchymal stem cellâ€“like cells induces chemoresistance in glioblastoma. Science Translational Medicine, 2020, 12, .	5.8	86
2198	New Di(heteroaryl)ethenes as Apoptotic Antiâ€proliferative Agents Towards Breast Cancer: Design, Oneâ€Pot Synthesis and In Vitro Evaluation. ChemistrySelect, 2020, 5, 2581-2587.	0.7	4
2199	A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129556.	1.1	6
2200	Proteomic Analysis Reveals that EPHX1 Contributes to 5â€Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. Proteomics - Clinical Applications, 2020, 14, e1900080.	0.8	8
2201	Tumorâ€Oriented Telomeraseâ€Terminated Nanoplatform as Versatile Strategy for Multidrug Resistance Reversal in Cancer Treatment. Advanced Healthcare Materials, 2020, 9, e1901739.	3.9	12
2202	Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer. Signal Transduction and Targeted Therapy, 2020, 5, 12.	7.1	41
2203	Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance. Molecules, 2020, 25, 764.	1.7	13
2204	IRE1Î±-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Letters, 2020, 476, 67-74.	3.2	34
2205	ROS in cancer therapy: the bright side of the moon. Experimental and Molecular Medicine, 2020, 52, 192-203.	3.2	1,260
2206	Polymeric Nanoparticles for the Treatment of Malignant Gliomas. Cancers, 2020, 12, 175.	1.7	63
2207	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	1.7	33
2208	Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1113-1129.	1.4	3

#	Article	IF	Citations
2209	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers, 2020, 12, 195.	1.7	25
2210	Exploration of docetaxel palmitate and its solid lipid nanoparticles as a novel option for alleviating the rising concern of multi-drug resistance. International Journal of Pharmaceutics, 2020, 578, 119088.	2.6	24
2211	SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. Pharmacological Research, 2020, 153, 104660.	3.1	29
2212	Smart drug carrier based on polyurethane material for enhanced and controlled DOX release triggered by redox stimulus. Reactive and Functional Polymers, 2020, 148, 104507.	2.0	18
2213	Zwitterionic Polymer Coating of Sulfur Dioxideâ€Releasing Nanosystem Augments Tumor Accumulation and Treatment Efficacy. Advanced Healthcare Materials, 2020, 9, e1901582.	3.9	43
2214	Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. PLoS ONE, 2020, 15, e0228331.	1.1	7
2215	Gallbladder Cancer Progression Is Reversed by Nanomaterial-Induced Photothermal Therapy in Combination with Chemotherapy and Autophagy Inhibition . International Journal of Nanomedicine, 2020, Volume 15, 253-262.	3.3	15
2216	Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin . Drug Design, Development and Therapy, 2020, Volume 14, 285-296.	2.0	31
2217	SNHG15 Contributes To Cisplatin Resistance In Breast Cancer Through Sponging miR-381 . OncoTargets and Therapy, 2020, Volume 13, 657-666.	1.0	25
2218	Multi-responsive drug delivery nanoplatform for tumor-targeted synergistic photothermal/dynamic therapy and chemotherapy. New Journal of Chemistry, 2020, 44, 3593-3603.	1.4	12
2219	Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact. Surgery Today, 2020, 50, 1560-1577.	0.7	20
2220	The combination of disulfiram and copper for cancer treatment. Drug Discovery Today, 2020, 25, 1099-1108.	3.2	95
2221	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products, 2020, 83, 1461-1472.	1.5	25
2222	The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer. Cancer Biology and Medicine, 2020, 17, 237-250.	1.4	15
2223	The role of noncoding RNAs and sirtuins in cancer drug resistance. European Journal of Pharmacology, 2020, 877, 173094.	1.7	11
2224	Synthesis and Cytotoxic and Antiviral Activity Profiling of Allâ€Four Isomeric Series of Pyridoâ€Fused 7â€Deazapurine Ribonucleosides. Chemistry - A European Journal, 2020, 26, 13002-13015.	1.7	12
2225	Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets. Journal of Clinical Pathology, 2020, 73, 243-249.	1.0	32
2226	Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells. Molecules, 2020, 25, 1748.	1.7	30

#	Article	IF	Citations
2227	Smart Biomimetic Nanocomposites Mediate Mitochondrial Outcome through Aerobic Glycolysis Reprogramming: A Promising Treatment for Lymphoma. ACS Applied Materials & Interfaces, 2020, 12, 22687-22701.	4.0	26
2228	Melanin-based nanomaterials: The promising nanoplatforms for cancer diagnosis and therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102211.	1.7	20
2229	An Artemisininâ€Derivativeâ€“(NHC)Gold(I) Hybrid with Enhanced Cytotoxicity through Inhibition of NRF2 Transcriptional Activity. Angewandte Chemie - International Edition, 2020, 59, 12062-12068.	7.2	27
2230	Overcoming Doxorubicin Resistance with Lipidâ€“Polymer Hybrid Nanoparticles Photoreleasing Nitric Oxide. Molecular Pharmaceutics, 2020, 17, 2135-2144.	2.3	24
2231	Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers, 2020, 12, 813.	1.7	20
2232	The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein. International Journal of Molecular Sciences, 2020, 21, 2630.	1.8	9
2233	Organosilicon Compounds, SILA-409 and SILA-421, as Doxorubicin Resistance-Reversing Agents in Human Colon Cancer Cells. Molecules, 2020, 25, 1654.	1.7	5
2234	Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy?. Cellular and Molecular Neurobiology, 2021, 41, 91-104.	1.7	2
2235	Paclitaxelâ€loaded polypeptideâ€polyacrylamide nanomicelles overcome drugâ€resistance by enhancing lysosomal membrane permeability and inducing apoptosis. Journal of Biomedical Materials Research - Part A, 2021, 109, 18-30.	2.1	7
2236	Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells. Biological Trace Element Research, 2021, 199, 1316-1331.	1.9	64
2237	Expedient synthesis and anticancer evaluation of dualâ€action 9â€anilinoacridine methyl triazene chimeras. Chemical Biology and Drug Design, 2021, 97, 237-252.	1.5	3
2238	Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy. Carbohydrate Polymers, 2021, 251, 117103.	5.1	69
2239	Inorganic Nanomaterialâ€Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities. Advanced Functional Materials, 2021, 31, 2007096.	7.8	32
2240	Copper(II)-disulfiram loaded melanin-dots for cancer theranostics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 32, 102340.	1.7	13
2241	Mitochondriaâ€Specific Agents for Photodynamic Cancer Therapy: A Key Determinant to Boost the Efficacy. Advanced Healthcare Materials, 2021, 10, e2001240.	3.9	42
2242	Plant extracts and betulin from Ligaria cuneifolia inhibit P-glycoprotein function in leukemia cells. Food and Chemical Toxicology, 2021, 147, 111922.	1.8	17
2243	Polymers and inorganic nanoparticles: A winning combination towards assembled nanostructures for cancer imaging and therapy. Nano Today, 2021, 36, 101046.	6.2	66
2244	Curcumin-loaded Polyethyleneimine and chitosan polymer-based Mucoadhesive liquid crystalline systems as a potential platform in the treatment of cervical Cancer. Journal of Molecular Liquids, 2021, 325, 115080.	2.3	22

#	Article	IF	Citations
2245	Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance. Pharmaceutical Development and Technology, 2021, 26, 21-29.	1.1	7
2246	Aptamer-Functionalized Upconverting Nanoformulations for Light-Switching Cancer-Specific Recognition and In Situ Photodynamicâ€“Chemo Sequential Theranostics. ACS Applied Materials & Interfaces, 2021, 13, 9316-9328.	4.0	18
2247	Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting Î²â€catenin nuclear translocation. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22620.	1.4	9
2248	ATP-responsive hollow nanocapsules for DOX/GOx delivery to enable tumor inhibition with suppressed P-glycoprotein. Nano Research, 2021, 14, 222-231.	5.8	15
2249	Nanomaterials multifunctional behavior for enlightened cancer therapeutics. Seminars in Cancer Biology, 2021, 69, 178-189.	4.3	29
2250	Nanostructures and innovative delivery systems for overcoming cancer resistance. , 2021, , 185-201.		0
2251	Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance. Nature Communications, 2021, 12, 312.	5.8	52
2252	Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resistance Updates, 2021, 54, 100742.	6.5	121
2253	Extracellular Vesicles in Chemoresistance. Sub-Cellular Biochemistry, 2021, 97, 211-245.	1.0	3
2254	From barriers to bridges; glycans in nonparenteral nanomedicines. , 2021, , 467-487.		0
2255	Involvement of DNA methyltransferase 1 (DNMT1) and multidrug resistance-associated proteins in 2-methoxyestradiol-induced cytotoxicity in EC109/Taxol cells. Translational Cancer Research, 2021, 10, 10-21.	0.4	3
2256	Prodrug Nanomedicine Inhibits Chemotherapy-Induced Proliferative Burst by Altering the Deleterious Intercellular Communication. ACS Nano, 2021, 15, 781-796.	7.3	8
2257	Coupling Methods of Antibodies and Ligands for Liposomes. Biomaterial Engineering, 2021, , 143-166.	0.1	1
2258	A multidrug-resistant P-glycoprotein assembly revealed by tariquidar-probe's super-resolution imaging. Nanoscale, 2021, 13, 16995-17002.	2.8	2
2259	Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1520-1538.	2.5	16
2260	Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance. Theranostics, 2021, 11, 6334-6354.	4.6	25
2261	Identification of differentially expressed genes and biological pathways in sanguinarine-treated ovarian cancer by integrated bioinformatics analysis. Pharmacognosy Magazine, 2021, 17, 106.	0.3	1
2262	Reversal of multidrug resistance and antitumor promoting activity of 3-oxo-6Î²-hydroxy- Î²-amyrin isolated from Pistacia integerrima. Biocell, 2021, 45, 139-147.	0.4	7

#	Article	IF	Citations
2263	SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma. Molecular Diagnosis and Therapy, 2021, 25, 99-110.	1.6	2
2264	Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation. Journal of Biological Chemistry, 2021, 296, 100515.	1.6	4
2265	Relation of Metal-Binding Property and Selective Toxicity of 8-Hydroxyquinoline Derived Mannich Bases Targeting Multidrug Resistant Cancer Cells. Cancers, 2021, 13, 154.	1.7	8
2266	Comprehensively enhanced delivery cascade by transformable beaded nanofibrils for pancreatic cancer therapy. Nanoscale, 2021, 13, 13328-13343.	2.8	7
2267	The Metabolic Reprogramming of Frem2 Mutant Mice Embryos in Cryptophthalmos Development. Frontiers in Cell and Developmental Biology, 2020, 8, 625492.	1.8	2
2268	NIR-II light triggered nitric oxide release nanoplatform combined chemo-photothermal therapy for overcoming multidrug resistant cancer. Journal of Materials Chemistry B, 2021, 9, 1698-1706.	2.9	35
2269	Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles. Scientific Reports, 2021, 11, 1788.	1.6	17
2270	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity. European Journal of Medicinal Chemistry, 2021, 211, 113107.	2.6	10
2271	Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. International Journal of Nanomedicine, 2021, Volume 16, 1313-1330.	3.3	139
2272	The Whole Is Bigger than the Sum of Its Parts: Drug Transport in the Context of Two Membranes with Active Efflux. Chemical Reviews, 2021, 121, 5597-5631.	23.0	31
2274	Immunoexpression and Prognostic Significance of Multidrug Resistance Markers in Feline Mammary Carcinomas. Journal of Comparative Pathology, 2021, 183, 13-25.	0.1	0
2275	Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site. European Journal of Medicinal Chemistry, 2021, 212, 113045.	2.6	17
2276	Unlocking the potential of antibodyâ€“drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 327-344.	12.5	498
2277	Progress and Clinical Application of Single-Cell Transcriptional Sequencing Technology in Cancer Research. Frontiers in Oncology, 2020, 10, 593085.	1.3	18
2279	3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. Scientific Reports, 2021, 11, 4259.	1.6	20
2280	A Novel Targeted Therapy System for Cervical Cancer:Â Co-Delivery SystemÂ ofÂ Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier. International Journal of Nanomedicine, 2021, Volume 16, 1051-1066.	3.3	20
2281	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 369-396.	1.5	37
2282	New 5-carba-pterocarpans: Synthesis and preliminary antiproliferative activity on a panel of human cancer cells. Bioorganic Chemistry, 2021, 107, 104584.	2.0	3

#	Article	IF	Citations
2283	Newly Developed Self-Assembling Antioxidants as Potential Therapeutics for the Cancers. Journal of Personalized Medicine, 2021, 11, 92.	1.1	14
2284	Combination of Simvastatin and FAC Improves Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Cancer Research and Treatment, 2021, 53, 1072-1083.	1.3	21
2285	Biocompatible nanoreactors of catalase and nanozymes for anticancer therapeutics. Nano Select, 2021, 2, 1849-1873.	1.9	8
2286	Pleiotropic Roles of ABC Transporters in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 3199.	1.8	29
2287	Drug penetration in pediatric brain tumors: Challenges and opportunities. Pediatric Blood and Cancer, 2021, 68, e28983.	0.8	10
2288	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 641469.	1.8	76
2290	Anti-Tumor Drug Discovery Based on Natural Product Î²-Elemene: Anti-Tumor Mechanisms and Structural Modification. Molecules, 2021, 26, 1499.	1.7	46
2291	Molecular Action of Polyphenols in Leukaemia and Their Therapeutic Potential. International Journal of Molecular Sciences, 2021, 22, 3085.	1.8	8
2292	The crystal structure of the CmABCB1 G132V mutant, which favors the outwardâ€facing state, reveals the mechanism of the pivotal joint between TM1 and TM3. Protein Science, 2021, 30, 1064-1071.	3.1	2
2293	Recent Progress of Alkyl Radicals Generationâ€Based Agents for Biomedical Applications. Advanced Healthcare Materials, 2021, 10, e2100055.	3.9	21
2294	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 3677-3693.	2.9	29
2295	Recent progress in nanoformulations of cabazitaxel. Biomedical Materials (Bristol), 2021, 16, 032002.	1.7	10
2296	A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity. JCI Insight, 2021, 6, .	2.3	22
2297	1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design. Expert Opinion on Drug Discovery, 2021, 16, 1119-1147.	2.5	17
2298	Î²-Carbolines as potential anticancer agents. European Journal of Medicinal Chemistry, 2021, 216, 113321.	2.6	50
2299	Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical setting. Critical Reviews in Oncology/Hematology, 2021, 160, 103281.	2.0	19
2300	Syntheses and Antitumor Properties of Furoxan Derivatives. Current Organic Chemistry, 2021, 25, 757-778.	0.9	3
2301	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. Frontiers in Pharmacology, 2021, 12, 576093.	1.6	17

#	Article	IF	Citations
2302	CRISPR/Cas9 mutagenesis reveals a role for ABCB1 in gut immune responses toVibrio diazotrophicusin sea urchin larvae. Journal of Experimental Biology, 2021, 224, .	0.8	15
2303	Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell. European Journal of Medicinal Chemistry, 2021, 216, 113336.	2.6	21
2304	Pyxinol bearing amino acid residues: Easily achievable and promising modulators of P-glycoprotein-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2021, 216, 113317.	2.6	11
2305	Facile production of chlorophyllides using recombinant CrCLH1 and their cytotoxicity towards multidrug resistant breast cancer cell lines. PLoS ONE, 2021, 16, e0250565.	1.1	2
2306	Hybrid Drugsâ€"A Strategy for Overcoming Anticancer Drug Resistance?. Molecules, 2021, 26, 2601.	1.7	63
2307	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine and Pharmacotherapy, 2021, 136, 111223.	2.5	12
2309	Sildenafil in Combination Therapy against Cancer: A Literature Review. Current Medicinal Chemistry, 2021, 28, 2248-2259.	1.2	9
2310	Stimuliâ€Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis. Advanced Materials Interfaces, 2021, 8, 2002200.	1.9	10
2311	PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance. Current Cancer Drug Targets, 2021, 21, 306-325.	0.8	4
2312	A Comparison of Doxorubicin-Resistant Colon Cancer LoVo and Leukemia HL60 Cells: Common Features, Different Underlying Mechanisms. Current Issues in Molecular Biology, 2021, 43, 163-175.	1.0	5
2313	Urban ethnobotany of Kolkata, India: a case study of sustainability, conservation and pluricultural use of medicinal plants in traditional herbal shops. Environment, Development and Sustainability, 2022, 24, 1207-1240.	2.7	7
2314	Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy. Nano Letters, 2021, 21, 4231-4240.	4.5	149
2315	Resistance to Intervention: Paclitaxel in Breast Cancer. Mini-Reviews in Medicinal Chemistry, 2021, 21, 1237-1268.	1.1	34
2316	Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study. Cell Biochemistry and Biophysics, 2021, 79, 189-200.	0.9	16
2318	DNAâ€Scaffolded Disulfide Redox Network for Programming Drugâ€Delivery Kinetics. Chemistry - A European Journal, 2021, 27, 8745-8752.	1.7	6
2319	Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP). Journal of Nanobiotechnology, 2021, 19, 146.	4.2	41
2320	The role of microRNAs on doxorubicin drug resistance in breast cancer. Journal of Pharmacy and Pharmacology, 2021, 73, 997-1006.	1.2	17
2321	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	1.7	17

#	Article	IF	Citations
2322	Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by Inducing Apoptosis and Targeting P-Glycoprotein. Nutrients, 2021, 13, 1719.	1.7	4
2323	Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature Communications, 2021, 12, 2804.	5.8	77
2324	Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy. Process Biochemistry, 2021, 104, 55-75.	1.8	15
2325	Combination Chemotherapy with Cisplatin and Chloroquine: Effect of Encapsulation in Micelles Formed by Self-Assembling Hybrid Dendriticâ€“Linearâ€“Dendritic Block Copolymers. International Journal of Molecular Sciences, 2021, 22, 5223.	1.8	10
2326	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127997.	1.0	9
2328	MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes and Environment, 2021, 43, 21.	0.9	18
2329	Designing potent inhibitors against the multidrug resistance P-glycoprotein. Journal of Biomolecular Structure and Dynamics, 2022, 40, 9403-9415.	2.0	3
2330	The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS. Antioxidants, 2021, 10, 949.	2.2	14
2331	Clinical and cost outcomes following genomicsâ€informed treatment for advanced cancers. Cancer Medicine, 2021, 10, 5131-5140.	1.3	8
2332	Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics. Pharmaceutics, 2021, 13, 890.	2.0	24
2333	Copper-binding anticancer peptides from the piscidin family: an expanded mechanism that encompasses physical and chemical bilayer disruption. Scientific Reports, 2021, 11, 12620.	1.6	9
2335	Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine. Pharmaceutical Research, 2021, 38, 1209-1219.	1.7	13
2336	The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology, 2021, 188, 114516.	2.0	21
2337	Electrospinning for drug delivery applications: A review. Journal of Controlled Release, 2021, 334, 463-484.	4.8	345
2338	Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2. Journal of Molecular Biology, 2021, 433, 166980.	2.0	52
2339	MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway. Cancer Gene Therapy, 2022, 29, 770-783.	2.2	7
2340	Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1621-1632.	1.4	17
2341	Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism. Nature Communications, 2021, 12, 4376.	5.8	46

#	Article	IF	Citations
2342	A tumor-penetrable drug nanococktail made from human histones for interventional nucleus-targeted chemophotothermal therapy of drug-resistant tumors. Bioactive Materials, 2022, 9, 554-565.	8.6	10
2343	A Personalized Therapeutics Approach Using an In Silico Drosophila Patient Model Reveals Optimal Chemo- and Targeted Therapy Combinations for Colorectal Cancer. Frontiers in Oncology, 2021, 11, 692592.	1.3	6
2344	Babao Dan Reverses Multiple-Drug Resistance in Gastric Cancer Cells via Triggering Apoptosis and Autophagy and Inhibiting PI3K/AKT/mTOR Signaling. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-13.	0.5	6
2345	Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells. Journal of Pharmacy and Pharmacology, 2021, 73, 1609-1616.	1.2	2
2346	Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP). International Journal of Molecular Sciences, 2021, 22, 7727.	1.8	8
2347	MicroRNAâ€'18aâ€'5p regulates the Warburg effect by targeting hypoxiaâ€'inducible factor 1Î± in the K562/ADM cell line. Experimental and Therapeutic Medicine, 2021, 22, 1069.	0.8	5
2348	Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologistâ€™s Perspective. Antibodies, 2021, 10, 30.	1.2	13
2350	Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based â€œcomboâ€•nanoagent together with PD-L1 blockade in reversing multidrug resistance. Journal of Nanobiotechnology, 2021, 19, 200.	4.2	18
2351	lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	1
2352	Branebrutinib (BMS-986195), a Brutonâ€™s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology, 2021, 9, 699571.	1.8	3
2353	Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. International Journal of Molecular Sciences, 2021, 22, 9451.	1.8	67
2354	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. Journal of Personalized Medicine, 2021, 11, 779.	1.1	11
2355	The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences, 2021, 22, 9440.	1.8	3
2356	Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics. Pharmaceutics, 2021, 13, 1246.	2.0	5
2357	Molecular characterization and functional analysis of multidrug resistance-associated genes of Pinewood nematode (Bursaphelenchus xylophilus) for nematicides. Pesticide Biochemistry and Physiology, 2021, 177, 104902.	1.6	13
2358	Mild hyperthermia-enhanced chemo-photothermal synergistic therapy using doxorubicin-loaded gold nanovesicles. Chinese Chemical Letters, 2021, 32, 2411-2414.	4.8	20
2359	Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer. PeerJ, 2021, 9, e11591.	0.9	11
2360	The miRNAs involved in prostate cancer chemotherapy response as chemoresistance and chemosensitivity predictors. Andrology, 2022, 10, 51-71.	1.9	7

#	Article	IF	Citations
2361	Colossolactone-G synergizes the anticancer properties of 5-fluorouracil and gemcitabine against colorectal cancer cells. Biomedicine and Pharmacotherapy, 2021, 140, 111730.	2.5	11
2362	Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. PLoS ONE, 2021, 16, e0254205.	1.1	9
2363	Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cellular and Molecular Biology Letters, 2021, 26, 39.	2.7	38
2364	Integrated analysis on the N6â€methyladenosineâ€related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma. Immunity, Inflammation and Disease, 2021, 9, 1596-1612.	1.3	16
2365	Quantum chemical computational studies on 4-(1-Aminoethyl)pyridine. Erzincan Ãœniversitesi Fen Bilimleri EnstitÃ¼sÃ¼ Dergisi, 2021, 14, 751-760.	0.1	0
2366	Reactive oxygen species in cancer: Current findings and future directions. Cancer Science, 2021, 112, 3945-3952.	1.7	207
2367	ATPâ€binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine, 2021, 14, 232-256.	0.7	57
2368	Improvement of cytotoxicity of mitoxantrone and daunorubicin by candidone, tephrosin, and bavachinin. Molecular Biology Reports, 2021, 48, 7105-7111.	1.0	3
2369	Viability of Nanostructured Lipid Carrier System in Overcoming the Barriers Associated with Chemotherapeutic Delivery. Current Nanoscience, 2021, 17, .	0.7	1
2370	Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells. Molecules, 2021, 26, 5785.	1.7	4
2371	Amplification of tumor oxidative stresses by Poly(disulfide acetal) for multidrug resistance reversal. Biomaterials, 2021, 276, 121005.	5.7	23
2372	Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. Chemical Reviews, 2021, 121, 13454-13619.	23.0	657
2373	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. Coordination Chemistry Reviews, 2021, 442, 214009.	9.5	29
2374	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 14895-14911.	2.9	27
2375	Organ-Chip Models: Opportunities for Precision Medicine in Pancreatic Cancer. Cancers, 2021, 13, 4487.	1.7	17
2376	Progress in the study of D-Î±-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance. Colloids and Surfaces B: Biointerfaces, 2021, 205, 111914.	2.5	17
2377	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products, 2021, 84, 2544-2553.	1.5	7
2378	Reversing Multidrug Resistance by Inducing Mitochondrial Dysfunction for Enhanced Chemo-Photodynamic Therapy in Tumor. ACS Applied Materials & Interfaces, 2021, 13, 45259-45268.	4.0	22

#	Article	IF	Citations
2379	Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell. Bioorganic Chemistry, 2021, 114, 105075.	2.0	8
2380	Conjugation with nanodiamonds via hydrazone bond fundamentally alters intracellular distribution and activity of doxorubicin. International Journal of Pharmaceutics, 2021, 606, 120872.	2.6	10
2381	Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters. Cancers, 2021, 13, 4413.	1.7	4
2382	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 26-41.	0.8	15
2383	Drug resistance: from bacteria to cancer. Molecular Biomedicine, 2021, 2, 27.	1.7	14
2384	Chloramphenicol loaded polylactide melt electrospun scaffolds for biomedical applications. International Journal of Pharmaceutics, 2021, 606, 120897.	2.6	4
2385	Development of aÂdry powder for inhalation of nanoparticles codelivering cisplatin and ABCC3 siRNA in lung cancer. Therapeutic Delivery, 2021, 12, 651-670.	1.2	6
2386	Recent advances in assembled AIEgens for image-guided anticancer therapy. Nanotechnology, 2021, 32, .	1.3	5
2387	Unique regioselective C H diacetoxylation of pyrrolo[2,3-d]pyrimidine derivatives promoted by sodium iodide. Tetrahedron Letters, 2021, 84, 153435.	0.7	2
2388	Chemoreversal Agents from Taiwanofungus Genus and Their More Potent Methyl Derivatives Targeting Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation. Pharmaceuticals, 2021, 14, 916.	1.7	0
2389	Cell death-inducing activities via P-glycoprotein inhibition of the constituents isolated from fruits of Nandina domestica. FÃ¬toterapÃ¬Â¢, 2021, 154, 105023.	1.1	7
2390	Sphere-forming cells display stem cell-like characteristics and increased xCT expression in a canine hepatocellular carcinoma cell line. Research in Veterinary Science, 2021, 139, 25-31.	0.9	2
2391	Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. Coordination Chemistry Reviews, 2021, 445, 213950.	9.5	45
2392	New insights into binding of natural chalcones to Bcl-2, Bcl-xL and Mcl-1 anti-apoptotic proteins. Journal of Molecular Structure, 2021, 1241, 130700.	1.8	0
2393	Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomedicine and Pharmacotherapy, 2021, 143, 112142.	2.5	50
2394	LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan. Biomedicine and Pharmacotherapy, 2021, 143, 112091.	2.5	15
2395	SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7/ADR cells. Phytomedicine Plus, 2021, 1, 100111.	0.9	2
2396	Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers. European Journal of Medicinal Chemistry, 2021, 226, 113795.	2.6	9

#	Article	IF	Citations
2397	A review of synthetic bioactive tetrahydro-Î²-carbolines: A medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2021, 225, 113815.	2.6	30
2398	Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. European Journal of Medicinal Chemistry, 2021, 225, 113775.	2.6	9
2399	Chinese ginseng. , 2021, , 853-864.		1
2400	The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. , 2021, 4, 784-804.		22
2401	Enhanced Photothermal-Photodynamic Therapy by Indocyanine Green and Curcumin-Loaded Layered MoS2 Hollow Spheres via Inhibition of P-Glycoprotein. International Journal of Nanomedicine, 2021, Volume 16, 433-442.	3.3	20
2402	Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy. Acta Biochimica Et Biophysica Sinica, 2021, 53, 1417-1427.	0.9	8
2403	Application of decoy oligodeoxynucleotides strategy for inhibition of cell growth and reduction of metastatic properties in nonresistant and erlotinibâ€resistant SW480 cell line. Cell Biology International, 2021, 45, 1001-1014.	1.4	7
2404	Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100054.	1.7	25
2405	Electrospun Nanofibers for Cancer Therapy. Advances in Experimental Medicine and Biology, 2021, 1295, 163-190.	0.8	10
2406	Self-delivery nanomedicine to overcome drug resistance for synergistic chemotherapy. Biomaterials Science, 2021, 9, 3445-3452.	2.6	17
2410	Stimuli-Sensitive Nanosystems: For Drug and Gene Delivery. Fundamental Biomedical Technologies, 2008, , 161-199.	0.2	8
2411	Multidrug Resistance Mediated by MDR-ABC Transporters. , 2009, , 1-20.		5
2412	Somatic Evolution in Neoplastic Progression and Cancer Prevention. , 2011, , 111-127.		6
2413	Cancer Stem Cell and ATP-Binding Cassette: Which Role in Chemoresistance?. , 2012, , 267-288.		1
2414	Linker Technology and Impact of Linker Design on ADC Properties. , 2013, , 117-135.		3
2415	Oxidative Stress and Lung Cancer. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 245-257.	0.4	1
2416	Radiosensitizing Silica Nanoparticles Encapsulating Docetaxel for Treatment of Prostate Cancer. Methods in Molecular Biology, 2017, 1530, 403-409.	0.4	10
2417	The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer. Methods in Molecular Biology, 2009, 542, 5-54.	0.4	31

#	Article	IF	Citations
2418	Immunosuppressors as Multidrug Resistance Reversal Agents. Methods in Molecular Biology, 2010, 596, 433-446.	0.4	36
2419	Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer. Methods in Molecular Biology, 2010, 596, 33-45.	0.4	9
2420	Jet-Injection of Short Hairpin RNA-Encoding Vectors into Tumor Cells. Methods in Molecular Biology, 2010, 629, 121-137.	0.4	5
2421	Drug-Cytokine Interactions. , 2011, , 167-201.		3
2422	Exosomes: Novel Players of Therapy Resistance in Neuroblastoma. Advances in Experimental Medicine and Biology, 2020, 1277, 75-85.	0.8	10
2423	Chemotherapy and Drug Resistance in Schistosomiasis and Other Trematode and Cestode Infections. , 2017, , 705-734.		5
2424	Multidrug Resistance. , 2010, , 121-133.		1
2425	Drugs to Treat Head and Neck Cancers: Mechanisms of Action. , 2013, , 861-913.		1
2426	Clinical Anticancer Drugs for Cancer Treatment. SpringerBriefs in Applied Sciences and Technology, 2017, , 7-13.	0.2	2
2427	Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase. Bioorganic Chemistry, 2020, 101, 103916.	2.0	44
2428	Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway. Biomedicine and Pharmacotherapy, 2020, 125, 109885.	2.5	19
2429	Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy. European Journal of Medicinal Chemistry, 2020, 201, 112446.	2.6	22
2430	TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance. Materials Science and Engineering C, 2018, 84, 108-117.	3.8	38
2431	In vitro vascular toxicity of tariquidar, a potential tool for in vivo PET studies. Toxicology in Vitro, 2017, 44, 241-247.	1.1	12
2432	Synthesis, Photophysical Properties, and Biological Profiling of Benzothieno-Fused 7-Deazapurine Ribonucleosides. Journal of Organic Chemistry, 2020, 85, 8085-8101.	1.7	7
2433	Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro. Gastroenterology Report, 2020, 8, 465-475.	0.6	6
2435	Structural definition of polyspecific compensatory ligand recognition by P-glycoprotein. IUCrJ, 2020, 7, 663-672.	1.0	24
2436	Phospholipid-based Nanomicelles in Cancer Nanomedicine. , 2011, , .		2

#	Article	IF	Citations
2437	Plant Compounds and Derivatives as Inhibitors of Cancer Cell Multidrug Resistance. , 2011, , 409-450.		2
2438	Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells. Medical Science Monitor, 2020, 26, e924922.	0.5	3
2439	Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells. Development & Reproduction, 2016, 20, 1-10.	0.1	8
2440	How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. PLoS Biology, 2017, 15, e2001110.	2.6	103
2441	Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors. PLoS Neglected Tropical Diseases, 2017, 11, e0005343.	1.3	26
2442	Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma. PLoS ONE, 2010, 5, e10764.	1.1	128
2443	Experimental Evolution of Resistance to Artemisinin Combination Therapy Results in Amplification of the mdr1 Gene in a Rodent Malaria Parasite. PLoS ONE, 2010, 5, e11593.	1.1	22
2444	Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance. PLoS ONE, 2011, 6, e16007.	1.1	77
2445	Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells. PLoS ONE, 2011, 6, e27222.	1.1	92
2446	Synthesis of a Dual Functional Anti-MDR Tumor Agent PH II-7 with Elucidations of Anti-Tumor Effects and Mechanisms. PLoS ONE, 2012, 7, e32782.	1.1	14
2447	Knocking Down Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) Reverts Chemoresistance through Inactivation of Src and Bcr-Abl Proteins. PLoS ONE, 2012, 7, e44312.	1.1	29
2448	Cellular Robustness Conferred by Genetic Crosstalk Underlies Resistance against Chemotherapeutic Drug Doxorubicin in Fission Yeast. PLoS ONE, 2013, 8, e55041.	1.1	20
2449	Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved. PLoS ONE, 2013, 8, e61524.	1.1	72
2450	Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging. PLoS ONE, 2013, 8, e66128.	1.1	57
2451	Changes in the Expression of miR-381 and miR-495 Are Inversely Associated with the Expression of the MDR1 Gene and Development of Multi-Drug Resistance. PLoS ONE, 2013, 8, e82062.	1.1	79
2452	Multiple Transport-Active Binding Sites Are Available for a Single Substrate on Human P-Glycoprotein (ABCB1). PLoS ONE, 2013, 8, e82463.	1.1	86
2453	mRNA Levels of Related Abcb Genes Change Opposite to Each Other upon Histone Deacetylase Inhibition in Drug-Resistant Rat Hepatoma Cells. PLoS ONE, 2014, 9, e84915.	1.1	7
2454	Reversal Effect of ST6GAL 1 on Multidrug Resistance in Human Leukemia by Regulating the PI3K/Akt Pathway and the Expression of P-gp and MRP1. PLoS ONE, 2014, 9, e85113.	1.1	49

#	Article	IF	Citations
2455	High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner. PLoS ONE, 2014, 9, e92047.	1.1	36
2456	A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS ONE, 2014, 9, e103050.	1.1	7
2457	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. PLoS ONE, 2015, 10, e0136396.	1.1	5
2458	Inhibition of Snail Family Transcriptional Repressor 2 (SNAI2) Enhances Multidrug Resistance of Hepatocellular Carcinoma Cells. PLoS ONE, 2016, 11, e0164752.	1.1	10
2459	Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells. PLoS ONE, 2017, 12, e0182870.	1.1	55
2460	Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2. PLoS ONE, 2017, 12, e0184578.	1.1	12
2461	Schizandrol A reverses multidrug resistance in resistant chronic myeloid leukemia cells K562/A02. Cellular and Molecular Biology, 2019, 65, 78-83.	0.3	8
2462	Taxane resistance in Breast Cancer. Cancer Cell & Microenvironment, 0, , .	0.8	4
2463	A single treatment of Selenate, a repositioning drug, specifically sensitizes P-gp-overexpressing resistant cancer cells. Cancer Cell & Microenvironment, 0, , .	0.8	2
2464	BCRP/ABCG2 inhibitors: a patent review (2009-present). Expert Opinion on Therapeutic Patents, 2015, 25, 1229-37.	2.4	15
2465	Reversal Effect of Docosahexaenoic Acid on Taxol Resistance in Human Ovarian Carcinoma A2780/T Cells. Obstetrics & Gynecology International Journal, 2014, 1, .	0.0	1
2466	Increased expressions of cellular ATP-binding cassette transporters may be a promising diagnostic marker for colorectal cancer. Journal of King Abdulaziz University, Islamic Economics, 2020, 41, 834-840.	0.5	1
2467	Classification of P-glycoprotein-interacting compounds using machine learning methods. EXCLI Journal, 2015, 14, 958-70.	0.5	12
2468	P-glycoprotein transporter in drug development. EXCLI Journal, 2016, 15, 113-8.	0.5	24
2469	Targeting multidrug-resistant ovarian cancer through estrogen receptor Î± dependent ATP depletion caused by hyperactivation of the unfolded protein response. Oncotarget, 2018, 9, 14741-14753.	0.8	22
2470	miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget, 2016, 7, 59714-59726.	0.8	75
2471	ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance. Oncotarget, 2016, 7, 58051-58064.	0.8	6
2472	Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 62034-62048.	0.8	32

#	Article	IF	Citations
2473	Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma. Oncotarget, 2016, 7, 70715-70737.	0.8	40
2474	MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells. Oncotarget, 2016, 7, 75118-75129.	0.8	39
2475	MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma. Oncotarget, 2017, 8, 5057-5068.	0.8	57
2476	P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade. Oncotarget, 2017, 8, 45072-45087.	0.8	2
2477	Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway. Oncotarget, 2017, 8, 25097-25106.	0.8	17
2478	USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt. Oncotarget, 2017, 8, 24728-24740.	0.8	23
2479	RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature. Oncotarget, 2017, 8, 38668-38681.	0.8	29
2480	Triterpenoids from Aglaia abbreviata exert cytotoxicity and multidrug resistant reversal effect in MCF-7/ADM cells via reactive oxygen species induction and P-glycoprotein inhibition. Oncotarget, 2017, 8, 69465-69476.	0.8	5
2481	Tumor reductive therapies and antitumor immunity. Oncotarget, 2017, 8, 55736-55749.	0.8	11
2482	Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget, 2014, 5, 2778-2791.	0.8	40
2483	MRP4 regulates ENaC-dependent CREB/COX-2/PGE2 signaling during embryo implantation. Oncotarget, 2017, 8, 78520-78529.	0.8	5
2484	B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells. Oncotarget, 2017, 8, 74856-74868.	0.8	16
2485	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. Oncotarget, 2017, 8, 93785-93799.	0.8	22
2486	Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer. Oncotarget, 2017, 8, 114756-114768.	0.8	16
2487	Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells. Oncotarget, 2018, 9, 3278-3291.	0.8	61
2488	AP-1 confers resistance to anti-cancer therapy by activating XIAP. Oncotarget, 2018, 9, 14124-14137.	0.8	12
2489	MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget, 2014, 5, 11957-11970.	0.8	22
2490	Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/Î²-catenin pathway. Oncotarget, 2014, 5, 12273-12290.	0.8	63

#	Article	IF	Citations
2491	Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget, 2014, 5, 11971-11985.	0.8	63
2492	Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells. Oncotarget, 2015, 6, 1750-1768.	0.8	51
2493	ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. Oncotarget, 2015, 6, 1049-1063.	0.8	33
2494	The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget, 2015, 6, 10853-10867.	0.8	37
2495	Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget, 2015, 6, 19592-19604.	0.8	23
2496	A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget, 2012, 3, 640-650.	0.8	79
2497	Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). Oncotarget, 2012, 3, 686-699.	0.8	33
2498	Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells. Oncotarget, 2015, 6, 40850-40865.	0.8	11
2499	The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Oncotarget, 2016, 7, 14279-14290.	0.8	30
2500	Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport. Oncotarget, 2016, 7, 11664-11676.	0.8	7
2501	Î²-casein nanovehicles for oral delivery of chemotherapeutic drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells. Oncotarget, 2016, 7, 23322-23334.	0.8	69
2502	ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. Oncotarget, 2016, 7, 25103-25112.	0.8	27
2503	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. Oncotarget, 2016, 7, 30678-30690.	0.8	36
2504	Drug-adapted cancer cell lines as preclinical models of acquired resistance. , 2019, 2, 447-456.		16
2505	Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. , 2019, 2, 710-743.		9
2506	Mitochondrial determinants of chemoresistance. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 634-646.	0.9	11
2507	Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. , 2020, 3, 930-946.		28
2508	State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer. Translational Cancer Research, 2019, 8, 319-329.	0.4	10

#	Article	IF	Citations
2509	Flavonoids as P-gp Inhibitors: A Systematic Review of SARs. Current Medicinal Chemistry, 2019, 26, 4799-4831.	1.2	22
2510	The Role of NIR Fluorescence in MDR Cancer Treatment: From Targeted Imaging to Phototherapy. Current Medicinal Chemistry, 2020, 27, 5510-5529.	1.2	4
2511	Conjugates of Curcumin with Graphene and Carbon Nanotubes: A Review on Biomedical Applications. Current Medicinal Chemistry, 2020, 27, 6849-6863.	1.2	11
2512	ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. Current Pharmaceutical Design, 2014, 20, 793-807.	0.9	441
2513	10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein. Current Pharmaceutical Design, 2019, 24, 5590-5597.	0.9	7
2514	Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters. Current Pharmaceutical Design, 2019, 25, 627-634.	0.9	16
2515	Curcumin Based Drug Delivery Systems for Cancer Therapy. Current Pharmaceutical Design, 2020, 26, 5430-5440.	0.9	6
2516	Polymer-Based Cancer Nanotheranostics: Retrospectives of Multi-Functionalities and Pharmacokinetics. Current Drug Metabolism, 2013, 14, 661-674.	0.7	15
2517	Nanomedicine to Overcome Cancer Multidrug Resistance. Current Drug Metabolism, 2014, 15, 632-649.	0.7	22
2518	Mechanisms of Resistance Against Cancer Therapeutic Drugs. Current Pharmaceutical Biotechnology, 2014, 15, 1105-1112.	0.9	16
2519	Biodegradable Stimuli-Responsive Polymeric Micelles for Treatment of Malignancy. Current Pharmaceutical Biotechnology, 2016, 17, 227-236.	0.9	34
2520	Multidrug Resistance Through the Spectacle of P-Glycoprotein. Current Cancer Drug Targets, 2009, 9, 281-297.	0.8	107
2521	Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer. Current Cancer Drug Targets, 2020, 20, 559-572.	0.8	14
2522	Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 471-480.	0.9	3
2523	Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 555-564.	0.9	4
2524	Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 605-615.	0.9	91
2525	The Role of ETS Transcriptional Regulation in Hormone Sensitive and Refractory Prostate Cancer. The Open Cancer Journal, 2010, 3, 40-48.	0.2	1
2526	Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies. Current Molecular Pharmacology, 2008, 1, 93-105.	0.7	229

#	Article	IF	Citations
2527	Polyphyllin D - A Potential Anti-Cancer Agent to Kill Hepatocarcinoma Cells with Multi-Drug Resistance. Current Chemical Biology, 2009, 3, 89-99.	0.2	5
2529	Whole Exome Sequencing Analysis of ABCC8 and ABCD2 Genes Associating With Clinical Course of Breast Carcinoma. Physiological Research, 2015, 64, S549-S557.	0.4	9
2531	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics, 2020, 12, 96.	2.0	83
2533	Epigallocatechinâ€‘3â€‘gallate inhibits selfâ€‘renewal ability of lung cancer stemâ€‘like cells through inhibition of CLOCK. International Journal of Molecular Medicine, 2020, 46, 2216-2224.	1.8	30
2534	Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatinâ€‘resistant nonâ€‘small cell lung cancer. International Journal of Oncology, 2020, 56, 1083-1092.	1.4	8
2535	Pairedâ€‘related homeoboxÂ1 overexpression promotes multidrug resistance via PTEN/PI3K/AKT signaling in MCFâ€‘7 breast cancer cells. Molecular Medicine Reports, 2020, 22, 3183-3190.	1.1	7
2536	Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer. Oncology Letters, 2020, 20, 1-1.	0.8	2
2537	Tumor microenvironment and nanotherapeutics. Translational Cancer Research, 2013, 2, 309-319.	0.4	77
2538	Role of microRNAs in chemoresistance. Annals of Translational Medicine, 2015, 3, 332.	0.7	65
2539	Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncology Reviews, 2020, 14, 448.	0.8	38
2540	Future role of endoscopic ultrasound in personalized management of pancreatic cancer. Endoscopic Ultrasound, 2017, 6, 300.	0.6	5
2541	Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells. Cancer Research and Treatment, 2012, 44, 195-201.	1.3	20
2542	Prediction of Acquired Taxane Resistance Using a Personalized Pathway-Based Machine Learning Method. Cancer Research and Treatment, 2019, 51, 672-684.	1.3	6
2543	Ritonavir: A Powerful Boosting Agent for Overcoming Drug Resistance in Cancer Chemotherapy. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	2
2544	DNA Damage and Repair in Cancer Therapy. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	3
2545	Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance. Gynecology & Obstetrics (Sunnyvale, Calif), 2012, 02, .	0.1	10
2546	Developing New Small Molecular Drugs for Prostate Cancer Therapy. Journal of Cancer Therapy, 2013, 04, 86-90.	0.1	2
2547	Natural Products Modulate the Multifactorial Multidrug Resistance of Cancer. Pharmacology & Pharmacy, 2015, 06, 146-176.	0.2	33

#	Article	IF	Citations
2548	Synthesis and Biological Evaluation of Decursin, Prantschimgin and Their Derivatives. Bulletin of the Korean Chemical Society, 2009, 30, 43-48.	1.0	7
2549	Discovery of Highly Potent Multidrug Resistance (MDR) Reversal Agents: Aminosulfonylaryl Isoxazole Derivatives. Bulletin of the Korean Chemical Society, 2009, 30, 779-780.	1.0	3
2550	Synthesis and Biological Evaluation of Phenoxy-N-phenylacetamide Derivatives as Novel P-glycoprotein Inhibitors. Bulletin of the Korean Chemical Society, 2011, 32, 3666-3674.	1.0	9
2551	Synthesis and Biological Activity of Benzopyranyl Urea and Benzopyranyl Thiourea Derivatives as MDR Reversal Agents. Bulletin of the Korean Chemical Society, 2012, 33, 3857-3860.	1.0	5
2552	Lysimachia foenum-graecum Herba Extract, a Novel Biopesticide, Inhibits ABC Transporter Genes and Mycelial Growth of Magnaporthe oryzae. Plant Pathology Journal, 2016, 32, 8-15.	0.7	4
2553	ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties. Chinese Journal of Cancer, 2012, 31, 150-158.	4.9	2
2554	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
2555	The Overexpression of ABCG2 Reduces the Efficacy of Volasertib (BI 6727) and GSK641364 in Human S1-M1-80 Colon Carcinoma Cells. Journal of Cancer Research Updates, 2014, 3, 108-116.	0.3	1
2556	Mechanistic Analysis of Taxol-induced Multidrug Resistance in an Ovarian Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4983-4988.	0.5	33
2557	PLGA-Based Nanoparticles as Cancer Drug Delivery Systems. Asian Pacific Journal of Cancer Prevention, 2014, 15, 517-535.	0.5	358
2558	4-Hydroxynonenal Promotes Growth and Angiogenesis of Breast Cancer Cells through HIF-1Î± Stabilization. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10151-10156.	0.5	27
2559	Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1403-1410.	0.5	77
2560	Enhancing Activity of Anticancer Drugs in Multidrug Resistant Tumors by Modulating P-Glycoprotein through Dietary Nutraceuticals. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6831-6839.	0.5	32
2561	Integrative Meta-Analysis of Multiple Gene Expression Profiles in Acquired Gemcitabine-Resistant Cancer Cell Lines to Identify Novel Therapeutic Biomarkers. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2793-2800.	0.5	2
2562	Reversal of Multidrug Resistance in Mouse Lymphoma Cells by Extracts and Flavonoids from Pistacia integerrima. Asian Pacific Journal of Cancer Prevention, 2016, 17, 51-55.	0.5	13
2563	Isolation and Structure Elucidation, Molecular Docking Studies of Screlotiumol from Soil Borne Fungi Screlotium rolfsii and their Reversal of Multidrug Resistance in Mouse Lymphoma Cells. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2083-2087.	0.5	4
2564	A multifunctional nano-delivery system enhances the chemo-co-phototherapy of tumor multidrug resistance via mitochondrial-targeting and inhibiting P-glycoprotein-mediated efflux. Journal of Materials Chemistry B, 2021, 9, 9174-9182.	2.9	14
2565	Isolation of Bioactive Compounds from Pistacia integerrima with Promising Effects on Reverse Cancer Multidrug Resistance. Russian Journal of Bioorganic Chemistry, 2021, 47, 997-1003.	0.3	3

#	Article	IF	Citations
2566	Persistent DNA damage signaling and DNA polymerase theta promote broken chromosome segregation. Journal of Cell Biology, 2021, 220, .	2.3	16
2567	Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-24.	1.9	93
2568	Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity. Journal of Medicinal Chemistry, 2021, 64, 15379-15401.	2.9	8
2569	Polymeric Nanoparticles for Mitochondria Targeting Mediated Robust Cancer Therapy. Frontiers in Bioengineering and Biotechnology, 2021, 9, 755727.	2.0	12
2570	Intracellular Condensates of Oligopeptide for Targeting Lysosome and Addressing Multiple Drug Resistance of Cancer. Advanced Materials, 2022, 34, e2104704.	11.1	47
2571	Innovative nanochemotherapy for overcoming cancer multidrug resistance. Nanotechnology, 2021, 33, .	1.3	6
2572	An Aptamer-Modified DNA Tetrahedron-Based Nanogel for Combined Chemo/Gene Therapy of Multidrug-Resistant Tumors. ACS Applied Bio Materials, 2021, 4, 7701-7707.	2.3	22
2573	P-glycoprotein suppression by photothermal-responsive nitric oxide releasing nanoplatform for triple-combination therapy of multidrug resistant cancer. Materials and Design, 2021, 211, 110160.	3.3	17
2574	Multidrug Efflux Pumps. , 2007, , 45-69.		2
2575	Making of glioma-initiating cells. Inflammation and Regeneration, 2008, 28, 537-542.	1.5	0
2576	Nanoparticles in Cancer Drug Delivery Systems. , 2008, , 143-169.		1
2577	DRUG RESISTANCE IN CANCER MODELS. Series in Mathematical Biology and Medicine, 2008, , 425-456.	0.1	0
2578	Functional Imaging of Multidrug Resistance and Its Applications. , 2009, , 601-643.		0
2579	Cancer Stem Cells: Potential Mediators of Therapeutic Resistance and Novel Targets of Anti-cancer Treatments. , 2009, , 559-579.		0
2581	microRNA: A Potential Therapy Able to Target Multiple Cancer Pathways. , 2011, , 155-170.		0
2582	Cancer Stem Cells in Melanoma. , 2011, , 117-138.		0
2583	Cloning, in silico structural characterization and expression analysis of MfAtr4, an ABC transporter from the banana pathogen Mycosphaerella fijiensis. African Journal of Biotechnology, 2011, 11, .	0.3	1
2584	Membrane Transporters. , 2011, , 2222-2224.		0

#	Article	IF	Citations
2585	Chemosensibilization. , 2011, , 790-792.		0
2586	Mouse Models in Preclinical Drug Development: Applications to CNS Models. , 2012, , 549-567.		0
2587	Refractory Neuroblastoma Cells: Statins Target ATP Binding Cassette-Transporters. Pediatric Cancer, 2012, , 177-183.	0.0	0
2588	Targeting Multidrug Resistance in Neuroblastoma. Pediatric Cancer, 2012, , 115-123.	0.0	1
2589	The Role of PDE-5 Inhibitors in Prostate Cancer. , 0, , .		0
2590	Melanoma Cell Propagation: Cancer Stem Cell, Clonal Evolution and Interconversion Models of Tumorigenicity. , 2012, , 227-241.		0
2591	Characteristic of p-glycoprotein as a drug peptide transporter. I P Pavlov Russian Medical Biological Herald, 2011, 19, 142.	0.2	2
2592	Role of Multidrug Resistance Associated Proteins in Drug Development. , 2012, , 3-35.		2
2593	Molecular Targets: Inhibition of Tumor Cell Invasion. , 0, , .		0
2594	Vemurafenib (PLX4032, ZelborafÂ®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance. Journal of Cancer Research Updates, 0, , .	0.3	0
2595	CHAPTER 16. Smart Carbon Nanotubes. RSC Smart Materials, 2013, , 90-116.	0.1	1
2596	Industrial Evaluation of Drug Transporters in ADME. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 285-307.	0.2	0
2597	The Reciprocal Interaction of Small Molecule Protein Kinase Inhibitors and ATP-Binding Cassette Transporters in Targeted Cancer Therapy. Journal of Cancer Research Updates, 0, , .	0.3	0
2598	ADVANCES IN APPLICATIONS OF NANOTECHNOLOGY TO DRUG DELIVERY. , 2013, , 1-24.		0
2599	Membrane Transporters. , 2014, , 1-5.		0
2600	Structure and Mechanism of a Eukaryotic ABC Multidrug Transporter. Nihon Kessho Gakkaishi, 2014, 56, 224-229.	0.0	0
2601	Effects of Momordica charantia Extract on the Expression of MDR 1 Gene in Human Lung Cancer Cells. WIMJ Open, 2014, 1, 92-98.	0.0	0
2602	Chemosensibilization. , 2014, , 1-4.		0

#	Article	IF	Citations
2603	Chemosensibilization. , 2014, , 953-956.		0
2604	Multiple Routes for Survival: Understanding How Cancer Evades Apoptosis. , 2014, , 179-203.		0
2605	Membrane Transporters. , 2014, , 2724-2727.		0
2607	Radiopharmaceuticals for the Imaging of ABC-Transporter-Mediated Multidrug Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 133-151.	0.1	0
2608	Anticancer Drug Development from Cyanobacteria. SpringerBriefs in Pharmaceutical Science & Drug Development, 2015, , 63-78.	0.4	0
2609	Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing. Journal of Cancer Therapy, 2015, 06, 455-465.	0.1	0
2613	Abstract 756: Inhibition of ABCB1 overcomes cancer stem cell-like properties and acquired resistance to MET inhibitor in non-small cell lung cancer. , 2015, , .		0
2614	Isoreserpine Reverses Multidrug Resistance Mediated by ABCB1. Journal of Cancer Research Updates, 2015, 4, 188-194.	0.3	0
2615	The Role of Exosomes and its Cargos in Drug Resistance of Cancer. Journal of Cancer Research Updates, 2015, 4, 179-187.	0.3	0
2616	CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN SKIN MELANOMA CELL LINES. , 2015, 14, 39-44.	0.3	0
2617	Study of CAPE Effect on Apoptosis Induction in AGS Human Gastric Cancer Cell Line. Jundishapur Journal of Natural Pharmaceutical Products, 2016, 11, .	0.3	0
2618	Strategies to Target Pancreatic Cancer. , 2016, , 1-20.		0
2619	The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer. Current Cancer Therapy Reviews, 2016, 11, 201-221.	0.2	0
2621	Organicâ€“Inorganic Nanocomposites for Biomedical Applications. , 2016, , 375-395.		0
2622	Physiologic and Molecular Basis of PET in Cancer Imaging. , 2017, , 399-427.		2
2623	Anticancer Activity of Salvia miltiorrhiza and Its Secondary Metabolites. , 2017, , 179-207.		1
2624	Principes van de medicamenteuze antikankerbehandeling. , 2017, , 137-159.		0
2626	The Roles of miR-25 and Its Targeted Genes in Human Cancer. , 2018, , 129-139.		0

#	Article	IF	Citations
2627	Integrated in Vitro and in Silico Modelling Delineates the Molecular Effects of a Symbiotic Regimen on Colorectal Cancer-Derived Cells. SSRN Electronic Journal, 0, , .	0.4	0
2628	Drug-induced resistance: nipping it in the â€˜buddingâ€™. Oncotarget, 2018, 9, 35873-35874.	0.8	0
2629	Coupling Methods of Antibodies and Ligands for Liposomes. Biomaterial Engineering, 2019, , 1-24.	0.1	0
2631	Overcoming chemoresistance using tumor mitochondria-targeted photodynamic therapy. , 2019, , .		0
2632	Effect of down-regulation of miR-221 on cell proliferation and cisplatin sensitivity in cisplatin-resistant gastric cancer cells and underlying mechanism. World Chinese Journal of Digestology, 2019, 27, 857-863.	0.0	0
2633	Leaf Extracts from Dillenia philippinensis Rolfe Exhibit Cytotoxic Activity to both Drug-Sensitive and Multidrug-Resistant Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3285-3290.	0.5	5
2636	Integration of Phytochemicals and Phytotherapy into Cancer Precision Medicine. Human Perspectives in Health Sciences and Technology, 2020, , 355-392.	0.2	1
2640	Jadomycins: A potential chemotherapy for multiâ€drug resistant metastatic breast cancer. Pharmacology Research and Perspectives, 2021, 9, e00886.	1.1	8
2641	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. Cancers, 2021, 13, 5480.	1.7	16
2642	Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. Journal of Medicinal Chemistry, 2021, 64, 16187-16204.	2.9	14
2643	Phytochemicals Plus Nanomaterialâ€™s on Colorectal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 171-191.	0.2	0
2644	A Marine Natural Products as Modulators of Multidrug Resistance. Journal of Cancer Research Updates, 0, 9, 96-101.	0.3	0
2645	Taxol: Occurrence, chemistry, and understanding its molecular mechanisms. , 2022, , 29-45.		4
2646	pH-Responsive luminescence sensing, photoredox catalysis and photodynamic applications of ruthenium(II) photosensitizers bearing imidazo[4,5-f][1,10]phenanthroline scaffolds. Coordination Chemistry Reviews, 2022, 452, 214272.	9.5	14
2647	Nanoemulsion Delivery of Herbal Products: Prospects and Challenges. , 2020, , 267-288.		2
2648	Discovery and Development of Mcl-1 Inhibitors as Anti-cancer Therapeutics: Hit to Clinical Candidate Optimization. RSC Drug Discovery Series, 2020, , 171-208.	0.2	0
2650	Investigation of GST Isoenzymes, Multi-Drug Resistance Proteins and Apoptotic Effect in MCF-7 Human Breast Cancer Cell Line Before and After Doxorubicin Treatment. Ä°stanbul GeliÅŸim Ãœniversitesi SaÄŸlÄ±k Bilimleri Dergisi, 2020, , 1-18.	0.0	2
2651	All-in-one nanosponge with pluronic shell for synergistic anticancer therapy through effectively overcoming multidrug resistance in cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102486.	1.7	2

#	Article	IF	Citations
2652	A polyplex human saliva peptide histatin 5-grafted methoxy PEG-b-polycaprolactone polymersome for intelligent stimuli-oriented doxorubicin delivery. Journal of Drug Delivery Science and Technology, 2022, 67, 102958.	1.4	3
2654	Construction of Peptide-Drug Conjugates for Selective Targeting of Malignant Tumor Cells. Methods in Molecular Biology, 2021, 2207, 327-338.	0.4	6
2655	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	0
2656	Combining kinase inhibitors for optimally coâ€targeting cancer and drug escape by exploitation of drug target promiscuities. Drug Development Research, 2021, 82, 133-142.	1.4	0
2663	UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. American Journal of Cancer Research, 2014, 4, 148-60.	1.4	6
2664	Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors. Iranian Journal of Pharmaceutical Research, 2014, 13, 3-14.	0.3	13
2665	ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging. Molecular Imaging, 2011, 10, 215-26.	0.7	10
2666	PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 8295-303.	0.5	18
2667	MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2. International Journal of Clinical and Experimental Medicine, 2015, 8, 12397-403.	1.3	11
2668	MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy. American Journal of Translational Research (discontinued), 2015, 7, 1510-27.	0.0	13
2669	MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. American Journal of Cancer Research, 2015, 5, 3015-29.	1.4	24
2670	Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma. American Journal of Cancer Research, 2016, 6, 1511-23.	1.4	26
2671	Wallichinine reverses ABCB1-mediated cancer multidrug resistance. American Journal of Translational Research (discontinued), 2016, 8, 2969-80.	0.0	11
2673	Nimodipine-Loaded Pluronic Block Copolymer Micelles: Preparation, Characterization, and Studies. Iranian Journal of Pharmaceutical Research, 2016, 15, 641-661.	0.3	11
2674	Inhibition of autophagy results in a reversal of taxol resistance in nasopharyngeal carcinoma by enhancing taxol-induced caspase-dependent apoptosis. American Journal of Translational Research (discontinued), 2017, 9, 1934-1942.	0.0	13
2675	Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. American Journal of Cancer Research, 2017, 7, 1350-1371.	1.4	49
2677	Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma. American Journal of Cancer Research, 2018, 8, 1297-1306.	1.4	12
2679	Overexpression of Rad51 predicts poor prognosis and silencing of Rad51 increases chemo-sensitivity to doxorubicin in neuroblastoma. American Journal of Translational Research (discontinued), 2019, 11, 5788-5799.	0.0	4

#	Article	IF	Citations
2680	Identification of genes associated with SiHa cell sensitivity to paclitaxel by CRISPR-Cas9 knockout screening. International Journal of Clinical and Experimental Pathology, 2018, 11, 1972-1978.	0.5	3
2681	MiR-211 inhibits cell epithelial-mesenchymal transition by targeting MMP9 in gastric cancer. International Journal of Clinical and Experimental Pathology, 2017, 10, 7551-7558.	0.5	3
2682	MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research, 2020, 10, 164-178.	1.4	5
2684	Cisplatin-Based Chemotherapy of Human Cancers. Journal of Cancer Science & Therapy, 2019, 11, .	1.7	24
2685	Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. American Journal of Translational Research (discontinued), 2020, 12, 3940-3952.	0.0	0
2686	Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells. Molecular Medicine Reports, 2021, 23, .	1.1	3
2687	The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition. American Journal of Translational Research (discontinued), 2020, 12, 8084-8098.	0.0	5
2688	Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. American Journal of Cancer Research, 2021, 11, 1428-1445.	1.4	4
2689	Epimedokoreanin C, a prenylated flavonoid isolated from , induces non-apoptotic cell death with the characteristics of methuosis in lung cancer cells. American Journal of Cancer Research, 2021, 11, 3496-3514.	1.4	0
2690	Supramolecular Dual Drug Nanomicelles for Circumventing Multidrug Resistance. ACS Biomaterials Science and Engineering, 2021, 7, 5515-5523.	2.6	6
2691	Targeting Ca2+ signaling: A new arsenal against cancer. Drug Discovery Today, 2022, 27, 923-934.	3.2	13
2692	Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System. Frontiers in Medicine, 2021, 8, 750170.	1.2	10
2693	Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPRâ€Cas9 screen. EMBO Reports, 2022, 23, e53054.	2.0	16
2694	Recent Advances in Multicellular Tumor Spheroid Generation for Drug Screening. Biosensors, 2021, 11, 445.	2.3	36
2695	Delineating the Role of Tailored Gold Nanostructures at the Biointerface. ACS Applied Bio Materials, 2021, 4, 8172-8191.	2.3	11
2696	LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer. Bioengineered, 2021, 12, 9239-9250.	1.4	17
2697	Ad-Apoptin-hTERTp-E1a Regulates Autophagy Through the AMPK-mTOR-eIF4F Signaling Axis to Reduce Drug Resistance of MCF-7/ADR Cells. Frontiers in Molecular Biosciences, 2021, 8, 763500.	1.6	1
2698	Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer. Cancers, 2021, 13, 5644.	1.7	1

#	Article	IF	Citations
2699	Synthesis, In Vitro and In Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors. International Journal of Molecular Sciences, 2021, 22, 12738.	1.8	5
2700	ATP binding cassette transporters and cancer: revisiting their controversial role. Pharmacogenomics, 2021, 22, 1211-1235.	0.6	12
2701	The Application of DNA Nanostructures in Vaccine Technology. , 2021, , 191-219.		0
2702	Novel Coumarin Derivatives Containing a Triazole Moiety: A Study on Synthesis, Cytotoxicity, Membrane Dysfunction, Apoptosis, Cell Cycle, and Antiangiogenic Effects. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 2429-2438.	0.9	2
2703	Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells. Molecular Medicine Reports, 2020, 23, .	1.1	9
2704	Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals. Frontiers in Bioengineering and Biotechnology, 2021, 9, 799806.	2.0	8
2706	The Microstructure, Antibacterial and Antitumor Activities of Chitosan Oligosaccharides and Derivatives. Marine Drugs, 2022, 20, 69.	2.2	50
2707	Inhibition of NPC1L1 disrupts adaptive responses of drugâ€tolerant persister cells to chemotherapy. EMBO Molecular Medicine, 2022, 14, e14903.	3.3	46
2708	[(WR)8WKÎ²A]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. Cells, 2022, 11, 301.	1.8	8
2709	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. Medicinal Research Reviews, 2022, 42, 1246-1279.	5.0	38
2710	Multi-ligand modified PC@DOX-PA/EGCG micelles effectively inhibit the growth of ER⁺, PR⁺ or HER²⁺ breast cancer. Journal of Materials Chemistry B, 2022, 10, 418-429.	2.9	3
2711	Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and Applied Pharmacology, 2022, 434, 115823.	1.3	9
2712	A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells. PeerJ, 2022, 10, e12594.	0.9	9
2713	Molecular Aspects of Resistance to Immunotherapiesâ€"Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences, 2022, 23, 1501.	1.8	13
2714	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. Drug Resistance Updates, 2022, 60, 100811.	6.5	13
2715	Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance. International Journal of Biological Sciences, 2022, 18, 742-759.	2.6	12
2716	S-20, a steroidal saponin from the berries of black nightshade, exerts anti-multidrug resistance activity in K562/ADR cells through autophagic cell death and ERK activation. Food and Function, 2022, , .	2.1	6
2717	Acidâ€Degradable Hydrogenâ€Generating Metalâ€Organic Framework for Overcoming Cancer Resistance/Metastasis and Offâ€Target Side Effects. Advanced Science, 2022, 9, e2101965.	5.6	40

#	Article	IF	Citations
2718	Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies. Molecules, 2022, 27, 616.	1.7	155
2719	Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals. Science Advances, 2022, 8, eabk2901.	4.7	26
2720	B-nor-methylene Colchicinoid PT-100 Selectively Induces Apoptosis in Multidrug-Resistant Human Cancer Cells via an Intrinsic Pathway in a Caspase-Independent Manner. ACS Omega, 2022, 7, 2591-2603.	1.6	6
2723	The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting BIRC5 to Elucidate the Synergistic Pathway of Survivin with P-Glycoprotein in Cancer Multi-Drug Resistance. Frontiers in Cell and Developmental Biology, 2021, 9, 797005.	1.8	2
2724	The Innate Immune System and Fever under Redox Control: A Narrative Review. Current Medicinal Chemistry, 2022, 29, 4324-4362.	1.2	3
2726	Defect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance. Bioactive Materials, 2023, 19, 1-11.	8.6	44
2727	Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. Drug Resistance Updates, 2021, 59, 100795.	6.5	38
2728	Legumain-mediated self-assembly of a ¹³¹I-labelled agent for targeted radiotherapy of tumors. Journal of Materials Chemistry B, 2022, 10, 2251-2259.	2.9	3
2729	Esterase-Responsive and Size-Optimized Prodrug Nanoparticles for Effective Intracranial Drug Delivery and Glioblastoma Treatment. SSRN Electronic Journal, 0, , .	0.4	0
2730	Overcoming the challenges of drug resistance through combination drug delivery approach. , 2022, , 31-46.		1
2731	Lemonâ€Derived Extracellular Vesicles Nanodrugs Enable to Efficiently Overcome Cancer Multidrug Resistance by Endocytosisâ€Triggered Energy Dissipation and Energy Production Reduction. Advanced Science, 2022, 9, e2105274.	5.6	40
2732	Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2022, 13, 796349.	2.2	12
2733	Platelets for cancer treatment and drug delivery. Clinical and Translational Oncology, 2022, 24, 1231-1237.	1.2	9
2734	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Frontiers in Pharmacology, 2022, 13, 843829.	1.6	5
2735	An engineered abcb4 expression model reveals the central role of <scp>NFâ€ºB</scp> in the regulation of drug resistance in zebrafish. Drug Development Research, 2022, , .	1.4	1
2736	Iron Promotes Cardiac Doxorubicin Retention and Toxicity Through Downregulation of the Mitochondrial Exporter ABCB8. Frontiers in Pharmacology, 2022, 13, 817951.	1.6	8
2737	Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, inÂvivo, and exÂvivo. Molecular Therapy - Oncolytics, 2022, 24, 636-649.	2.0	9
2738	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Frontiers in Pharmacology, 2022, 13, 861642.	1.6	7

#	Article	IF	Citations
2739	Molecular Switchesâ€"Tools for Imparting Control in Drug Delivery Systems. Frontiers in Chemistry, 2022, 10, 859450.	1.8	13
2740	Chalcone Derivatives as Potential Inhibitors of P-Glycoprotein and NorA: An In Silico and In Vitro Study. BioMed Research International, 2022, 2022, 1-9.	0.9	2
2741	Single-Cell Image-Based Analysis Reveals Chromatin Changes during the Acquisition of Tamoxifen Drug Resistance. Life, 2022, 12, 438.	1.1	4
2742	The molecular mechanism of METTL3 promoting the malignant progression of lung cancer. Cancer Cell International, 2022, 22, 133.	1.8	15
2743	Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective. Drug Discovery Today, 2022, 27, 759-776.	3.2	36
2744	Conquering multidrug resistant lung cancer by upconversion <scp>nanoparticlesâ€mediated</scp> photodynamic therapy and gene silencing. Journal of the Chinese Chemical Society, 2022, 69, 1305-1317.	0.8	1
2745	Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells. Biomedicines, 2022, 10, 601.	1.4	17
2746	Design, Synthesis, and Bioevaluation of Novel Enzyme-Triggerable Cell Penetrating Peptide-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy. Journal of Medicinal Chemistry, 2022, 65, 5850-5865.	2.9	9
2747	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European Journal of Medicinal Chemistry, 2022, 237, 114346.	2.6	22
2748	Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights. Pharmacological Research, 2022, 178, 106138.	3.1	26
2749	MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis. Cellular Signalling, 2022, 94, 110326.	1.7	7
2750	MicroRNAs in Pancreatic Cancer and Chemoresistance. Pancreas, 2021, 50, 1334-1342.	0.5	1
2752	LGCMDS: Predicting miRNA-Drug Sensitivity based on Light Graph Convolution Network. , 2021, , .		2
2753	A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway. Journal of Nanobiotechnology, 2021, 19, 444.	4.2	16
2754	Acquired Drug Resistance Enhances Imidazoquinoline Efflux by P-Glycoprotein. Pharmaceuticals, 2021, 14, 1292.	1.7	3
2755	Assembly Transformation Jointly Driven by the LAP Enzyme and GSH Boosting Theranostic Capability for Effective Tumor Therapy. ACS Applied Materials & Interfaces, 2021, 13, 59787-59802.	4.0	12
2756	A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7. Frontiers in Oncology, 2021, 11, 809410.	1.3	8
2757	Anthocyanidins Inhibit Growth and Chemosensitize Triple-Negative Breast Cancer via the NF-ÎºB Signaling Pathway. Cancers, 2021, 13, 6248.	1.7	7

#	Article	IF	Citations
2758	Targeting Mitochondrial Metabolism and RNA Polymerase POLRMT to Overcome Multidrug Resistance in Cancer. Frontiers in Chemistry, 2021, 9, 775226.	1.8	6
2759	Near-infrared light-triggered nano-prodrug for cancer gas therapy. Journal of Nanobiotechnology, 2021, 19, 443.	4.2	31
2760	The Role of Chloride Channels in the Multidrug Resistance. Membranes, 2022, 12, 38.	1.4	8
2761	The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin. Journal of Cellular and Molecular Medicine, 2022, 26, 491-506.	1.6	7
2763	Polyoxovanadates as new Pâ€glycoprotein inhibitors: insights into the mechanism of inhibition. FEBS Letters, 2022, 596, 381-399.	1.3	3
2764	PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors. Pharmaceutics, 2021, 13, 2181.	2.0	11
2765	High efficacy of tamoxifen-loaded L-lysine coated magnetic iron oxide nanoparticles in cell cycle arrest and anti-cancer activity for breast cancer therapy. BioImpacts, 2022, 12, 301-313.	0.7	9
2766	Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions. , 2022, , 425-449.		0
2767	Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4â€Substituted Quinazoline Derivatives. ChemMedChem, 2022, 17, .	1.6	6
2786	Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy. Journal of Controlled Release, 2022, 346, 250-259.	4.8	8
2787	Down-regulation of ABCB1 by collateral sensitivity drugs reverses multidrug resistance and up-regulates enolase I. Journal of Biochemistry, 2022, 172, 37-48.	0.9	5
2788	Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4. BMC Cancer, 2022, 22, 446.	1.1	6
2789	Targeted therapy in head and neck cancer. Tumori, 2011, 97, 137-41.	0.6	5
2790	Micro- and Nanosecond Pulses Used in Doxorubicin Electrochemotherapy in Human Breast and Colon Cancer Cells with Drug Resistance. Molecules, 2022, 27, 2052.	1.7	5
2792	Nanoemulsion Formulations in Targeted Delivery of Cancer Therapeutics. Advances in Bioinformatics and Biomedical Engineering Book Series, 2022, , 44-72.	0.2	2
2794	Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors. Journal of Oncology, 2022, 2022, 1-25.	0.6	13
2795	Lung cancer targeting efficiency of Silibinin loaded Poly Caprolactone /Pluronic F68 Inhalable nanoparticles: In vitro and In vivo study. PLoS ONE, 2022, 17, e0267257.	1.1	22
2796	A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer. Nano Letters, 2022, 22, 3983-3992.	4.5	14

#	Article	IF	Citations
2797	Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study. Molecules, 2022, 27, 3104.	1.7	12
2798	Structural insight into SSE15206 in complex with tubulin provides a rational design for pyrazolinethioamides as tubulin polymerization inhibitors. Future Medicinal Chemistry, 2022, 14, 785-794.	1.1	1
2799	Phytochemical profiling, molecular docking, and anti-hepatocellular carcinoid bioactivity of extracts. Arabian Journal of Chemistry, 2022, 15, 103950.	2.3	15
2800	Dietary lipids and malignant tumor of the digestive system. , 2022, , 83-109.		0
2801	Editorial: Non-Coding RNAs in Gastrointestinal and Gynecological Cancers: New Insights Into the Mechanisms of Cancer Therapeutic Resistance. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	0
2802	Quantification of vincristine and tariquidar by liquid chromatographyâ€tandem mass spectrometry in mouse whole blood using volumetric absorptive microsampling for pharmacokinetic applications. Journal of Separation Science, 2022, 45, 2508-2519.	1.3	3
2803	Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	35
2804	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia, 2022, 36, 1759-1768.	3.3	4
2805	Advances in nanotechnology-based platforms for survivin-targeted drug discovery. Expert Opinion on Drug Discovery, 2022, 17, 733-754.	2.5	10
2806	Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines, 2022, 10, 1158.	1.4	10
2807	Exosomes Derived from SW480-Resistant Colon Cancer Cells Are Promote Angiogenesis via BMP-2/Smad5 Signaling Pathway. Applied Bionics and Biomechanics, 2022, 2022, 1-13.	0.5	4
2808	Structureâ€based alteration of tryptophan residues of the multidrug transporter <scp>CmABCB1</scp> to assess substrate binding using fluorescence spectroscopy. Protein Science, 2022, 31, .	3.1	2
2809	GSTs, MRP and Apoptototic Markers in DLD-1 Human Colon Cancer Cell Line Before and After 5-FU Treatment. International Journal of Nature and Life Sciences:, 2022, 6, 25-40.	0.2	1
2810	A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211051.	1.0	1
2811	Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. Nature Cancer, 2022, 3, 734-752.	5.7	12
2812	Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1. Cell Death and Disease, 2022, 13, .	2.7	1
2813	Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer. Marine Drugs, 2022, 20, 370.	2.2	12
2814	Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors. Cancers, 2022, 14, 2804.	1.7	5

#	Article	IF	Citations
2815	Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	8
2816	Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells. Cell Death and Disease, 2022, 13, .	2.7	29
2818	Expression of the Stem Cell Marker ABCB5 in Normal and Tumor Tissues. In Vivo, 2022, 36, 1651-1666.	0.6	8
2819	Novel insights on [1,2]oxazolo[5,4â€e]isoindoles on multidrug resistant acute myeloid leukemia cell line. Drug Development Research, 2022, 83, 1331-1341.	1.4	21
2820	High drug loading polymer micelle@ZIF-8 hybrid coreâ€"shell nanoparticles through donorâ€"receptor coordination interaction for pH/H2O2-responsive drug release. Frontiers of Materials Science, 2022, 16, .	1.1	4
2821	Optimized Synthesis and Cytotoxic Activity of Î±-Aminophosphonates Against a Multidrug Resistant Uterine Sarcoma Cell Line. Letters in Drug Design and Discovery, 2023, 20, 365-371.	0.4	5
2822	Generation of a homozygous mutant drug transporter (ABCB1) knockout line in the sea urchinLytechinus pictus. Development (Cambridge), 2022, 149, .	1.2	13
2823	Ferrous ions doped calcium carbonate nanoparticles potentiate chemotherapy by inducing ferroptosis. Journal of Controlled Release, 2022, 348, 346-356.	4.8	31
2824	The Synergistic Effect of Ruthenium Complex Î"-Ru1 and Doxorubicin in a Mouse Breast Cancer Model. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 174-186.	0.8	2
2825	ABC transporters in breast cancer: their roles in multidrug resistance andÂbeyond. Journal of Drug Targeting, 2022, 30, 927-947.	2.1	27
2826	Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers. International Journal of Molecular Sciences, 2022, 23, 7168.	1.8	4
2827	Targeting the Mitochondria with Pseudo-Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment. ACS Nano, 2022, 16, 10242-10259.	7.3	14
2828	Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers. Pharmaceutics, 2022, 14, 1470.	2.0	12
2829	Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics. ACS Omega, 2022, 7, 25844-25852.	1.6	10
2830	Oneâ€Pot Synthesis of Some New Isatinâ€1,2,4â€oxadiazole Hybrids as VEGFRâ€2 Aiming Anticancer Agents. ChemistrySelect, 2022, 7, .	0.7	7
2831	Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Materials Today Bio, 2022, 16, 100358.	2.6	14
2832	Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 44, 102581.	1.7	3
2833	Nanotechnology-integrated ferroptosis inducers: a sharp sword against tumor drug resistance. Journal of Materials Chemistry B, 2022, 10, 7671-7693.	2.9	9

#	Article	IF	Citations
2835	Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells. Frontiers in Immunology, 0, 13, .	2.2	4
2836	Effects and Mechanisms of Curcumin for the Prevention and Management of Cancers: An Updated Review. Antioxidants, 2022, 11, 1481.	2.2	37
2837	Functionalized Magnetic Nanoparticles for Alternating Magnetic Field- or Near Infrared Light-Induced Cancer Therapies. Micromachines, 2022, 13, 1279.	1.4	18
2838	Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy. Acta Biomaterialia, 2022, 152, 380-392.	4.1	9
2839	Ambra1 in cancer: implications for clinical oncology. Apoptosis: an International Journal on Programmed Cell Death, 0, , .	2.2	2
2841	Synthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents. Applied Biochemistry and Biotechnology, 2022, 194, 6349-6366.	1.4	2
2842	Pilot Study of Jadomycin B Pharmacokinetics and Anti-Tumoral Effects in Zebrafish Larvae and Mouse Breast Cancer Xenograft Models. Canadian Journal of Physiology and Pharmacology, 0, , .	0.7	1
2843	Coating a Self-Assembly Nanoconstruct with a Neutrophil Cell Membrane Enables High Specificity for Triple Negative Breast Cancer Treatment. ACS Applied Bio Materials, 2022, 5, 4554-4566.	2.3	4
2844	P-Glycoprotein Activity at Diagnosis Does Not Predict Therapy Outcome and Survival in Canine B-Cell Lymphoma. Cancers, 2022, 14, 3919.	1.7	1
2845	Advancement in use of silicon pthalocyanine derivatives for cancer treatment. Dyes and Pigments, 2022, 206, 110608.	2.0	4
2846	TM2, a novel semi-synthetic taxoid, exerts anti-MDR activity in NSCLC by inhibiting P-gp function and stabilizing microtubule polymerization. Apoptosis: an International Journal on Programmed Cell Death, 2022, 27, 1015-1030.	2.2	2
2847	Role of DNA De-methylation intermediate â€˜5-hydroxymethylcytosineâ€™ in ovarian cancer management: A comprehensive review. Biomedicine and Pharmacotherapy, 2022, 155, 113674.	2.5	3
2848	Nanoarchitectured assembly and surface of two-dimensional (2D) transition metal dichalcogenides (TMDCs) for cancer therapy. Coordination Chemistry Reviews, 2022, 472, 214765.	9.5	15
2849	Anticancer effect of rationally designed Î±-helical amphiphilic peptides. Colloids and Surfaces B: Biointerfaces, 2022, 220, 112841.	2.5	9
2850	Erythrocyte membrane camouflaged siRNA/chemodrug nanoassemblies for cancer combination therapy. Biomaterials Science, 2022, 10, 6601-6613.	2.6	9
2851	Chemical Structures and Cell Death Inducing Activities of Constituents Isolated from Hibiscus tiliaceus. Heterocycles, 2022, 104, 1477.	0.4	0
2852	Supramolecular grafting of stimuli-responsive, carrier-free, self-deliverable nanoparticles of camptothecin and antisense DNA for combination cancer therapy. New Journal of Chemistry, 2022, 46, 16813-16820.	1.4	3
2853	Delineating the Role of PI3K Signaling Pathway in the Stem Cell Therapeutics of ROS-Induced Carcinomas. , 2022, , 2153-2177.		0

#	Article	IF	Citations
2854	Anti-cancer Nanotechnology. Micro/Nano Technologies, 2022, , 1-50.	0.1	0
2856	The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	24
2857	Multifunctionality of Calebin A in inflammation, chronic diseases and cancer. Frontiers in Oncology, 0, 12, .	1.3	9
2858	Effects of Ion-Transporting Proteins on the Digestive System Under Hypoxia. Frontiers in Physiology, 0, 13, .	1.3	2
2859	NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma. Nanoscale Research Letters, 2022, 17, .	3.1	8
2860	Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2710-2724.	2.5	1
2861	Ursolic acid-piperazine-dithiocarbamate ruthenium(II) polypyridyl complexes induced necroptosis in MGC-803 cells. Metallomics, 2022, 14, .	1.0	1
2862	Advances in Pharmacokinetic Mechanisms of Transporter-Mediated Herb-Drug Interactions. Pharmaceuticals, 2022, 15, 1126.	1.7	3
2863	In silico drug repurposing and lipid bilayer molecular dynamics puzzled out potential breast cancer resistance protein (BCRP/ABCG2) inhibitors. Journal of Biomolecular Structure and Dynamics, 0, , 1-14.	2.0	2
2864	Enzymatic Nanosphereâ€toâ€Nanofiber Transition and Autophagy Inducer Release Promote Tumor Chemotherapy. Advanced Healthcare Materials, 2022, 11, .	3.9	4
2865	Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Communication and Signaling, 2022, 20, .	2.7	8
2866	The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers. Frontiers in Genetics, 0, 13, .	1.1	9
2867	Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	8
2868	Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study. European Journal of Medicinal Chemistry, 2022, 244, 114827.	2.6	12
2869	Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors. Nature Communications, 2022, 13, .	5.8	2
2870	The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers. Current Topics in Medicinal Chemistry, 2022, 22, 2535-2569.	1.0	1
2871	Synthesis of Polycyclic Hetero-Fused 7-Deazapurine Heterocycles and Nucleosides through Câ€“H Dibenzothiophenation and Negishi Coupling. Journal of the American Chemical Society, 2022, 144, 19437-19446.	6.6	4
2872	Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 12763.	1.8	0

#	Article	IF	Citations
2873	Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells. Pharmaceuticals, 2022, 15, 1245.	1.7	4
2874	The function and clinical implication of circular RNAs in lung cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2875	Mechanistic insights into cancer drug resistance through optogenetic PI3K signaling hyperactivation. Cell Chemical Biology, 2022, 29, 1576-1587.e5.	2.5	2
2876	Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. Molecules, 2022, 27, 6608.	1.7	7
2877	Multifunctional bovine serum albumin-based nanocarriers with endosomal escaping and NIR light-controlled release to overcome multidrug resistance of breast cancer cells. Journal of Drug Delivery Science and Technology, 2022, 77, 103869.	1.4	3
2878	Recent progress in nitric oxide-generating nanomedicine for cancer therapy. Journal of Controlled Release, 2022, 352, 179-198.	4.8	14
2879	Reversal of multidrug resistance by Fissistigma latifoliumâ€“derived chalconoid 2-hydroxy-4,5,6-trimethoxydihydrochalcone in cancer cell lines overexpressing human P-glycoprotein. Biomedicine and Pharmacotherapy, 2022, 156, 113832.	2.5	2
2880	STRATEGIE WALKI ZE ZJAWISKIEM OPORNOÅšCI WIELOLEKOWEJ NOWOTWORÃ“W. , 2012, 10, 1-8.		0
2881	Convergent synthesis of tetrahydropyranyl side chain of verucopeptin, an antitumor antibiotic active against multidrug-resistant cancers. Chemical Communications, 2022, 58, 13447-13450.	2.2	2
2882	From plasma membrane to mitochondria: Time-dependent photodynamic antibacterial and anticancer therapy with a near-infrared AIE-active photosensitizer. Chemical Engineering Journal, 2023, 454, 140189.	6.6	5
2883	The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation. Frontiers in Oncology, 0, 12, .	1.3	1
2884	Relationship between miRNA and ferroptosis in tumors. Frontiers in Pharmacology, 0, 13, .	1.6	12
2885	Dynamic covalent macrocycles co-delivering genes and drugs against drug-resistant cancer. Cell Reports Physical Science, 2022, 3, 101150.	2.8	1
2886	Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	0
2888	ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resistance Updates, 2023, 66, 100905.	6.5	31
2889	PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment. Journal of Controlled Release, 2023, 353, 63-76.	4.8	8
2890	Research progress on the antitumor effects of astragaloside IV. European Journal of Pharmacology, 2023, 938, 175449.	1.7	8
2891	Polymeric Nanoparticles to Target Glioblastoma Tumors. Environmental Chemistry for A Sustainable World, 2022, , 329-349.	0.3	0

#	Article	IF	Citations
2892	Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients. Technology in Cancer Research and Treatment, 2022, 21, 153303382211391.	0.8	1
2893	In vivo methods for imaging bloodâ€“brain barrier function and dysfunction. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1051-1083.	3.3	14
2894	Co-delivery of immunochemotherapeutic by classified targeting based on chitosan and cyclodextrin derivatives. International Journal of Biological Macromolecules, 2023, 226, 1396-1410.	3.6	3
2895	Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment. Biomedicines, 2022, 10, 2988.	1.4	7
2896	Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Molecular Cancer Therapeutics, 2023, 22, 155-167.	1.9	9
2897	Polymer Materials Synthesized through Cell-Mediated Polymerization Strategies for Regulation of Biological Functions. Accounts of Materials Research, 2023, 4, 57-70.	5.9	7
2898	Molecular docking, ADMET profiling of gallic acid and its derivatives (N-alkyl gallamide) as an anti-breast cancer agent. F1000Research, 0, 11, 1453.	0.8	0
2899	Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms. Cancers, 2022, 14, 6080.	1.7	0
2900	STAT3 potentiates RNA polymerase I-directed transcription and tumor growth by activating RPA34 expression. British Journal of Cancer, 2023, 128, 766-782.	2.9	1
2901	Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions. , 2023, 40, .		9
2902	Targeted Drug Delivery System Based on Copper Sulfide for Synergistic Near-Infrared Photothermal Therapy/Photodynamic Therapy/Chemotherapy of Triple Negative Breast Cancer. Langmuir, 2022, 38, 15766-15775.	1.6	7
2903	Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC. Molecular Cancer, 2022, 21, .	7.9	4
2904	Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, 0, 13, .	2.2	3
2906	A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International Journal of Molecular Sciences, 2023, 24, 989.	1.8	4
2907	Anti-cancer Nanotechnology. Micro/Nano Technologies, 2023, , 389-438.	0.1	0
2908	Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemoâ€•and radioresistances. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	8
2909	Perspectives of the Application of Non-Steroidal Anti-Inflammatory Drugs in Cancer Therapy: Attempts to Overcome Their Unfavorable Side Effects. Cancers, 2023, 15, 475.	1.7	7
2910	Reaching new lights: a review on photo-controlled nanomedicines and theirin vivoevaluation. Biomaterials Science, 2023, 11, 1607-1624.	2.6	3

#	Article	IF	Citations
2911	Triazole-fused pyrimidines in target-based anticancer drug discovery. European Journal of Medicinal Chemistry, 2023, 249, 115101.	2.6	13
2912	Polymorphic renal transporters and cisplatinâ€™s toxicity in urinary bladder cancer patients: current perspectives and future directions. , 2023, 40, .		3
2913	Nanocracker capable of simultaneously reversing both P-glycoprotein and tumor microenvironment. Journal of Controlled Release, 2023, 354, 268-278.	4.8	1
2914	Synthesis, antiproliferative and enzymatic inhibition activities of quinazolines incorporating benzenesulfonamide: Cell cycle analysis and molecular modeling study. Journal of Molecular Structure, 2023, 1278, 134928.	1.8	2
2915	Metal Complexes of a 5-Nitro-8-Hydroxyquinoline-Proline Hybrid with Enhanced Water Solubility Targeting Multidrug Resistant Cancer Cells. International Journal of Molecular Sciences, 2023, 24, 593.	1.8	4
2916	A literature review of the promising future of TROP2: a potential drug therapy target. Annals of Translational Medicine, 2022, 10, 1403-1403.	0.7	9
2917	Recent Advances in Tetrakis (4â€Carboxyphenyl) Porphyrinâ€Based Nanocomposites for Tumor Therapy. Advanced NanoBiomed Research, 2023, 3, .	1.7	2
2918	Is it possible to change milk secretion of drugs with soy enriched diets in lactating ruminants?. Journal of Istanbul Veterinary Sciences, 2022, 6, 145-151.	0.3	0
2919	Intense endoplasmic reticulum stress (ERS) / IRE1Î± enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells. BMC Cancer, 2022, 22, .	1.1	1
2920	Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines. International Journal of Molecular Sciences, 2023, 24, 666.	1.8	4
2921	Mechanisms of Cancer-killing by Quercetin; A Review on Cell Death Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 999-1012.	0.9	5
2922	4-methylthiobutyl isothiocyanate synergize the antiproliferative and pro-apoptotic effects of paclitaxel in human breast cancer cells. Biotechnology and Genetic Engineering Reviews, 0, , 1-25.	2.4	2
2923	Upregulation of miR-101-3p Overcomes Ibrutinib Resistance by Targeting ABCC5 in Diffuse Large B-Cell Lymphoma (DLBCL). Journal of Hard Tissue Biology, 2023, 32, 11-20.	0.2	1
2924	Mitochondria-Targeting Polyprodrugs to Overcome the Drug Resistance of Cancer Cells by Self-Amplified Oxidation-Triggered Drug Release. Bioconjugate Chemistry, 2023, 34, 377-391.	1.8	6
2925	The Role of MicroRNAs in Chemoresistance. , 2023, , 1-39.		32
2926	Nanotheranostics in CNS Malignancy. , 2023, , 307-321.		0
2927	Ursonic acid inhibits migration and invasion of human osteosarcoma cells through the suppression of mitogen-activated protein kinases and matrix metalloproteinases. Molecular Biology Reports, 0, , .	1.0	0
2928	Membrane fusion-mediated delivery of small-molecule HER2 tyrosine kinase inhibitor for effective tumor chemosensitization. Journal of Controlled Release, 2023, 357, 222-234.	4.8	0

#	Article	IF	Citations
2929	Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomedicine and Pharmacotherapy, 2023, 162, 114643.	2.5	26
2930	PDT for Gastric Cancer â€" the view from China. Photodiagnosis and Photodynamic Therapy, 2023, 42, 103366.	1.3	5
2931	Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer. Journal of Controlled Release, 2023, 354, 784-793.	4.8	4
2932	2,2-Diphenethyl Isothiocyanate Enhances Topoisomerase Inhibitor-Induced Cell Death and Suppresses Multi-Drug Resistance 1 in Breast Cancer Cells. Cancers, 2023, 15, 928.	1.7	2
2933	Conformational space exploration of cryo-EM structures by variability refinement. Biochimica Et Biophysica Acta - Biomembranes, 2023, 1865, 184133.	1.4	5
2934	Mitomycin C enhanced the antitumor efficacy of Rocaglamide in colorectal cancer. Pathology Research and Practice, 2023, 243, 154350.	1.0	1
2935	Inhibiting Effect of Cationic Procyanidin Nanoparticles on Drug-Resistant Oral Squamous Cell Carcinoma Cell Lines. Letters in Drug Design and Discovery, 2024, 21, 782-789.	0.4	0
2936	Drug repurposing for development of effective anticandidals. , 2023, , 137-146.		0
2937	Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing. Drug Design, Development and Therapy, 0, Volume 17, 403-418.	2.0	0
2939	Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. Journal of Medicinal Chemistry, 2023, 66, 2804-2831.	2.9	7
2940	Targeted degradation of ABCG2 for reversing multidrug resistance by hypervalent bispecific gold nanoparticle-anchored aptamer chimeras. Chemical Communications, 2023, 59, 3118-3121.	2.2	1
2941	Palladium-catalysed site-selective arene ortho Câ€"H fluoroalkoxylation of 4-aryl-pyrrolo[2,3-d]pyrimidines. Organic and Biomolecular Chemistry, 2023, 21, 2748-2753.	1.5	3
2942	In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31. International Journal of Molecular Sciences, 2023, 24, 4377.	1.8	3
2943	N6-methyladenosine (m6A) as a regulator of carcinogenesis and drug resistance by targeting epithelial-mesenchymal transition and cancer stem cells. Heliyon, 2023, 9, e14001.	1.4	2
2944	Inhibition of CD73 expression or A2AR blockade reduces MRP1 expression and increases the sensitivity of cervical cancer cells to cisplatin. Cell Biochemistry and Function, 2023, 41, 321-330.	1.4	1
2945	Emerging trends and research foci of berberine on tumor from 2002 to 2021: A bibliometric article of the literature from WoSCC. Frontiers in Pharmacology, 0, 14, .	1.6	4
2946	Cannabimimetic N-Stearoylethanolamine as â€œDouble-Edged Swordâ€•in Anticancer Chemotherapy: Proapoptotic Effect on Tumor Cells and Suppression of Tumor Growth versus Its Bio-Protective Actions in Complex with Polymeric Carrier on General Toxicity of Doxorubicin In Vivo. Pharmaceutics, 2023, 15, 835.	2.0	1
2947	Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an in silico drug discovery study. Journal of Biomolecular Structure and Dynamics, 2023, 41, 13977-13992.	2.0	4

#	Article	IF	Citations
2948	Design, synthesis, anticancer evaluation, in silico docking and ADMET analysis of novel indole-based thalidomide analogs as promising immunomodulatory agents. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15106-15123.	2.0	7
2949	Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy. Journal of Medicinal Chemistry, 2023, 66, 4086-4105.	2.9	6
2950	Genomic Landscape and Potential Regulation of RNA Editing in Drug Resistance. Advanced Science, 2023, 10, .	5.6	4
2952	Introduction to chemotherapy. , 2023, , 1-18.		0
2953	PLGA-based nanoparticles for enhanced diagnosis and cancer therapy. , 2023, , 179-210.		0
2954	Antiproliferative Activity, Multikinase Inhibition, Apoptosis- Inducing Effects and Molecular Docking of Novel Isatinâ€“Purine Hybrids. Medicina (Lithuania), 2023, 59, 610.	0.8	6
2955	Recent Advancements on Selfâ€Immolative System Based on Dynamic Covalent Bonds for Delivering Heterogeneous Payloads. Advanced Healthcare Materials, 2023, 12, .	3.9	4
2956	Development of a Novel Tool to Demystify Drug Distribution at Tissueâ€Blood Barriers. ChemBioChem, 0, , .	1.3	0
2957	EMT-Activating Transcription Factor Slug is Involved in the Phenotypic Change as Well as Drug Sensitivity in Adriamycin- Resistant MCF-7 Cells. , 2023, 2, 1-11.		0
2958	The Battlefield of Chemotherapy in Pediatric Cancers. Cancers, 2023, 15, 1963.	1.7	4
2959	Intracellular cGMP increase is not involved in thyroid cancer cell death. PLoS ONE, 2023, 18, e0283888.	1.1	0
2960	Nanoparticle-Based Combination Therapy for Ovarian Cancer. International Journal of Nanomedicine, 0, Volume 18, 1965-1987.	3.3	4
2961	Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery. Pharmaceutics, 2023, 15, 1259.	2.0	0
2962	NFR2/ABC transporter axis in drug resistance of breast cancer cells. Molecular Biology Reports, 2023, 50, 5407-5414.	1.0	5
3008	Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nature Reviews Cancer, 2023, 23, 762-779.	12.8	12
3017	MicroRNA-495: a therapeutic and diagnostic tumor marker. Journal of Molecular Histology, 0, , .	1.0	0
3046	Epigenetic changes driving therapy resistance in prostate cancer. , 2024, , 85-106.		0
3069	Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype. Discover Oncology, 2024, 15, .	0.8	0

#	Article	IF	Citations